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Abstract 
The qualitative determination of various opiates and benzodiazepines in human serum is 
described using a two-dimensional gas chromatograph (GC x GC) coupled to a time of flight mass 
spectrometer (TOFMS). Human serum was `spiked' with known quantities of benzodiazepines and 
a `street heroin' mixture including some of the major metabolites and impurities. The sample 
components were extracted from the matrix by solid phase extraction (SPE). Constituents 
containing polar hydroxyl and/or secondary amine groups were derivatised with N-methyl-N-(tert- 
butyldimethyl)trifluoracetamide (MTBSTFA) to improve the chromatographic performance. 
The sensitivity and repeatability of the method were evaluated by the preparation of 
calibration standards for flunitrazepam and its major metabolite 7-aminoflunitrazepam (7-amino- 
FN), in the concentration range 5- 1000 ng/ml. The limits of detection (LOD) and limits of 
quantitation (LOQ), calculated by repeat injections (x10) of the lowest standard, were 1.6 and 5.4 
ng/ml (flunitrazepam); 2.5 and 8.5 ng/ml (7-amino-FN), respectively. 
A qualitative analysis of hair samples provided by an external collaborator was performed 
and various drug types detected including opiates, cocaine, methadone and diazepam. The analysis 
also identified many of the minor components in street drugs which may help forensic scientists to 
identify the source of the drug. 
We propose a method to extract and analyse the pseudo-endogenous drug, gamma- 
hydroxybutyric acid (GHB), in urine, by gas chromatography-combustion-isotope ratio mass 
spectrometry (GC-C-IRMS). 
Urine samples (<1.62 µg/ml endogenous GHB) were `spiked' with 10 tg/ml synthetic 
GHB, extracted using SPE and derivatised with BSTFA. We obtained S13C values for 3x reference 
standards (#1 mean -31.7 %o; an_I 0.15; n=3: #2 mean -34.0 %o; a_j 0.85; n=3: #3 mean -42.2 %o; 
(7,,. 10.64; n=3). 
Selective extraction of GHB by affinity chromatography was investigated as a means to 
improve the sensitivity. A method was developed to synthesise tetrahydro-5-oxo-3-furanyl acetic 
acid (furanyl acetic acid) which was identified to contain the GHB sub-structure. It was postulated 
that the reaction of this compound with the lysine residues of a protein would produce an antigen 
whereby antibodies, with specific binding sites to GHB, could be created. 
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Chapter 1 
Introduction 
Introduction 
1.0 Background 
Chemical analysis is the process by which constituent molecules within a matrix are 
isolated and subsequently analysed. Matrix matching is the process that can provide the qualitative 
and quantitative information contained within the sample matrix by comparing the sample against 
known reference standards. In many different fields of research, analytical chemistry underpins 
what we know about the natural world. 
Analytical procedures for testing drugs of abuse in biological matrices are routinely 
employed in clinical and forensic toxicology. This represents tens of millions of drug tests 
performed annually worldwide. Clinical toxicology is concerned with the analysis of biological 
samples from people receiving medical treatment or involved in epidemiological studies. This 
includes patients undergoing rehabilitation for drug and/or alcohol dependence, and therapeutic 
drug monitoring of patients administered drugs for treatment of illness or disease. Forensic 
toxicology is concerned with matters such as police investigation into illegal drug use, and family 
law and child protection casework. Also of great importance is the area of doping control which 
includes the testing of elite athletes for performance enhancing drugs and workplace testing 
programmes whereby positive identification of illegal drug use may lead to dismissal but not 
necessarily to a criminal prosecution. Workplace testing has become increasingly more common in 
the last 20 years and is not restricted to the `high-risk' professions. 
Drug testing laboratories routinely screen for various drug types and have developed 
accredited methods that provide reliable data to the agencies involved in these types of analyses. 
The rapid expansion of the drug-testing industry has led to the development of procedures using 
new technologies which has enabled higher throughput and sensitivity. This process is ongoing and 
method development is vital to improve the existing methodology. 
This thesis explores the application of separation science to the testing of drugs of abuse in 
biological matrices. Specialised chromatographic techniques form the basis of this study. However, 
a wide variety of analytical techniques are employed and will be discussed. 
2 
1.1 Techniques -A Brief Review 
1.1.1 Gas Chromatography 
It was the development of gas chromatography (GC) that really advanced the field of 
separation science. In 1952 James and Martin described the separation of volatile fatty acids by 
gas-liquid partition chromatography (GLC). 1 This is widely regarded as the first paper on GC. 2 It 
demonstrated that tiny amounts (<1 µg) of material could be separated and analysed in the gas- 
liquid phase. 
Chromatographic separation has been understood since ancient times. The principle is that 
a mixture of compounds (e. g. ink dyes) when passed along a medium or stationary phase (e. g. 
paper) by another medium or mobile phase (e. g. liquid) will move at different rates and therefore 
become separated. The word `chromatography' is derived from Greek meaning `description of 
colours'. However, the principle can be applied to any type of separation. Thin layer 
chromatography (TLC) is a common chromatographic technique where paper has been replaced by 
more robust materials (e. g. silica). Column chromatography uses a packing material (e. g. silica gel) 
as the stationary phase. Both techniques use liquid as the mobile phase. 
GC uses a permanent gas (hydrogen, helium or nitrogen) as the mobile phase. Martin and 
Synge discovered that by using an inert gas, instead of a solvent as the mobile phase, a mixture of 
volatile substances, when passed over a stationary phase, separated according to the relative vapour 
pressures of its constituents. 3 Therefore, compounds could be separated by their volatility as well as 
partitioning to a stationary phase. The system is far more dynamic than in liquid mobile phases and 
much more refined separations can be achieved. This is because gas is compressible meaning a 
constant linear velocity can be applied and, unlike a liquid, has a negligible effect on the overall 
vapour pressure within the matrix. 4 In GC systems, higher temperatures can be applied and, 
therefore, less volatile compounds can be separated according to the same principle. The 
application of a temperature gradient can improve the resolution in mixtures of volatile 
components. 
The intrinsic value of GC was only really realised with the development, in the late 1950s, 
of the flame ionisation detector (RD) by McWilliam and Dewar. 5 Prior to this the early 
experiments described by Martin and James used acid-base titration to detect sample components. 
3 
This led to the development of quite sophisticated recording burettes that could perform quite rapid 
analyses. 4 More sophisticated techniques such as thermal conductivity cells (TCC) had already 
been developed as gas analysers. Ray applied GC coupled to TCC for the separation and analysis 
of gas mixtures. 6 The gas density meter was developed, by Martin and James, specifically for GC 
detection. 7 Both techniques were reasonably successful but high background `noise' and low 
sensitivity were major issues that could not be resolved. 8 
The principle of FID is that molecules passing through a flame are ionised and a response 
signal is generated by measuring the ion current in the flame. McWilliam and Dewar discovered 
that by filtering the air of tiny dust particles the background noise could be virtually eliminated. 
Complex separations at very low concentrations (< 1 ng) could be realised. FID requires very small 
sample volumes (<1 µl) and has very fast response times (-1 ms). 8 
The potential of GC-FID as a diagnostic tool in the analysis of biological fluids was soon 
recognised. Pauling demonstrated the potential of GC-FID for the analysis of volatile components 
in human breath and urine; 250 and 280 compounds were resolved, respectively. 
The development of FID and the increase in sensitivity led to new developments in column 
technology. The earliest columns comprised of packed open tubes usually of activated silicone oil. 
These types of columns are referred to as `packed columns'. Other types of mediums included 
activated charcoal which was applied to gas analysis and diatomaceous earth (kieselguhr) applied 
to gas-liquid partitions. Modem packed columns usually consist of activated silica gel. 
The development of capillary columns greatly improved separation efficiencies i. e. shorter 
run times with more peak capacity. The column efficiency is often expressed by the number of 
theoretical plates which is related to the ratio of the retention time and the peak width. The concept 
of the theoretical plate in chromatography is described in various text books. In short, peak widths 
are much narrower with capillary columns compared to packed columns. Therefore, the number of 
components which can be resolved (or peak capacity) is increased. 
Capillary columns are narrower than packed columns (typically 0.1 to 0.5 mm internal 
diameter) consisting of a fused silica tube and activated polysiloxane coated with polyimide resin 
which can withstand high temperatures (<370°C). The flexibility of the material 
is the key to its 
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success; columns can be wound very tight, therefore, the lengths of columns are usually >_15 m. 
The column phases are generally used in reverse phase and normal phase separations. However, 
analysis of highly volatile mixtures can be achieved with porous layer open tube (PLOT) columns 
which trap vapours and thereby increase the partition times. The development of metal columns has 
enabled capillary separation at much higher temperatures and, because of their intrinsic strength 
and flexibility, has been applied to portable instruments. 
The electron capture detector (ECD), invented by James E. Lovelock, 1° has extremely high 
sensitivity to electron rich compounds such as PCBs, pesticides, CFCs and as such revolutionised 
environmental analysis. Sensitivity levels of <100 femtograms (fg) at point of analysis have been 
reported. " 
The thermal energy analyser (TEA) is a highly specialised technique designed to detect 
compounds containing nitro and N-nitroso groups. '2 This technique has provided a reliable and 
robust method for the quantitation of compounds such as nitrosamines found in tobacco smoke 
with detection limits <50 pg at point of analysis. 13 
1.1.2 Mass Spectrometry 
The coupling of GC to a mass spectrometer (GC-MS) is the most effective tool for GC 
analysis. MS enables the differentiation of molecules of different relative molecular mass (RMM). 
The standard measurement is the dalton (Da) based on the12C isotope value of 12.0000. The 
separation of molecules of different mass and charge was first described by J. J. Thomson in 1912 
but the real pioneer of this technology was Francis Aston who, in 1919 invented the mass 
spectrograph, the forerunner of the mass spectrometer (MS). He discovered that ionised atomic 
nuclei could be separated according to their mass using electrostatic and magnetic fields. 14 This 
breakthrough was crucial in the field of nuclear physics. It enabled the isotopic values of the 
different elements to be calculated and ultimately led to the accurate identification of fission 
products of the radioactive elements. '5"16 
The early mass spectrograph ionised gases and coatings inside cathode ray tubes but it was 
the development of electron ionisation (EI) by A. J. Dempster, in 1921,17 that greatly simplified this 
process and made possible more complex separations. This led to the development of the magnetic 
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sector MS which is still widely in use today. The principle of the operation is that neutral particles 
are ionised in the ionisation chamber to form ions which can then be deflected by the magnetic 
field according to their mass to charge ratio (m/z) and detected using Faraday cups. The trajectory 
and velocity are dependent on the m/z ratios. Therefore, a singly charged species of 1,000 Da will 
behave the same as a species of 10,000 Da with 10 charges. Most small organic compounds 
(<1,000 Da) produce only single charged species, therefore, a sample matrix can potentially be 
separated according to the mass of its individual components. EI is most suitable for volatile and 
thermally stable components. The first commercial instruments were produced in the 1940s and 
were used mainly for petroleum analysis. 18 However, applications for MS remained limited until 
the development of GC and by the late 1950s the first GC-MS were developed. 19'20 By coupling 
MS to GC, volatile mixtures can be partitioned prior to entering the MS and compounds not 
resolved by the GC can potentially be resolved by MS. EI tends to cause fragmentation of organic 
molecular ions; interpretation of mass spectral fragmentation patterns can provide invaluable 
information as to the identity of a compound. 
The development of double focusing magnetic sector instruments enabled very high 
resolution to be achieved so that the precise atomic composition of small organic compounds could 
be determined and molecules with differences of less than 0.001 Da could be resolved. 
'8 This has 
also enabled precise mass measurements of multiple charged large bio-molecules (>10,000 Da). 
The resolution of the instrument is often defined by the full width half maximum (FWHM) derived 
from the m/z value divided by the mid-point peak width (e. g. a resolution of 20,000 FWHM 
indicates a species which produces an ion of 20,000 m/z will have a mid-point peak width of 1 
m/z). Because large bio-molecules tend to form multiple charged species and contain multiplicities 
due to the isotope compositions, the mass spectrum can be quite complex. Low resolution MS are 
often referred to as providing unit-resolution. These are usually applied for low mass species 
(<4,000 Da) where the accurate mass is not needed. 
In the 1950s two major developments occurred with the design of the quadrupole mass 
analyser (quadrupole) by Wolfgang Paul 21.22 and the time-of-flight (TOFMS) by Wiley and 
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McClaren 23 Both techniques greatly improved the sensitivity of GC-MS. Anecdotal evidence 
suggests that most modem instruments can detect <10 pg at point of analysis. 
The quadrupole is a scanning instrument which separates ions by the application of direct 
current (DC) and radiofrequency (RF) oscillations. It allows specific target ions to be monitored 
whilst other ions, which may interfere, are removed. This is known as single ion monitoring (SIM). 
Target ions are usually identified in scan mode prior to application of SIM. The process is often 
referred to as `target analysis' and is generally used for quantitative analysis where greater 
sensitivity is required. The development of triple quadrupole MS allows the user to study mass 
transitions (MS/MS). It is a three stage MS consisting of two quadrupoles with a collision cell. The 
molecular or precursor ion can be isolated by the first stage instrument and then by the application 
of a collision energy, fragment or product ions are produced that can be resolved in the second 
stage. This is called selected reaction monitoring (SRM). These transition spectra give more 
comprehensive proof of the target analyte and higher sensitivity than single quadrupole systems. 
Modern triple quadrupole MS can detect <50 fg at point of analysis. 24 
SIM and SRM transitions can also be studied by ion trap MS developed by Paul. 21 22 The 
principle is very similar to quadrupole MS but because the ions are trapped inside a chamber and 
sequentially ejected, multiple order transitions can be studied. 
TOFMS is different to quadrupole and ion trap in so far as it is a non-scanning MS. Ions 
are separated across a flight tube and analysed by a time-array detector. When the same kinetic 
energy is applied to a mixture of ions, the lighter ions will move faster across the flight tube than 
heavier ions. A reflectron (or ion mirror) is usually incorporated to reduce the drift effect (time of 
flight distribution) and to increase the path length. Ions are sampled virtually simultaneously. 
TOFMS instruments have been developed for high-resolution and unit-resolution applications. 
The extent of molecular fragmentation in the ion source is dependent on the stability of the 
molecular ion and the ionisation energy applied. Ionisation energy of 70 eV is widely accepted as 
the standard setting in MS studies. Extensive spectral library databases are available for most 
organic compounds using this convention. However, it should also be noted that different mass 
analysers may also produce a different mass spectrum for the same compound. 
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EI is often referred to as a `hard' ionisation technique and produces ions with high energy; 
hence, a degree of molecular fragmentation is usually observed. The detection of thermally labile 
compounds by GC-MS has been greatly improved with the development of chemical ionisation 
(CI). 25 Cl is an example of a `soft' ionisation technique. Positive ions are produced by proton 
transfer, charge transfer or hydride abstraction from an ionised gas (e. g. methane, ammonia). The 
analyte ions (or secondary ions) produced have much less energy than with EI mode. This can 
prevent the complete dissociation of the target analyte in the ionisation chamber. 
There are certain limitations to GC analysis. Many of these are easily overcome. The 
analysis of samples in aqueous solution can be achieved by extraction techniques such as solid- 
phase extraction (SPE) and liquid-liquid extraction (LLE). The analysis of highly polar and/or non- 
volatile compounds (e. g. bio-organics and pesticides) can be achieved by chemical modification 
(derivatisation). However, large bio-organic molecules (e. g. proteins, peptides, oligonucleotides) 
are not readily derivatised and, therefore, because of the non-volatile nature of these molecules, GC 
analysis is not usually possible. 
1.1.3 Liquid Chromatography 
The development of high performance liquid chromatography (HPLC) has reduced the 
need for complex clean-up procedures and derivatisation. 26 Aqueous matrices can be analysed 
directly and large bio-organic molecules (e. g. proteins, peptides, oligonucleotides) are easily 
resolved. The development of electrospray ionisation (ESI) enabled the detection of large bio- 
organic molecules by HPLC interfaced with MS (LC-MS) 27'28 ESI is a soft ionisation technique 
that produces multiple charged species (positive or negative) by application of an ionising voltage 
to the solvent droplets. Mass spectral analysis of proteins and peptides have been achieved by ESI 
interfaced with high resolution double focusing magnetic sector MS. 29'30 Further developments 
including atmospheric pressure chemical ionisation (APCI)31,32 and matrix assisted laser desorption 
ionisation (MALDI)33 have eliminated many of the problems associated with ESI, in particular the 
fragmentation of the molecular ion and ion suppression. This has led to a new generation of MS 
technology that has allowed the precise spectral determination of these large bio-organic 
molecules. HPLC and MALDI coupled to high resolution mass spectrometers (e. g. TOFMS) has 
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enabled the analysis of large proteins (>100,000 Da). The combination of quadrupole and TOFMS 
(Q-TOF) has enabled highly sensitive studies of large bio-molecules (>20,000 Da). 34 Recent 
developments have resulted in ultra performance liquid chromatography (UPLC) which use higher 
pressure injections and smaller particle columns to increase the partitioning to the stationary phase. 
This results in an increase in column efficiency and, therefore, much narrower peak widths. There 
is now the potential to perform complex separations by LC-MS. 35 
1.1.4 Microextraction 
Clean-up methods, prior to GC analysis, are increasingly being performed `online' or 
automatically. Solid phase microextraction (SPME) was developed by Arthur and Pawliszyn. 36 
Volatile organic compounds (VOCs) are extracted onto an adsorbent material (e. g. 
polydimethylsiloxane (PDMS) or carbowax) then directly injected and desorbed onto the head of 
the column. As the material is hydrophobic this allows for the direct analysis from an aqueous 
sample. 
Stir bar sorptive extraction (SBSE) is a similar technique which can also be applied directly 
to aqueous samples. 37 Components are adsorbed onto the stationary phase coated onto a magnetic 
stierer bar and desorbed, into a cryo-cooled injection port, using thermal desorption. The 
components are then cryo-focused onto the head of the GC column. This technique enables a 
greater load capacity compared with SPME analysis due to the significantly thicker layer of 
stationary phase. 
Thermal desorption systems (TDS) interfaced to the GC allow the user to extract and 
analyse volatile components from a solid sample. 
Programmable temperature vaporisation (PTV) injectors have enabled GC to handle larger 
sample volumes 38 However, online analysis may be more hampered by matrix interferences 
compared with liquid injections. 
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1.1.5 Drugs of Abuse 
The focus of this study has been the application of chromatographic techniques to testing 
for drugs of abuse in biological matrices. Traditionally drug testing has been associated with 
criminal activity and/or drug overdoses. However, in the 1980s, the United States Government 
embarked on a programme of mandatory drug testing for Government employees. 39'40 Concerns 
over drug use were echoed throughout the developed world. There was a perception that illegal 
drug use, often regarded as the preserve of social misfits, artists and poets, had entered mainstream 
society. Drug testing became common in society in various sectors including rehabilitation clinics, 
claims and family courts, medical and legal requirements and in the workplace. Therefore, drug 
testing became commercially viable and as a result great deal of investment has gone into research 
and development of drug testing protocols. 
Drug testing protocols using immunoassay tests had been introduced in the 1970s over 
concerns about illegal drug abuse in the United States Navy. 41 The armed forces in most developed 
countries adhere to strict drug testing procedures. In 2006 the UK armed forces dismissed 769 
service personnel for failing random drug tests 42 
Whereas a blood test is the best possible indicator as to whether someone is under the 
influence of a drug, the detection times are relatively short. The urine test is the most commonly 
employed to determine recent drug exposure. Drugs and their metabolites tend to be detectable in 
urine for longer than in blood [Figure 1]. Some drugs are retained longer in the body due to the 
lipophilic character of the drug which means they are stored within the fat and released over time 
through the process of lipolysis. This means far greater variations in detection time frames are 
observed. The testing of saliva and hair are also commonly employed in drug testing. The taking of 
a saliva sample can be advantageous because it is the least invasive technique and in roadside 
testing, where driving under the influence of drugs (DUID) is suspected, it is possible to obtain 
very rapid test results. 43' 44 Hair testing provides a record of drug use with potentially an almost 
unlimited time frame of detection. Cocaine and nicotine has been detected in the hair of South 
American mummies over 900 years old. 45 Drugs are deposited in the hair shaft by deposition from 
the bloodstream or from sweat and sebaceous glands. As the hair grows any drugs or metabolites 
are carried along with it and by roughly estimating how quickly the hair grows it is possible to 
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estimate approximately when the drug use had occurred. 46 Hair testing is now used extensively for 
routine screening but also it has been invaluable for detecting drugs in cases of drug facilitated 
crime (DFC) whereby drugs are often administered surreptitiously and rapidly metabolised, 47 and 
in post-mortem examination to determine whether a person has consumed drugs in life. 8 
A positive drug test in a biological matrix (e. g. blood, urine and hair) usually requires 
screening by a diagnostic test (e. g. immunoassay) and a chromatographic method. 49 Immunoassays 
are highly sensitive techniques that use antibodies with specific binding sites to the target drug 
compounds. Detection limits <100 fg at point of analysis can be achieved. 50 Assays are available 
for most common drug groups including cannabis, opiates, cocaine, barbiturates, benzodiazepines 
and amphetamines. They are relatively inexpensive and the test results can be obtained very 
quickly. Diagnostic tests such as Enzyme-Linked ImmunoSorbent Assay (ELISA) are highly 
sensitive and can determine concentrations with very high precision. The specificity is usually 
limited to a drug type rather than an actual compound e. g. a positive ELISA test for opiates would 
only indicate that opiate type compounds such as morphine, codeine and dihydrocodeine may be 
present in the sample. Therefore, diagnostic tests are usually the first phase of a test and if the result 
is positive then a chromatographic procedure is used to determine the actual components in the 
sample. This is often referred to as screening and confirmation. 
11 
(a) Typical drug detection times in urine 
25 
20 
15 
days 
10 
r°ý ýQý \co °5 °5 °5 Sei 
AGO 
t` Nýee 4ý 
°a Qr 
aýQr 
(b) Typical drug detection times in blood 
25 
20 
15 
days 
10 
'n rl a C; 0 91 1 row ýý \ýý 
Q' O Gam 
Figure 1. Time frames of detection in (a) urine and (b) blood. The purple bars represent the 
approximate maximum detection limits of the actual drug or specific metabolites of the drug. 
Information was obtained from Medscreen Ltd. (London. UK) www. medscreen. co. uk 
and I)DL Inc. (Sacramento. CA. USA) www. drugdetection. net 
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1.1.6 Positive Identification of Drug Compounds 
Drugs are often rapidly metabolised in the body and, therefore, unlikely to be present in 
biological fluids. Drugs can also be absorbed from contact with contaminated surfaces or from the 
atmosphere and result in trace levels in non-drug users. Specific metabolites should only be present 
if the drugs have been ingested at therapeutic levels. The `poppy seed' issue highlights the 
complexities involved with drug testing. 51 Heroin (diacetylmorphine or diamorphine) is a synthetic 
drug produced from refined opium. However, it is unlikely to be found at detectable levels in the 
blood or urine of a heroin user due to its rapid metabolism. 52 The dried poppy seed contains trace 
levels of naturally occurring opiates such as morphine; however, morphine is also the major 
metabolite of heroin. Morphine is also a metabolite of codeine, an over-the-counter analgesic. 
Therefore, positive identification of morphine cannot be attributed to heroin. This requires the 
detection of the minor metabolite 6-monoacetylmorphine (6-MAM). However, case studies 
indicate that concentration levels of 6-MAM are considerably lower than morphine in heroin users. 
Morphine is usually found >2,000 ng/ml in urine whereas 6-MAM may be <10 ng/ml in urine. 53 
Identification of cannabis use presents issues due to environmental exposure. Diagnostic 
test kits test are usually only specific to the cannabinoid group of compounds which includes E 9- 
tetrahydrocannabinol (THC), the active component of cannabis. However, positive identification of 
THC is only used as an indicator of cannabis use. Confirmation is determined by detection of the 
metabolite A9-tetrahydrocannabinol-carboxylic acid (THC-COOH). The concentration levels of 
THC-COOH are much lower than THC but most importantly it cannot be attributed to 
environmental exposure? ` The concentrations of THC-COOH are typically <10 ng/ml in urine and 
<100 pg/mg of hair, even in chronic users of cannabis. Therefore, detection of these metabolites is 
usually performed by target analysis with high sensitivity LC-MS or GC-MS. 
Positive identification of drug use is confirmed by the chromatographic method if the 
concentration is greater than an interpretative `cut-off level. Interpretative cut-offs are not 
universally defined but the forensic toxicology community are fairly cohesive and most countries 
adopt very similar practices. Workplace drug testing has the clearest guidelines and the 
confirmation cut-offs tend to reflect the need to provide legally defensible limits. Urinary cut-off 
values for confirmation tests, adopted by most European countries including the UK, are outlined 
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in Table 1.55,56 The cut-off limits vary considerably and reflect the different therapeutic doses and 
rates of metabolism. Other areas of drug testing where the burden of proof is not the priority (e. g. 
therapeutic monitoring and rehabilitation) may employ lower cut-off values. The sensitivity of 
modem GC-MS and LC-MS especially tandem MS instruments such as triple quadrupole have 
enabled target analytes to be detectable at levels much lower than the defined cut-off values. Feng 
et al. reported limits of detection of these common drugs in urine by LC-MS/MS at between 9 
pg/ml and 2.29 ng/ml 5.7 Deveaux et al. tested drugs and metabolites routinely screened in cases of 
DFC (e. g. benzodiazepines, tranquilisers and barbiturates) and reported limits of quantitiation <0.5 
ng/ml. 58 
Table 1. European Workplace Drug Testing Society (EWDTS)55 recommended urinary cut-off 
values. 
Substance Concentration 
(nglml) 
Amphetamine 200 
Methamphetamine 200 
MDA 200 
MDMA 200 
MDEA 200 
Benzodiazepines 
Temazepam 100 
Oxazepam 100 
Nordiazepam 100 
Opiates 
Morphine 300 
Codeine 300 
Dihydrocodeine 300 
6-MAM 10 
Cannabis metabolite 15 
Cocaine (benzoylecgonine) 150 
Methadone 250 
Barbiturates 150 
Phencyclidine 25 
Buprenorphine 5 
LSD 1 
Propoxyphene 300 
Methaqualone (Quaalude) 300 
14 
1.1.7 The Future of Drug Testing 
A recent publication by Cowan et al., 59 looked at the future of drug testing and concluded 
that the three most likely advances will come in miniaturisation, high-throughput screening and 
enhanced separation techniques. The work in this study has focused on the science of separation 
and the application of two specialised techniques: comprehensive two-dimensional gas 
chromatography-time of flight mass spectrometry (GC x GC-TOFMS) and gas chromatography- 
combustion-isotope ratio mass spectrometry (GC-C-IRMS). 
1.1.8 Comprehensive Two-Dimensional Gas Chromatography (GC x GC) 
Comprehensive two-dimensional gas chromatography (GC x GC) has been recognised as a 
technique capable of providing improved resolution of complex matrices compared to conventional 
single dimensional GC (1D-GC) 62 The technique has been applied successfully to 
petrochemical, environmental and food analysis 63 Drug analysis using comprehensive GC x GC 
was first described by Kueh et al. for anti-doping control in equine and canine sports . 
64 Song et al. 
applied GC x GC to analyse a drug standard mixture containing 78 drug compounds 65 To our 
knowledge no other publications involving drug of abuse analysis by comprehensive GC x GC are 
available. 
1.1.9 Column Coupling 
Column coupling has been applied, successfully, to LC and GC systems. Its primary 
purpose has been to improve peak capacity or the number of analytes that can be resolved within a 
chromatogram. 
The principle of GC x GC involves the coupling of two separate phase types usually of 
different polarity. The first column separates the compounds of interest prior to entering a type of 
modulator or switching device which focuses the eluant onto the secondary column. Therefore, the 
actual chromatographic separation, which is of interest to the analyst, is performed on the second 
column. The most basic technique is known as `heart cutting' whereby only a portion of the GC run 
is transferred onto a secondary column using a switching device. 66 The second dimension 
separation is performed very rapidly by increasing the flow rate through the secondary column. 
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Therefore, co-eluting analytes from the first dimension column are resolved by the transfer onto a 
different, usually more polar stationary phase. Comprehensive GC x GC incorporates a type of 
rapid sampling device. Various approaches either by valve modulation 67 or cryo-modulation 
68 
have been described. The technique involves taking `slices' from the first dimension column which 
results in a series of short chromatograms or modulations. Cryo-modulation is achieved using cold 
gas to trap the eluant, at the head of the second column, which can then be focused onto the second 
column by re-heating [Figure 2]. 
The result is an `orthogonal' separation or separation by two mechanisms which can be 
transformed to produce contour and surface plots (Figure 3). This is usually achieved by coupling a 
relatively non-polar capillary column in the first phase to a moderately polar or polar column in the 
second phase. Subsequently, the analytes are separated mainly by volatility in the first phase and by 
polarity in the second phase. The fast retention times on the second column are achieved by the 
transfer to a narrower and shorter column. The rapid modulations make the second dimension 
separation essentially isothermal. The mid-point peak widths are greatly reduced allowing for much 
improved peak capacity. Typical peak widths are -0.1 to 0.5 s. 62 The increased peak capacity 
means that compounds with very similar properties can be resolved chromatographically without 
changing the column phase. 
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Figure 2. Schematic of a twin stage cryo-modulator: (a) Three different analytes co-eluting on the 
first dimension column are trapped at the first stage by cold gas: b) a hot pulse (0, ) moves these 
molecules to the second stage as molecules trailing behind are trapped at the first stage by cold gas 
so molecules from the three analytes are now at stages I and 2; (c) the next hot pulse (A2) moves 
the molecules onto the more polar second dimension column and any polarity difference separates 
the three analytes. 
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Figure 3. GC x GC surface plot, total ion chromatogram (TIC), showing the orthogonal separation 
of a multi-component drug standard, provided by TrichoTech Ltd. The sample contained 
methamphetamines, cocaine group, opiates and benzodiazepines (4 - 10. tg/ml). A `fanning out' of 
compounds is observed with the less volatile and more polar drug types retained longer on the ls' 
and 2"d dimension columns. 
1.1.10 High-Throughput Drug Screening 
High-throughput multi-component screening procedures, in analytical toxicology, have the 
potential to screen thousands of drugs and poisons in one protocol. Maurer has described this 
approach as a systematic toxicological analysis (STA). 69 The coupling of GC x GC to high 
sensitivity mass spectrometers (MS) providing added mass spectral resolution means this technique 
has the potential to be a very powerful tool in forensic analysis. 
Simultaneous screening of various drug compounds and metabolites is advantageous 
because it reduces laboratory analysis time. It is clear that forensic analysis may often require the 
need to detect multiple drug compounds in a given sample e. g. it has been reported that heroin 
users also commonly abuse other drugs especially benzodiazepines such as diazepam (Valium®), 
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flunitrazepam (Rohypnol®) and bromazepam (Lexomil®) because of their powerful sedative 
effect. 53a0 The benzodiazepine group contains 235 drug compounds. The detection of minor opiates 
and impurities (e. g. papaverine and acetylcodeine) are used as a means to determine whether 
pharmaceutical or illicit heroin has been ingested. " Other commonly abused drug groups such as 
cocaine, barbiturates, amphetamines, methamphetamines, hallucinogenics (e. g. LSD), 
phencyclidine (PCP) and methadone are routinely screened but many other drugs including minor 
tranquilisers, anti-depressants, tryptamines and phenylethylamines may go unnoticed. 
Confirmation analysis of the various drug groups by GC-MS or LC-MS usually requires 
the application of various protocols. However, high-throughput chromatographic methods have 
been developed to screen a large range of drugs and metabolites and there is a great deal of interest 
in broader based analyses. Mass spectrometry methods have been described using scanning MS, 72 
accurate mass measurement, 73 and multiple SRM. 74 The enhanced chromatographic separation of 
GC x GC may eliminate some of the difficulties, associated with these techniques, caused by ion 
suppression and co-eluting compounds with similar mass spectra. 
Song et al. applied comprehensive GC x GC coupled to TOFMS to analyse 78 drug 
compounds spiked in whole blood and although the concentrations were relatively high (-I µg/ml), 
the study demonstrated one of the specific advantages of GC x GC-TOFMS compared with target 
analysis by SIM or SRM which is that prior knowledge of the suspected sample components is not 
necessarily required 65 TOFMS with rapid spectral acquisition (5500 spectra/s) is ideally suited to 
this application. GC x GC produces very sharp peaks typically -0.1 to 0.5 s (mid-point peak 
widths). Therefore, sufficient data points (10 - 20) across the peak can easily be obtained. The data 
processing software is essential for this application. Biological matrices may contain thousands of 
endogenous compounds or other contaminants. Peak recognition matches compounds contained 
within a library database. Peaks that almost co-elute are resolved by mass spectral deconvolution 
software which can extract a clean mass spectrum for each peak detected [Figure 4]. 
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Figure 4. GC x GC raw data (m/z ions 299 and 301) from a multi-component drug standard, 
provided by TrichoTech Ltd. Mass spectral deconvolution extracts clean mass spectra of two 
compounds which almost co-elute: dihydrocodeine (m/z 301) and codeine (m/z 299). The retention 
time difference between the apexing peaks is 0.03 s. 
1.1.11 (; as Chromatography-Combustion-Isotope Ratio Mass Spectrometry 
Gas Chromatography-Combustion-Isotope Ratio Mass Spectrometry (GC-C-IRMS) is a 
specialised technique that can determine stable isotopic ratios of the common elements (carbon, 
hydrogen, nitrogen and oxygen) in organic compounds. IRMS is designed to analyse pure gases 
mainly CO2, H,, N, and CO. Therefore, eluant from the GC is passed through a 2-stage catalytic 
interface, to convert organic molecules to C02, H2O and N2, prior to entering the MS. A magnetic 
sector MS with very high resolution can precisely determine small isotopic variations and give vital 
information as to the source of a particular compound. 75 Multiple Faraday Cup Detectors, first 
described by Alfred Nier, enable the simultaneous detection of the target ions and improve the 
stability. "'. " 
Stable isotopic ratios of the common elements ('3C/12C, 2W'H, 15N/14N and 180/160) found 
in organic molecules show very small variations due to the processes and feedstocks involved in 
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their production. The symbol S is a standard notation and refers to the isotopic shift against a 
known reference standard. Therefore, the carbon isotopic composition is expressed as S13C, 
measured per mil (or per thousand) (%o), as defined by the Urey equation [Equation 1.1]. 
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Equation 1.1 Urey equation 
The international primary reference standard used in stable carbon isotope analysis is the 
Pee Dee Belemnite (PDB) carbonate. 78 This reference is the zero point of S13C and has now been 
replaced by the Vienna Pee Dee Belemnite (VPDB). The most common process involving carbon 
is the biological process of photosynthesis, whereby atmospheric CO2 is taken up by plants and 
converted to simple carbohydrates. Atmospheric CO2 is slightly depleted at roughly -8 % relative 
to PDB 79 However, variability of &'3C in plants is affected by temperature and diffusion rates as 
well as variability in atmospheric CO2. Therefore, the 813C values of plants grown in sub-tropical 
regions (or C4 plants) are generally far less depleted in 13C (-17 to -9 %o) compared to plants grown 
in temperate climates (or C3 plants) (-20 to -32 %0). 
79.80 Therefore, dietary factors are likely to 
determine the 6'3C values of endogenous compounds found in humans. 
These isotopic differences have been recognised as a means to determine pseudo- 
endogenous drug use. This has received considerable interest in the field of sports drug testing to 
detect performance enhancing drugs such as testosterone and dehydroepiandrosterone (DHEA). 
These compounds occur naturally in the body and concentration levels vary considerably. 
However, it has been shown that a significant difference of 813C values (>6 %o) may exist between 
the synthetic and natural compounds. 8' Unlike conventional mass spectrometry, GC-C-IRMS can 
achieve the isotopic precision to measure these small variations. It has been postulated that S13C 
values may enable the discrimination of the pseudo-endogenous drug gamma-hydroxybutyric acid 
(GHB) which has been associated with DFC. 59 
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GC-C-IRMS is a 3-stage process consisting of the GC, the combustion interface and the 
MS. The analytes are separated by GC then the effluent is passed through a combustion oven 
(-'900°C), typically consisting of platinum, nickel and copper catalysts inside an alumina tube. 
Organic compounds are converted to C02, H2O and NO, if nitrogen is present. The eluant is then 
passed through a reduction oven (-. 600°C) containing a copper catalyst. This reduces NO,, to N2 
which is important to obtain a clear definition between the carbon and nitrogen isotopes; and 
removes the oxygen bleed. The eluant is then passed through a Nafion trap to remove the water 
prior to entering the MS. S13C isotopes are determined by measurement of the specific isotope 
masses of CO2 (m/z 44,45 and 46). The m/z 46 measurement is taken as a correction for the 
natural abundance of 180 and a further correction is made for the "O abundance present in m/z 45 
based on the known 180/170 ratios. The calculation is usually based on the Santrock algorithm. 
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1.2 Thesis Overview 
This project has been undertaken in PSSRI and the Department of Chemistry and 
Analytical Sciences at The Open University. There is not a tradition of drug testing in either 
department and all of the work presented in this thesis has been developed within the time frame of 
the project. 
The remit was to apply gas chromatographic techniques to provide improved methodology 
in drug detection. The extraction methods and instrument operating conditions have been 
developed by a mixture of experience, critical review work of published literature and a degree of 
trial and error. 
Chapter 2 outlines the experimental methods, the chemicals and reagents, the 
instrumentation, and the preparative procedures undertaken for this thesis. 
Chapter 3 deals with the issues involved in correctly identifying drugs in complex 
matrices. Opiates and benzodiazepines are commonly abused `street drugs' but are also prescribed 
medication for a range of disorders including drug dependency. 83 A method is described which can 
discriminate these drugs from the sample matrix using comprehensive two dimensional gas 
chromatography (GC x GC) coupled with time of flight mass spectrometry (TOFMS). The reason 
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for choosing these two drug groups was because co-dependence on these drug types is well 
documented and the compounds are quite similar in terms of their volatility and polarity. 
To our knowledge, a comprehensive GC x GC screening method for these drug types is not 
available. The benefit would be that other non-specified compounds may also be identified from 
the sample matrix. 
The benzodiazepines were supplied pre-spiked in lyophilised human serum at quantitated 
concentrations. The opiates were supplied as a non-quantitated mixture. The aim was to evaluate 
the selectivity and sensitivity of the GC-MS system. We have developed a method to screen these 
compounds in serum which has been accepted for publication which can be found in Appendix 5.84 
Chapter 4 is a blind analysis of extracts from various hair samples which contained 
'unknown' drug types. These samples were kindly provided by the Institute of Environmental 
Science and Research Limited (ESR) (Porirua, New Zealand). This study is a short postscript to 
Chapter 3 and is an evaluation of how GC x GC-TOFMS analysis may be applied to actual sample 
analysis. 
Chapter 5 deals with the pseudo endogenous drug gamma-hydroxybutyric acid (GHB) and 
detection using gas chromatography-combustion-isotope ratio mass spectrometry (GC-C-IRMS). 
The aim has been to explore the potential of GC-C-IRMS to differentiate endogenous from 
exogenous GHB by precise determination of the S13C values. GHB is produced naturally in the 
body by the metabolism of the neurotransmitter gamma-aminobutyric acid (GABA). 85 However, it 
can also be produced by bacterial decay 96 and is found in trace levels in many foodstuffs and 
beverages along with its pre-cursor, gamma-butyrolactone (GBL), which is rapidly metabolised to 
GHB in the body .' It is this natural abundance that places a relatively high cut off value on the 
positive identification of the synthetic drug compound. When taken at therapeutic levels it is 
unlikely to be detectable beyond 12 hours in urine due to its rapid metabolism . 
98 813C 
measurements, potentially, open a window beyond this by exploiting the inherent isotopic make up 
of the drug which may differ from the endogenous compound. A series of analyses were performed 
to evaluate the precision and sensitivity. Urine was spiked with three different synthetic GHB 
reference standards and the isotopic values compared. The results were presented to The 
International Association of Forensic Toxicologists (TIAFT), annual conference of 2007.89 
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Chapter 6 explores novel approaches for the clean-up of GHB by affinity chromatography. 
We identified the compound, tetrahydro-5-oxo-3-furanyl acetic acid (furanyl acetic acid), as a 
potential pre-cursor to the development of an immunising antigen. This study comprises the first 
step needed to raise antibodies with specific binding sites to GHB. At present an immunoassay 
method is not available for the detection of GHB. 90 Furanyl acetic acid is not readily available; 
however, a synthetic procedure, described by Walraven and Pandit, 91 was used successfully. Clean- 
up methods have been described using immunoaffinity chromatography for the extraction of 
specific bio-markers in biological matrices 92 Selective extraction of GHB should greatly improve 
the sensitivity which can be achieved by GC-C-IRMS. 
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Experimental 
2.0 The Detection of Various Opiates and Benzodiazepines by Comprehensive Two- 
Dimensional Gas Chromatography-Time of Flight Mass Spectrometry 
2.0.1 Chemicals and Reagents 
All reagents were analytical grade. Benzodiazepines (50 - 800 ng/ml) in lyophilised human 
serum and the stock standard solutions of flunitrazepam (1 mg/ml), flunitrazepam-D7 (100 pg/ml), 
7-aminoflunitrazepam (7-amino-FN) (1 mg/ml) and 7-amino-FN-D7 (100 pg/ml), in methanol, 
were purchased from LGC Promochem. 
The street heroin mixture (20 mg heroin; 30 mg minor components) was purchased from 
Lipomed AG under import licence (8/1/2) issued by the Home Office. The drug was held in 
accordance with Schedule 1: Licence to Possess issued on 14' December 2006 by the Home 
Office. 
N-methyl-N-(tert-butyldimethyl)trifluoracetamide (MTBSTFA), tert- 
butyldimethychlorosilane (TBMCS), bis-N, O- (trimethylsilyl)trifluoroacetamide: 
trimethylchlorosilane (BSTFA: TMCS (99: 1)), heptafluorobutyric anhydride (HFBA) and ethyl 
acetate were supplied by Sigma-Aldrich. 
Methanol, dichloromethane, hexane and acetonitrile were supplied by Fisher Scientific. 
De-ionised water was obtained from a Synergy 185 purification system (Millipore). 
Blank human serum was kindly supplied from stock by research staff in Chemistry and 
Analytical Sciences, The Open University. 
2.0.2 Apparatus and Equipment 
Solid-phase extraction (SPE) was performed using a 12-port vacuum manifold (Sigma- 
Aldrich). C18 (EC) and C4 (EC) (3 ml, 500 mg) SPE cartridges (United Chemical Technologies) 
were purchased from Fluorochem Ltd. Centrifugation was performed using a Biofuge® Heraeus 
Primo R (Thermo Fisher Scientific). Centrifugal evaporation was performed using an Eppendorf 
Concentrator Plus. 
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2.03 Standard Solutions 
Street heroin mixture (6.25 mg; containing 40% heroin, 8% 6-MAM, 4% morphine, 4% 
codeine, 8% acetylcodeine, 8% narcotine, 4% papaverine, 12% caffeine, 12% paracetamol (w/w)) 
was dissolved in methanol in a 25 ml volumetric flask and made up to the mark. The total 
concentration was 250 µg/m1. The component concentrations were 100 µg/m1 heroin, 20 µg/m16- 
MAM, 10 µg/m1 morphine, 10 µg/ml codeine, 20 µg/ml acetylcodeine, 20 µg/ml narcotine, 10 
µg/m1 papaverine, 30 µg/ml caffeine and 30 µg/ml paracetamol. After use the flask was stored at 
-5°C. 
The stock solutions of flunitrazepam and 7-amino-FN (1 mg/ml methanolic) were 
transferred to separate 2 ml amber autosampler vials. Serial dilutions were prepared from these 
stock solutions, in methanol, at 100,10 and 1 pg/ml. Internal standards (100 tg/ml), flunitrazepam- 
D7 and 7-amino-FN-D7, were transferred to 2 ml amber autosampler vials. All stock standard 
solutions were stored at -18°C. 
2.0.4 Sample Preparation 
Lyophilised human serum containing benzodiazepines was reconstituted with 2.5 ml 
deionised water and mixed by gentle inversion to give quantitated concentrations of 600 ng/ml 
diazepam, 800 ng/ml nordiazepam, 800 ng/ml temazepam, 600 ng/ml oxazepam, 400 ng/ml 
bromazepam, 100 ng/ml lorazepam, 50 ng/ml flunitrazepam and 50 ng/ml 7-amino-FN. 
A volume of 0.5 ml serum was transferred to a 1.5 ml Eppendorf tube and spiked with 10 
µl street heroin mixture (250 µg/ml) to give concentrations of 2,000 ng/ml heroin, 400 ng/ml 6- 
MAM, 200 ng/ml morphine, 200 ng/ml codeine, 400 ng/ml acetylcodeine, 400 ng/ml narcotine, 
200 ng/ml papaverine, 600 ng/ml caffeine and 600 ng/ml paracetamol. Then 5 µl of each internal 
standard (100 µg/ml), flunitrazepam-D7 and 7-amino-FN-D7, was added to the sample and the 
mixture briefly vortexed. 
The sample clean-up was as described in Section 2.0.5 and the derivatisation procedures as 
described in Section 2.0.6. 
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2.0.5 SPE Clean-up 
C18 (EC) or C4 (EC) cartridges were conditioned, sequentially, with 3 ml methanol and 3 
ml water. The sample (prepared on the same day) was loaded onto the cartridge and the eluant 
removed to waste. The cartridge was left to stand for 10 min then washed with 3 ml water and dried 
under vacuum for 10 min. The cartridge was then washed with 3 ml hexane and dried under 
vacuum for 5 min. The analytes were eluted with 6 ml ethyl acetate: methanol (8: 2) and collected 
in 70 mm glass tubes. The solvent was evaporated to dryness on a centrifugal evaporator. 
2.0.6 Derivatisation 
2.0.6.1 MTBSTFA 
Acetonitrile (50 µl; containing 1% TBMCS) and MTBSTFA (50 µl) were added to the 
dried residue and heated on a dry block (90°C, 1 hour). After cooling the excess solvent was 
evaporated to dryness under a gentle stream of nitrogen (40°C). The dried residue was reconstituted 
in 200 gl hexane: dichloromethane (1: 1) and 1 gl aliquots were injected into the GC system (5 µl 
for PTV injections). 
2.0.6.2 BSTFA 
BSTFA (50 t1; containing 1% TMCS) was added to the dried residue and heated on a dry 
block (60°C, 45 min). The rest of the procedure was as described in Section 2.0.6.1 except the 
excess solvent was removed, under nitrogen, at room temperature. 
2.0.6.3 HFBA 
Hexane: dichloromethane (1: 1) (180 µ1) and HFBA (20 µl) were added to the dried residue. 
The vial was capped and left overnight at room temperature. 1 µl aliquots were injected into the 
GC system. 
2.0.6.4 No derivatisation 
The dried residue was reconstituted in 200 µ1 hexane: dichloromethane (1: 1) and 1 µl 
aliquots were injected into the GC system. 
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2.0.7 Calibration Standards 
Standards of flunitrazepam and 7-amino-FN were prepared in drug-free serum at 
concentrations of 5,20,50,100,1000 ng/ml. The internal standards, flunitrazepam-D7 and 7- 
amino-FN-D7, were added to each standard at a concentration of 1000 ng/ml. The sample clean-up 
and derivatisation by MTBSTFA were as previously described in Sections 2.0.5 and 2.0.6.1, 
respectively. The data was used to prepare a 5-point calibration curve. 
2.0.8 Recovery Standards 
Recovery standards were prepared in methanol (0.5 ml) and drug-free serum (0.5 ml) for 
the street heroin mixture (2000 ng/ml heroin, 400 ng/m16-MAM, 200 ng/ml morphine, 200 ng/ml 
codeine, 400 ng/ml acetylcodeine, 400 ng/ml narcotine, 200 ng/ml papaverine, 600 ng/ml caffeine 
and 600 ng/ml paracetamol), and flunitrazepam and 7-amino-FN (1000 ng/ml). The standards in 
methanol were derivatised by MTBSTFA as previously described in Section 2.0.6.1 without clean- 
up. The standards in serum were extracted and derivatised by MTBSTFA, as previously described 
in Sections 2.0.5 and 2.0.6.1, respectively. The dried residues were reconstituted in 500 µl hexane: 
dichloromethane (1: 1) and 1 µl aliquots were injected into the GC system. This analysis was 
performed using an ion trap GC-MS (Thermo). 
2.0.9 Liquid-liquid Extraction (LLE) 
The sample was prepared as described in Section 2.0.4. The spiked serum sample (0.5 ml) 
was placed in a 15 ml centrifuge tube. Ethyl acetate (3 ml) was added and the mixture briefly 
vortexed. The tube was centrifuged (10 min; 2500 g). The upper layer was transferred to a glass 
vial and evaporated to dryness using a centrifugal evaporator. The dried residue was reconstituted 
in acetonitrile (50 µl; containing 1% TBMCS) and MTBSTFA (50 µl), and heated on a dry block 
(90°C, 15 min). After cooling the mixture, hexane (100 µl) was added and transferred to an amber 
autosampler vial and 191 aliquots were injected into the GC system. 
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2.0.10 Summary of Applications 
2.0.10.1 GC x GC-TOFMS analysis 
The analysis for this study was performed using a Leco Pegasus® N time-of-flight (TOF) 
mass spectrometer incorporating an Agilent 6890 GC modified to house a secondary oven and 
twin stage cryo-modulator (Leco Quad-Jet). Cryo-cooling was enabled by nitrogen gas passed 
through a liquid nitrogen dewar. The GC was equipped with Agilent splitlsplitless and CIS 4 PTV 
(Gerstel) injection ports and a CombiPAL autosampler (CTC). The TOF mass spectrometer 
provided unit-resolution in the mass range 5- 1000 m/z. The separation was performed using a 
J&W DB-5ms (30 mx0.25 mm x 0.25 gm; Agilent Technologies)* capillary column in the first 
phase and SGE BPX50 (2 mx0.1 mm x 0.1 gm; SGE) in the second phase. The carrier gas used 
was helium (Grade 5.5; 1.0 ml/min). The modulation time was 6s with 0.4 s hot pulses. The 
injection temperature was held at 250° C with a1 tl splitless injection (1 min). The purge flow was 
30 ml/min. The main oven temperature programme was 50° (1 min), 15° C/min to 230° C (1 min), 
5° C/min to 330° C (5 min). The modulator temperature was kept 30° C higher and the secondary 
oven 15° C higher than the main oven throughout the entire run. The TOF mass spectrometer was 
operated at 50 spectra/s acquisition rate in the mass range: m/z 40 - 650 (EI). A solvent delay of 10' 
min was used. The ion source was held at 230° C and the ionisation energy set at 70 eV. The MS 
was calibrated against m/z ions 69,131,219 and 502 using perfluorotributylamine (PFTBA). The 
automated data processing and mass spectral deconvolution software was performed with Leco 
ChromaToF® software. 
* Analyses were also run with a J&W DB-1ms (30 mx0.25 mm x 0.25 gm) in the first phase. The 
second dimension column configuration was unchanged. 
2.0.10.2 1D-GC Analysis 
The conditions were as described in Section 2.0.10.1 except without the second-dimension 
column. The modulator and secondary oven were disabled. The TOFMS was operated at 6 
spectra/s acquisition rate in the mass range: m/z 40 - 650. 
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2.0.10.3 PTV Injection (Solvent Vent) 
The injection temperature was held at 40° C (1 min) with a5 µl injection. The solvent vent 
time was 30 s at 100 ml/min. Temperature ramp rate was 40° C (1 min), 5°C/s to 290° C (10 min). 
The purge valve was closed for 2 min. The purge flow was 30 ml/min. The main oven temperature 
programme was 40° (3 min), 15° C/min to 230° C (1 min), 50 C/min to 330° C (5 min). The 
modulator temperature was kept 30° C higher and the secondary oven 15° C higher than the main 
oven throughout the entire run. The rest of the conditions were as described in Section 2.0.10.1. 
2.0.11 GC-MS (Ion Trap) Conditions 
The analysis was performed using a Thermo Focus GC/ Polaris Q MS equipped with an 
AS 3000 autosampler. The separation was performed using a Varian VF-5ms (15 mx0.25 mm x 
0.25 µm). The carrier gas used was helium (Grade 4.5; 1.1 ml/min). The injection temperature was 
held at 250° C with a1 t1 splitless (1 min) injection. The purge flow was 50 mUmin. The oven 
temperature programme was 50° (1 min), 20° C/min to 230° C (1 min), 10° C/min to 320° C (2 
min). The mass spectrometer was operated in scan mode m/z 40-650 (EI). The ion source was held 
at 230° C and the ionisation energy was 70 eV. The mass spectrometer was calibrated against m/z 
ions 69,131,264,414 and 502 using PFTBA. The data was processed with Thermo Excalibur@ 
software. 
2.1 An Evaluation of GC x GC-TOFMS to the Application of Testing Drugs of Abuse in 
Hair 
2.1.1 Sample Preparation 
Dried samples containing organic extracts from hair, provided by ESR, were derivatised 
with MTBSTFA as described in Section 2.0.6.1. 
2.1.2 GC x GC-TOFMS Analysis 
The samples were run using splitless and PTV injection modes as previously described in 
Section 2.0.10. 
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2.2 Stable Isotopes (S13C): A Proposed Means of Identifying the Source of Gamma- 
hydroxybutyric Acid (GHB) 
2.2.1 Chemicals and Reagents 
All reagents were analytical grade. Gamma-hydroxybutyric acid (GHB) (50 mg sodium 
salt) (NMIA reference; Lot 03-D-04) was purchased from LGC Promochem. Gamma- 
butyrolactone (GBL) (Fluka; Lot 1275167), gamma-valerolactone (GVL) (Fluka; Lot 1211567), 
1,4-butanediol (Sigma-Aldrich; Lot S29835-016), BSTFA: TMCS (99: 1) (Supelco; Lot LB27758) 
MTBSTFA (Acros; Lot A018305501), tert-butylmethylether (TBME), perchloric acid, sulphuric 
acid, copper chromite catalyst, potassium hydroxide (KOH) and sodium hydroxide (NaOH) were 
supplied by Sigma-Aldrich. 
Methanol, dichloromethane, hexane and acetone were supplied by Fisher Scientific. 
De-ionised water was obtained from a Synergy 185 purification system. NMR grade 
deuterated solvents were supplied by Cambridge Isotope Laboratories. 
2.2.2 Apparatus and Equipment 
Solid-phase extraction (SPE) was performed using a vacuum manifold. CLEAN SCREEN, 
GHB® SPE cartridges (3 ml; 500 mg) (United Chemical Technologies) were purchased from 
Fluorochem Ltd. Tin capsules (8 x5 mm) were supplied by Elemental Microanalysis Ltd. 
21.3 GHB Synthetic Standards 
2.2.3.1 Preparation of GHB Ref #1 by Base Hydrolysis of GBL 
NaOH (2 g) was dissolved in 100 ml deionised water in a 500 ml round bottomed flask. 
GBL (4.3 g) was added slowly, whilst stirring. The mixture was left stirring at room temperature 
overnight (at least 12 hours). The water was removed by a rotary evaporator with a liquid nitroge* 
trap. The solid residue was washed with acetone (x2) and the excess liquid decanted to waste. T*, 
flask was placed on a high vacuum apparatus for I hour and 5.50 g white crystals were obtained 
(87% yield). The identity and purity was confirmed by NMR (Appendix 1). 1H NMR (CD30D): 
1.81 (m, 2H, CpHA 2.23 (t, J=7.1 Hz, 2H, C,, -H2), 3.56 (t, J=6.6 Hz, 2H, CrH2)- 
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2.2.3.2 Preparation of Gamma-Hydroxyvaleric Acid (GHV; Internal Standard) by Base 
Hydrolysis of GVL 
NaOH (2 g) was dissolved in of 100 ml deionised water in a 500 ml round bottomed flask. 
GVL (5.0 g) was added slowly, whilst stirring. The rest of the procedure was as described in 
Section 2.2.3.1. White crystals (6.61 g) were obtained (94% yield). The identity and purity was 
confirmed by NMR (Appendix 1). 'H NMR (CD3OD): 1.14 (d, J=6.2 Hz, 3H, CH3), 1.69 (q, 2H, 
Cß-H2), 2.25 (t, 2H, J=7 Hz, Ca-H2), 3.73 (m, 1H, Cy-H). 
2.2.33 GHB Ref #2 - National Measurements Institute of Australia (NMIA) standard 
GHB (50 mg; sodium salt) was supplied with a certificate of analysis. No further 
preparation was required. 
2.2.3.4 Preparation of GHB Ref#3 by Dehydrogenation of 1,4-Butanediol to GBL and 
Subsequent Base Hydrolysis to GHB. 
Copper chromite catalyst (0.4 g) and KOH (0.02 g) were added to 1,4-butanediol (9 g) and 
held at reflux for 3 hours. The mixture was left to cool and vacuum filtered. The crude mixture was 
distilled under reduced pressure to yield 6.2 g of the clear viscous liquid (73% yield). The identity 
and purity was confirmed by NMR and IR (Appendix 1). IR (DCM): 1773 cm' (C = 0, lactone). 
1H NMR (CDC13): 2.23 (m, 2H, C4-H2), 2.46 (t, J=7.1 Hz, 2H, C3-H2)9 4.31 (t, J=6.1 Hz, 2H, C5- 
H2). This liquid (4.3 g) was then converted to GHB as previously described in Section 2.2.3.1. 
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2.2.4 Stock Standards 
2.2.4.1 GHB Stock Standard (10 mg/ml and 1 mg/ml) 
GHB (0.61 g; sodium salt) equivalent to 0.5 g acid was dissolved in methanol in a 50 tail 
volumetric flask and made up to the mark. A 1/10 dilution in methanol was made up to give a 
working standard (1 mg/ml). 
2.2.4.2 GHV Stock Internal Standard (10 mg/ml and 1 mg/ml) 
GHV (0.59 g; sodium salt) equivalent to 0.5 g acid was dissolved in methanol in a 50 ml 
volumetric flask and made up to the mark. A 1/10 dilution in methanol was made up to give a 
working standard (1 mg/ml). 
2.2.4.3 GBL Stock Standard (1 mg/nd) 
GBL (50 mg) was added to TBME in a 50 ml volumetric flask and made up to the mark. 
2.2.4.4 GVL stock standard (1 mg/ml) 
GVL (50 mg) was added to TBME in a 50 ml volumetric flask and made up to the mark. 
2.2.5 Sample Preparation 
2.2.5.1 Spiked Urine (10 pg/ml) 
GHB (10 µl; 1 mg/ml methanolic) and GHV (10 91; 1 mg/ml methanolic) were added to 
volume of 1 ml urine (collected on the day of analysis with ethical approval from the Human 
Participants and Materials Ethics Committee (HPMEC), The Open University) to give a 
concentration of 10 gg/ml. The sample was centrifuged (10 min; 3000 g) and the supernatant 
transferred to 1.5 ml Eppendorf tube. 
The sample clean-up was as described in Section 2.2.6 and derivatisation as described in 
Section 2.2.7. 
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2.2.5.2 Standard Preparation (10 µg/m1) 
GHB (10 µl; 1 mg/ml methanolic) and I GHV (10 µl; 1 mg/ml methanolic) were added to a 
volume of 1 ml deionised water to give a concentration of 10 µg/ml. The sample was evaporated to 
dryness using a centrifuge evaporator (-1 mbar). 
The samples were derivatised as described in Section 2.2.7. 
2.2.53 Solid samples for Elemental analysis 
3x solid GHB (sodium salt) samples (756 - 1344 µg) and 3x solid GHV (sodium salt) 
samples (672 - 1195 µg) were weighed into tin capsules (8 x5 mm). The weighed amounts were 
equivalent to -320 tg carbon. 
2.2.6 SPE Clean-up 
CLEAN SCREEN GHB SPE cartridges (x4) were conditioned sequentially with 3 ml 
methanol and 3 ml deionised water. Urine samples (3 x1 ml; spiked with 10 gg/ml GHB and 10 
µg/ml GHV) and 1 urine sample (1 x1 ml; spiked with 10 gg/ml GHV internal standard) were 
added to the cartridges. Methanol (2 ml) was added. The load and elution solvent were collected in 
70 mm glass tubes. The eluant was evaporated to dryness using a centrifugal evaporator (-1 mbar). 
The dried residue was reconstituted with 0.5 ml methanol and transferred to an Eppendorf tube. 
The samples were placed in a micro-centrifuge (6000 RPM, 10 min) and the supernatant 
transferred to a2 ml autosampler vial. The solution was evaporated to dryness using a centrifugal 
evaporator (-1 mbar). 
2.2.7 Derivatisation 
The dried residue was reconstituted with either BSTFA (50 µl; containing 1% TMCS) and 
heated (60°C, 30 min), or MTBSTFA (50 µl) and heated (90°C, 1 hour) on a dry block. The 
solution was allowed to cool then the excess solvent was evaporated under a gentle stream of 
nitrogen at room temperature (BSTFA) or at 50°C (MTBSTFA). The dried residue was 
reconstituted in 200 µl hexane and 1 µl aliquots were injected into the ion trap GC-MS or GC-C- 
IRMS system. 
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2.2.8 Calibration Standards 
Standard solutions of GHB were prepared in 1 ml de-ionised water at 0.1,0.5,1,2,5,10, 
50 µg/ml. The internal standard, GHV, was added to each standard at a concentration of 10 µg/ml. 
The standard solutions were evaporated to dryness using a centrifugal evaporator and derivatised 
with BSTFA: TMCS (99: 1) as described in Section 2.2.7. 
2.2.9 Recovery Standards (50 µg/ml) 
GHB (50 µl; 1 mg/ml methanolic) were added to a volume of 1 ml deionised water or 1 ml 
urine to give a concentration of 50 µg/ml. The standards in water were derivatised as previously 
described in Section 2.2.7. The standards in urine were extracted as previously described in Section 
2.2.6 and derivatised as described in Section 2.2.7. 
2.2.10 Intra-Molecular Conversion to GBL (GC-MS) 
A volume of 1 ml of urine was spiked with GHB and GHV (50 µg/m1), and 1 ml perchloric 
acid (6%) was added, in a centrifuge tube. The mixture was centrifuged (4000 g; 10 min). The 
supernatant was transferred to a test tube and 0.2 ml sulphuric acid (5M) was added. The sample 
was heated at 80°C for 45 min. After cooling 2 ml NaOH (2M) was added. Further increments of 
NaOH (100 µl) were added to achieve a pH -4. The analytes were extracted into 2 ml TBME 
by 
brief vortex then centrifuge (2500 g; 10 min). The organic layer was transferred to a2 ml 
autosampler vial and evaporated down to -200 gl under a gentle stream of nitrogen at room 
temperature. 
Standards of GBL and GVL (50 µg/ml) were prepared in 200 µl TBME. 1 µl aliquots were 
injected into the GC-MS (ion trap and quadrupole) or GC-C-IRMS system. 
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2.2.11 Summary of Applications 
2.2.11.1 GC-C-IRMS 
The analysis was performed using a Thermo Finnigan Trace Ultra GC and Combustion in 
interface coupled to a MAT 253 IRMS which incorporates a continuous-flow gas introduction 
system. The separation was performed using a J&W DB-5 (30 mx0.25 mm x 0.25 p. m; Agilent 
Technologies) capillary GC column. The carrier gas used was helium (Grade 5.5; 1.1 ml/min). The 
injection temperature was held at 2500 C with a1 µl splitless (2 min) injection. The purge flow was 
50 n-/min. The oven temperature programme gradient was 50°C (1 min), 5°/min to 150°C (1 min), 
25°/min to 320°C (2 min). The backflush mode was operated for 10 min. The combustion and 
reduction oven temperatures were held at 900°C and 507°C, respectively. Oxygen (Grade 5.8) was 
bled into the combustion interface containing platinum, nickel and copper catalysts. The reduction 
oven contained a copper catalyst. The water generated in the combustion interface was removed by 
a Nafion® trap. CO2 reference gas (-35.1%o VPDB; secondary reference standard calibrated to a 
NIST 19 standard) was employed in 3 pulses. The reference standard was taken from the 3rd pulse 
The MS was operated in EI mode (230°C) and the ionisation energy was 150 eV. The target mass 
ions were m/z 44,45 and 46. The data was processed with Thermo IsoDat software. 
2.2.11.2 GC-MS (Ion Trap) 
The analysis was performed using a Thermo Focus GC/ Polaris Q MS equipped with an 
AS3000 autosampler. The separation was performed using a Restek Rxi-5ms (30 mx0.25 mm x 
0.25 µm). The carrier gas used was helium (Grade 4.5; 1.0 n-/min). The injection temperature was 
held at 2500 C with a1 µl splitless (1 min) injection. The purge flow was 50 ml/min. The oven 
temperature programme for the analysis of GHB di-TMS was 50° (1 min), 100 C/min to 150° C (I 
min), 25° C/min to 320° C (2 min). The oven temperature programme for the analysis of GBL was 
50° (1 min), 5° C/min to 120° C (1 min), 25° C/min to 320° C (2 min). The mass spectrometer was 
operated in scan mode m/z 40-550 (EI). The ion source was held at 230° C and the ionisation 
energy was 70 eV. The mass spectrometer was calibrated against m/z ions 69,131,264,414 and 
502 using PFTBA. The data was processed with Thermo Excalibur® software. 
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2.2.11.3 GC-MS (Quadrupole) 
The analysis was performed using an Agilent 6890 GC/5973 MS equipped with a 7863' 
Series autosampler. The separation was performed using a J&W DB-5ms (30 mx0.25 mm x 
0.25 µm; Agilent Technologies). The carrier gas used was helium (Grade 4.5; 1.0 ml/min). The 
injection temperature was held at 250° C with a1 tl splitless (1 min) injection. The purge flow was 
50 ml/min. The oven temperature programme was 40° (1 min), 5° C/min to 120° C (1 min), 25° 
C/min to 3 10° C (2 min). The MS was operated in scan mode m/z 40-550 (EI). The ion source was 
held at 230° C and the ionisation energy was 70 eV. The data was processed with Agilent 
Chemstation software. 
2.2.11.4 Elemental Analyser-IRMS 
The analysis was performed using a Europa ANCA Elemental Analyser coupled to a 
Europa GEO 20-20 IRMS with continuous-flow gas introduction system (Sercon Ltd. ). The 
samples were introduced to a ceramic furnace at 1000°C. A pulse of oxygen (Grade 5.8) was 
employed. Helium carrier gas (Grade 5.0; 15 n-/min) was employed and the gas stream was passed 
through a chromium oxide catalyst, held at 1000°C; and a reduction oven, containing copper, held 
at 638°C. Any water generated was removed with anhydrous magnesium perchlorate. The gas 
stream was then passed through a GC column (0.5 mx 12 mm outer diameter; Packed Carbosieve 
G 60-80 column). The target mass ions were m/z 44,45 and 46. The S13C values were calculated 
against a CANENOU2 reference standard calibrated to IAEASUCN2. 
40 
23 Preparation of an Immunising Antigen for Raising an Antibody Specific to the 
Structure of Gamma-Hydroxybutyric Acid (GHB) 
23.1 Chemicals and Reagents 
All reagents were analytical grade. Furfural (2-furaldehyde), eosin Y, sodium hydride 
(NaH) in mineral oil (60%), diethylmalonate, magnesium sulphate (MgS04), hydrobromic acid 
(HBr) (30% in acetic acid), active charcoal, sodium borohydride (NaBH4), hydrochloric acid (HCI), 
potassium hydroxide (KOH) and sodium hydroxide (NaOH) were supplied by Sigma-Aldrich. 
Methanol, dichloromethane, hexane, ethyl acetate, diethyl ether (ether) and glacial acetic acid were 
supplied by Fisher Scientific. Ethanol (100% absolute) was supplied by Hayman Distillers. De- 
ionised water was obtained from a Synergy 185 purification system (Millipore). NMR grade 
deuterated solvents were supplied by Cambridge Isotope Laboratories. 
231 Apparatus and Equipment 
Photo-oxidation was performed using a mercury arc vapour lamp with photo-irradiation 
vessel (1.5 Q. Oxygen supply was attached to the vessel. 
2.3.3 Method 
O 
32 p3 
54 
Et-0 Et-. p CO2Et 
5-etboxy-2 (511)-furanone EtO2C 
tans diethyl 5-ethoxytetrahydro-2-oxo-4-furanylmalonate 
O 
O30 
2 5\)244 HH t0 3 OH 0 
6 
0a0 
cis dihydrofuro[4,5][uran-2,2'-dione to hydro-2-oxo-4-furanyl acetic acid 
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2.33.1 Preparation of 5-ethoxy-2 (5H)-furanone 
Furfural (75 g) was distilled in the presence of argon under vacuum with a liquid nitrogen 
trap. The distillate was collected in three flasks at constant temperature (36-38'C) as a colourless 
solution. The first flask was discarded. The eluants of the other two flasks were combined (58.0 g, 
77%). IR (DCM): 1676,1697 cm-1 (C = 0, aldehyde) 
Distilled furfural, (53 g) and eosin Y (1.5 g) were added to 1500 ml ethanol (100%). The 
solution was irradiated by mercury arc UV light source while 02 was bubbled through the solution. 
The reaction was monitored by IR spectroscopy. The reaction was stopped after the disappearance 
of the aldehyde absorption. The solvent was evaporated on a rotary evaporator and distilled under 
reduced pressure to give S-ethoxy-2 (SH)-furanone as a clear oil (33.30 g, 48%). The identity and 
purity was confirmed by NMR and IR (Appendix 2). IR (DCM): 1762,1796 cm-1 (C = 0, lactone). 
1H NMR (CDC13): 1.23 (t, J=7 Hz, 3H, CHO, 3.71 (m, I H, CH2), 3.90 (m, I H, CH2)t 5.87 (t, 1 H, 
C5-H, J=I Hz), 6.15 (dd, J4,3 =5 Hz, J4,5 =I Hz, IH, C4-H), 7.14 (dd, J3,4 =5 Hz, J3,5 = lHz, 1H, 
C3-H). 
2.3.3.2 Preparation of trans diethyl 5-ethoxytetrahydro-2-oxo-4-furanylmalonate 
NaH (230 mg) dispersion in mineral oil (60%) was placed in a 500 ml flask and washed 
with hexane. The hexane layer was removed to waste. The flask was placed in an argon atmosphere 
at room temperature and - 150 ml dried THF added with stirring. Diethyl malonate (4.7 g) was 
added dropwise and the dropping funnel washed with a further -50 ml THF and added to the flasL 
The mixture was cooled to YC and 5-ethoxy-2 (5H)-furanone (3.75 g) was added and left to stir 
overnight. The THF was evaporated under reduced pressure to leave a brown oily residue. Then 
100 ml ether and 100 ml water was added to the residue. Acetic acid was added dropwise, until the 
solution was clear. The mixture was added to a separating funnel and thoroughly mixed. The 
aqueous layer was removed and extracted again in ether (100 ml). The combined ether layers were 
dried over magnesium sulphate and filtered. The ether was evaporated under reduced pressure to 
give 8.5 g crude trans diethyl 5-etho3Wtetrahydro-2-oxo-4-furanylnmlonate slightly discoloured 
clear oil. The identity and purity was confirmed by NMR and IR (Appendix 2). IR (DCM): 1785 
cm-1 (C = 0, lactone), 1732 cm-1 (C = 0, ester). 
1H NMR (CDC13): 1.23 (t, J=7 Hz, 3H, CH3)11-29 
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(t, J=7.1 Hz, 6H, CH3), 2.43 (dd, J3,3=9.1 Hz, J3,4= 3.7 Hz, 1H, C3-H), 2.91(d, J3,3 = 9.3 Hz, 1H, 
C3-H), 2.98 (m, 1H, C4-H), 3.50 (d, Jaa = 7.3 Hz, 1H, Ca-H), 3.60 (q, 1H, CHZ), 3.86 (q, 1H, CH2), 
4.24 (q, 4H, CH2), 5.44 (d, J5,4 = 2.4 Hz, 1H, C5-H). 
233.3 Preparation of cis dihydrofuro[4,5]furan-2,2'-dione 
Crude trans diethyl5-ethoxytetrahydro-2-oxo-4-furanylmalonate (4.0 g) was added to 
HBr (40 ml; 30% in acetic acid) and water (2.5 ml). The flask was placed in an oil bath and 
refluxed with stirring for 72 hours. The acetic acid was removed on a rotary evaporator with a 
liquid nitrogen trap to give a brown oily residue. The residue was reconstituted in 100 ml of ethyl 
acetate and dissolved by applying heat to the flask. When fully dissolved active charcoal was added 
and the solvent brought to boiling point. The solution was filtered and a further 100 ml ethyl 
acetate added and filtered. The excess solvent was removed under reduced pressure leaving dirty 
white crystals. This was recrystallised in ethyl acetate to give white needle crystals (1.2 g). The 
identity and purity was confirmed by melting point, NMR and IR (Appendix 2). Mpt. 1350 C. IR 
(KBr): 1734,1794 cm-1 (C = 0, lactone). 1H NMR (DMSO-D6): 2.61 (dd, J3,30.31 = 18 Hz, J3(31.4 = 
4.5 Hz, 2H, C301-H), 2.88 (dd, J3,3(3.31 = 18 HZ, 4314 = 10.2 Hz, 2H, C3(3 I-H), 3.43 (m, I H, C4-H), 
6.32 (d, J5,4 = 6.3,1 H, Cs-H). 
2.3.3.4 Preparation of tetrahydro-2-oxo-4-furanyl acetic acid (furanyl acetic acid) 
cis Dihydrofuro[4,5]furan-2,2'-dione (1 g) was dissolved in 30 ml KOH (1M) and then 
placed in an ice bath. NaBH4 (0.9 g) was added to the cold mixture in small portions over a period 
of 10 min. The mixture was held at reflux for 4 hours. The flask was then cooled in ice and HCI 
(conc. ) was added dropwise to lower the pH to - 1. The flask was then removed from the ice and 
left to warm up to room temperature. The mixture was extracted with ethyl acetate (2 x 150 ml), 
dried over MgSO4 and filtered using fluted filter paper. The solvent was evaporated under reduced 
pressure. When the solvent was almost evaporated i. e. a precipitate began to appear, the solvent 
was transferred to a small 50 ml flask and evaporated under reduced pressure to dryness. The crude 
compound was recrystallised with a few ml of ethyl acetate by leaving in the freezer overnight. The 
solvent was decanted then placed on the hi-vac for 30 min and 320 mg of tetrahydro-2-oxo-4- 
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furanyl acetic acid was collected (32%). The identity and purity was confirmed by melting point, 
NMR and IR (Appendix 2). Mpt. 750C. IR (KBr): 1714,1780 cm-1 (C = 0, lactone). 1H NMR 
(CD3OD): 2.36 (dd, J3,3 = 17.6 Hz, J3,4 = 7.9 Hz, 1H, C3-H), 2.57 (d, Ja 4=7.1 Hz, 2H, Ca-H), 2.69 
(dd, J3,3 = 17.6 Hz, J3,4 = 8.6 Hz, 1H, C3-H), 2.98 (m, 1H, C4-H), 4.00 (dd, J5,5 = 9.1 Hz, J5,4= 7.1 
Hz, 1H, C5-H), 4.44 (dd, J5.5 =9 Hz, J5,4 = 7.5 Hz, 1H, C5-H). 
2.3.4 Instrumentation 
2.3.4.1 NNIR Analysis 
The analysis was performed using a Jeol Lamda, 300 (Jeol Ltd. ). The operating frequencies 
were 300 MHz (proton) and 75 MHz) carbon. 16 scans for proton and 512 scans for carbon were 
used. Sample tube size was 5 mm. 
2.3.4.2 IR Analysis 
The analysis was performed using a Perkin-Elmer 1700 Infra-Red Fourier Transform 
Spectrometer (PerkinElmer). Scan range 400 to 4000 cm 1. 
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Chapter 3 
The Detection of Various Opiates and Benzodiazepines by 
Comprehensive Two-Dimensional Gas Chromatography-Time 
of Flight Mass Spectrometry 
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The Detection of Various Opiates and Benzodiazenines by Comprehensive Two- 
Dimensional Gas Chromatograyhy-Time of Flight Mass Spectrometry 
3.0 Introduction 
3.0.1 Background 
Opiates and benzodiazepines are routinely screened in drug testing laboratories. The opiate 
group [Figure 1] includes common analgesics (e. g. codeine and dihydrocodeine) and powerful 
narcotics (e. g. heroin and morphine). It also includes many minor opiates (e. g. narcotine and 
papaverine) which have little or no therapeutic benefit. 
Heroin (diacetylmorphine or diamorphine) is a semi-synthetic opiate (opioid) derived from 
morphine by acetylation with either acetic anhydride or acetic acid. The potency of heroin, when 
smoked or injected intravenously, is due to its lipophilic character which allows it to pass through 
the blood-brain barrier very rapidly. ' It is a Class A controlled substance in the UK under the 
Misuse of Drugs Act 197 1. The pharmaceutical drug is only administered for certain treatments 
such as acute pain and palliative care. The illegal drug (street drug) is produced from crude opium 
and contains various natural opiates carried through the refining process; and also acety1codeine 
which is produced by acetylation of the natural opiate codeine. Street heroin is also likely to 
contain various impurities (e. g. caffeine and paracetamol) added deliberately to 'cut' the drug. The 
detection of minor opiates and impurities may help to identify the source of the drug or to 
2-5 differentiate whether the user has taken pharmaceutical or illicit heroin. 
Keto-opiates, hydromorphone and hydrocodone [Figure 1], are analgesics which are 
structurally almost identical to their respective analogues, morphine and codeine, and this can 
hinder GC analysis. 6 Hydromorphone and hydrocodone, like heroin, are semi-synthetic opiates 
(opioids) derived from natural opiates. Fully synthetic opiates (opioids) include fentanyl, pethidine, 
buprenorphine, and methadone [Figure 11. Many of these drugs are prescribed for the management 
of opiate addiction and withdrawal. Therefore, heroin addicts may test positive for a multitude of 
drugs and metabolites. 
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Benzodiazepines [Figure 2] represent the largest group of drugs of abuse. They were 
introduced in the early 1960s for the treatment of disorders such as insomnia, epilepsy, alcohol 
withdrawal, and anxiety. They were considered a safer alternative to barbiturates which can 
produce severe side-effects and a high risk of overdose. However, concerns over addiction and 
side-effects caused by some of these early benzodiazepines (e. g. chlordiazepoxide, alprazolam, 
diazepam and temazepam) led to the development of a newer generation of benzodiazepine-like 
drugs (e. g. zopiclone and zolpidem) with less adverse side-effects. There are >35 benzodiazepines 
or benzodiazepine-like drugs available on prescription. The large volumes in circulation have, not 
surprisingly, led to high levels of abuse . 
7,8 They are favoured by heroin addicts to alleviate the 
effects of withdrawal; however, co-dependence may exacerbate withdrawal symptoms for patients 
in detoxification treatment. 9 
Many of the benzodiazepine group have been associated with drug facilitated crimes 
(DFQ whereby drugs are administered either knowingly or surreptitiously to render a victim 
incapacitated. 10"' Flunitrazepam. (Rohypnol@) is notorious due to its association with DFC and 
especially drug facilitated sexual assault (DFSA). It is a very powerful hypnotic usually only 
prescribed for severe insomnia. It is a low dose (typically 1-2 mg) benzodiazepine. There are 
particular concerns over flunitrazepam. because of its rapid onset time and rapid metabolism and 
removal from the body. It has been reported this breakdown may continue in vitro. 12 It may also 
cause amnesia. This is of particular concern with DFSA cases where the victim may not be able to 
provide a sample until some time after the assault. " 
Co-dependence on these drug types is well documented and as such drug screening that can 
facilitate simultaneous detection is advantageous. Opiates and benzodiazepines are similar in terms 
of their volatility and polarity and; therefore, co-elution of peaks in the chromatogram are often 
observed which requires further resolution by mass spectrometry. As a result, the detection of these 
drug types requires the development of a high-throughput procedure. 
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3.0.2 GC-MS Methods 
Multi-component drug analysis of opiates and benzodiazepines by GC-MS has been 
described in various publications. 5,14-19 A case report, involving a lethal heroin overdose, published 
by Rop et al., described the simultaneous clean-up of heroin, 6-MAM and morphine, from blood, 
urine and gastrointestinal fluids using a liquid-liquid extraction (LLE) procedure. 14 The 
components were derivatised with BSTFA to convert the polar hydroxyl groups in 6-MAM and 
morphine to trimethylsilyl (TMS) ethers [Figure 3]. However, it was also suspected that another 
drug possibly bromazepam had been taken by the victim but this was not detected. The analysis 
was performed using a quadrupole GC-MS. 
BSTFA 
Figure 3. Morphine derivatised by BSTFA. The polar functional hydroxY groups are converted to 
less polar trimethylsilyl (TMS) ethers. 
Reiter et al. studied the drug profiles from 52 patients undergoing drug dependence 
treatment. 15 Drug compounds were extracted from urine and serum by solid phase extraction (SPE) 
and derivatised by N-methyl-N-(trimethylsilyl)trifluoroacetaniide (MSTFA) to form TMS ethers. 
Paterson et al. applied GC-MS to detect illicit heroin use in patients receiving 
5 
pharmaceutical heroin for the management of opioid dependence. The detection of various minor 
opiates as well as 6-MAM and morphine was described using SPE extraction and derivatisation, by 
BSTFA. 
The simultaneous analysis of keto-opiates including hydrocodone, hydromorphone, 
oxycodone, and oxymorphone, have been described using two-step derivatisation procedures. '6"a 
The ketone functional groups were converted to oxime derivatives prior to derivatisation of the 
hydroxy groups by BSTFA or propionic anhydride. This technique was found to greatly improve 
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the separation from other opiates such as morphine and codeine, and therefore, eliminated the 
problem of co-eluting interference. 
Gunnar et al. reported the analysis of 14 benzodiazepines extracted from blood using 
LLE. '9 Compounds containing polar hydroxyl and/or secondary amine groups were derivatised 
using different silylating agents. MTBSTFA was reported to be the most stable, reproducible and 
sensitive. 
3.0.3 High-Throughput Screening Techniques 
There is often a need to provide a comprehensive analysis of a biological sample. This may 
be due to a suspected overdose caused by an unknown substance or that drug use is suspected but 
the sample does not test positive by routine screening. A multitude of drugs have been identified in 
cases of DFC including benzodiazepines, barbiturates, opiates, neuroleptics, antidepressants, 
antihistamines, ketamine, GHB and analogues, and PCP. 10'20 Drug-testing laboratories have 
developed validated methods to screen most of the drugs in these drug groups. However, methods 
are generally applied to single or a small group of components. Therefore, a considerable amount 
of time and resources is needed to screen for all of these drugs and their metabolites. 
The GC-MS methods described in Section 3.0.2 all use single ion monitoring (SIM) and, 
therefore, only target compounds are detectable. Maurer and Peters applied GC-MS in scanning 
mode and have reported the detection of >2,000 drugs, poisons, and metabolites. 2' Advances in 
software technology have enabled rapid processing of samples against spectral databases. 
However, practical applications of this technique may be limited due to its low sensitivity and poor 
selectivity. 
Multi-component target analysis by LC-MS/MS is highly advantageous because 
components do not generally require derivatisation prior to analysis and a huge increase in 
sensitivity can be achieved using selected reaction monitoring (SRM) transitions. Laloup et al. 
developed a validated method for the simultaneous quantitation of 26 benzodiazepines and 
metabolites in blood, urine and hair. 22 Feng et aL described the simultaneous determination of 30 
drugs of abuse in urine, including opiates, barbiturates, amphetamines, cocaine, cannabinoids, PCP, 
methadone, and benzodiazepineS. 23 Gergov et aL applied LC-MS/MS to the simultaneous detection 
51 
24 
of 238 drugs and metabolites. However, there is a finite limit on the number of analytes that can 
be targeted by SRM. Although modem MS/MS can, in theory, perform: 5300 SRM transitions; in 
reality this is unlikely to be realised. The typical dwell time on each transition is -10 ms (20 ms if 
greater sensitivity is required); therefore, to perform 100 transitions would require -I s time on 
detector and only provide I data point per second. Therefore, issues arise as to whether sufficient 
data points across the peak can be obtained. 
LC-MS using high-resolution time-of-flight (TOFMS) and fourier transform mass 
spectrometry (FrMS) has been applied to drug detection whereby accurate mass measurements to 
within 3 ppm have been achieved. 25 This technique is particularly advantageous to identify 
compounds in which a reference standard is not available. 
The disadvantage of high-throughput drug screening techniques, by LC-MS or LC- 
MS/MS, is in the application to actual samples. Biological matrices (e. g. blood, urine, hair) may 
contain thousands of compounds and clean-up techniques such as LLE or SPE can be employed to 
remove much of the interference. These techniques tend to separate compounds based on polarity 
and hydrophilic/hydrophobic interactions. Therefore, small organic drug compounds can be 
separated from the protein and inorganic matrix relatively easily. However, many small organic 
compounds will be present in the final extract. MS can resolve co-eluting peaks, however, 
interfering compounds within the biological matrix and target analytes with similar chemical 
properties can inhibit the detection and/or accurate quantitation. 
High-throughput target analysis can require a considerable degree of instrument method 
optimisation. 24 This is further complicated by the application to actual biological samples. Drugs of 
abuse are often detected at very low concentrations (<1 ng/ml), however, endogenous compounds 
(e. 8. long-chain fatty acids and amides) may be present at relatively high levels (>1 mg/ml). Co- 
elution can result in 'ion suppression' or incomplete ionisation in the source . 
26 Co-eluting 
compounds which produce similar quantitation or confirmation mass ions may cause interference 
on the detector ('cross- taffdng') resulting in inaccurate quantitation. 
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3.04 Comprehensive GC x GC 
Comprehensive GC x GC coupled to TOFMS has the potential to resolve these issues. The 
basic principle of comprehensive GC x GC is a slow chromatographic step in the first phase is 
combined with a very rapid one in the second phase. The result is a series of short chromatograms 
with very fast eluting, sharp peaks with mid-point peak widths typically 0.1 - 0.5 s. Therefore, 
components are resolved chromatographically prior to entering the mass spectrometer. The mass 
spectrum of each peak can then be compared with the spectra contained within a library database. 
This eliminates many of the problems associated with other high-throughput screening tools and 
may enable a more rapid approach to unknown sample analysis. 
Testing for drugs of abuse by GC x GC is relatively new technique in forensic science. 
Kueh et aL applied comprehensive GC x GC to analyse 27 common drugs including diazepam, 
codeine and morphine which had been spiked in horse urine and extracted by SPE. 27 The detection 
was performed using quadrupole MS. 
Song et al. applied GC x GC-TOFMS to analyse 78 drug compounds, including diazepam, 
nordiazepam and temazepam, I spiked, in whole blood and extracted by LLE . 
28 All the drugs were 
analysed underivatised and at relatively high concentrations (- I 99/ml). The authors point out that 
whilst derivatisation improves the chromatographic performance of many compounds, the 
emphasis of this study was detection and whether the drug compounds could be resolved by the 
peak find algorithm (mass spectral deconvolution software). Although most compounds were 
detected (70 out of 78) some drugs such as flunitrazepam, 7-amino-FN and zopiclone were not 
detected by this method. This research group also analysed 4 drug positive blood samples from 
actual forensic cases using the same procedure. 14 out of 19 compounds were detected and 
identified by use of a library database. However, compounds that were not detected included 
oxazepam, 7-aminoclonazepam and paracetamol (acetaminophen). This is obviously a major 
shortcoming in the practical application of this method. To our knowledge no other publications are 
available in this area of research. 
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3.05 Research Work 
We have investigated the clean-up and detection of human serum containing 
benzodiazepines (diazepam, nordiazepam, bromazepam, oxazepam, temazepam, lorazepam, 
flunitrazepam. and 7-amino-FN) and a street heroin mixture (diacetylmorphine, 6-MAM, morphine, 
acetylcodeine, codeine, narcotine, papaverine, caffeine and paracetamol) at therapeutic levels 
between 50 and 2,000 ng/ml. It is clear from previous studies that successful GC analysis must 
include derivatisation. Although they are often not well represented in library databases; 
identification, in the first instance, can be performed by mass spectral interpretation then added to 
an 'in-house' library database for future analyses. 
The method and conditions were developed from extensive literature studies from previous 
work. The main bulk of the work was performed by reverse phase SPE followed by derivatisation 
with MTBSTFA to form tert-butyldimethylsilyl (TBDMS) derivatives of polar hydroxyl and/or 
secondary an-dne groups. The choice of column configuration for the 2D analysis was non-polar 
DB-5ms (or DB-Ims) in the first-dimension and a moderately polar BPX50 in the second- 
dimension. Comparative studies were run in ID mode. 
We have also performed extractions by LLE and investigated BSTFA and non-derivatised 
methods. Large volume injections by PTV were investigated, as an alternative to split/splitless 
injection, as a means to increase the sensitivity. 
Online analysis was considered as an alternative to SPE and LLE. Multi-component drug 
29 
analysis by stir bar sorptive extraction (SBSE) has been described by, Crifasi et al., to detect drug 
standards spiked in whole blood. Diazeparn and nordiazepam were detected with high recoveries 
(84.1 and 87.2 %, respectively). However, spiked opiates 6-MAM, morphine, hydromorphone mid 
oxycodone, were either not detected or the recoveries were extremely low (<5%). Staerk and 
Kulpmann 30 reported multiple drug analysis in urine by solid phase microextraction (SPME). On- 
fibre derivatisation was performed with MSTFA. Heroin, morphine and codeine (200 ng/ml), and 
flunitrazeparn (100 ng/ml) were detected. However, 6-MAM and 7-aminoflunitrazepam were not 
included in this study. Because of the large variations in the recoveries reported in these two 
articles it was decided not to pursue this approach. 
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The accuracy of quantitation and sensitivity was evaluated, in this thesis study, by the 
preparation of calibration standards of flunift-azepam and its major metabolite 7-amino-FN (5 - 
1,000 ng/ml). Deuterated analogues were used as internal standards. The detection of flunitrazepam 
and its major metabolite, 7-aminoflunitrazepam (7-amino-FN), is severely hampered due to their 
rapid removal from the body. The therapeutic blood concentration range is very low (5 - 20 ng/ml) 
compared with many other drugs .8 Time fi-ames of detection in blood may be as low as 4h 
(flunitrazepam) and 12 h (7-amino-FN) . 
31 The detection of 7-amino-FN in urine by GC-MS has 
been reported up to 72 h . 
32 GC-MS detection of these compounds has been reported whereby the 
primary amine group of 7-amino-FN was converted to the heptafluorobutyrate derivative. Limits of 
detection (LOD) of 1 ngtml have been reported . 
31 "33 Both of these published procedures used 5 
ngtml lowest standards. Therefore, if this level of sensitivity can be replicated it could have 
considerable implications for drug testing in cases of DFC. It would enable a far greater range of 
drugs to be screened in one protocol at concentration levels below the therapeutic range for most 
drugs and sufficient to detect certain low-dose compounds such as flunitrazepam. 
The overall aim was to provide a platform from which a validated method to detect and 
quantify opiates and benzodiazepines from biological matrices could be established. The 
development of this non-validated procedure has included most of the common opiate and 
benzodiazepine compounds. However, it is recognised that a larger range of compounds will need 
to be evaluated before validation can be considered. 
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3.1 Results and Discussion 
3.1.1 SPE Recoveries 
The percentage recoveries have demonstrated that C4 (EQ and C 18 (EQ reverse phase 
SPE cartridges obtain sufficiently high recoveries (>69%) of all the components [Table 11. The 
percentage recoveries of street heroin, flunitrazeparn and 7-amino-FN were calculated from the 
mean peak areas (n = 4) of each target ion from a spiked drug-free serum sample against the mean 
peak area of the target ion peak from standard solutions prepared with no clean-up. The clean-up 
method employed, outlined in Section 2.0.5, was kept relatively simple. No buffer was added and 
the pH was neutral (-7). All of the compounds analysed contained basic nitrogen groups and were 
assumed to have slightly basic characteristics. It was expected that analytes would bind to the 
stationary phase by hydrophobic and van der Waals type interactions. The sample was loaded in 
aqueous solution and eluted with polar organic solution. 
It was found that high recoveries (>69%) were obtained for all the components. However, 
the chemical properties of each component and the method employed to calculate the percentage 
recoveries indicate a degree of uncertainty from this data. it may be postulated that the percentage 
recoveries obtained for heroin (69% and 76%) and codeine (7 1% and 72%) are lower than for other 
components because at neutral pH they are partly ionised and, therefore, partly hydrophilic: 
resulting in removal in the load or wash steps. However, the literature data available for the pKa 
values of these compounds are similar to the other opiate compounds (pKa -8) and much higher 
recoveries were obtained (>89%) for the other 5 opiates. 
Certain analytes may undergo greater degradation in the sample inlet dependent upon the 
matrix conditions i. e. samples extracted from serum may not degrade to the same extent as standard 
solutions that are more exposed to high temperature degradation. To minimise this effect a final 
sample volume of 0.5 ml was employed compared with the samples prepared for GC x GC analysis 
which had a final volume of 0.2 ml. 
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The recoveries obtained between the C4 (EQ and C 18 (EQ cartridges were very similar. The only 
exception was for 7-amýino-FN which had a very recovery (>99%) using C4 (EQ cartridge 
compared with C 18 (EQ (72%). The C4 (EQ has increased polarity compared to the C 18 (EQ 
due to the shorter alkyl chain attached to the silica structure. This may improve the affinity to this 
particular component because of the primary amine group present in 7-amino-FN. 
This study was performed using an ion trap GC-MS, described in Section 2.0.10.4. The 
percentage recoveries of the remaining benzodiazepines were not possible to measure because 
these were only analysed from 'pre-spiked' serum and, therefore, standard solutions were not 
available. 
3.1.2 MTBSTFA Derivatisation 
The derivatisation procedure using NffBSTFA, described in Section 2.0.6.1, was used to 
convert polar hydroxyl and/or secondary an-dne groups to less polar TBDMS ethers. This was 
found to greatly improve the stability and sensitivity of target analytes containing polar hydroxyl 
and/or secondary amine groups. MTBSTFA has been reported to form more stable derivatives than 
other silylating reagents such as MSTFA especially of secondary amine groups. '9 It is also likely 
that silylation of non-volatile matrix constituents will prevent build up of constituents in the inlet 
liner or at the head of the column that may result in carryover between samples. To improve the 
performance of the GC and avoid contamination of the GC column, the excess derivatising agent 
was removed under a gentle stream of nitrogen (400C) and the dried residue reconstituted in 
hexane: dichloromethane (1: 1). These solvents were chosen to ensure components were completely 
miscible whilst retaining a non-polar element that is more amenable for non-polar phases. 
Paracetamol (acetaminophen) was not completely derivatised and formed mono- and di- 
substituted TBDMS ethers with the di-TBDMS as the most abundant (-70%) [Figure 4]. Codeine 
was derivatised with MTBSTFA but was also detected in underivatised form (<40%). The amount 
of underivatised codeine was found to increase the more the GC column was used which suggests 
that some deterioration in the column stationary phase may affect the stability of the derivative. 
The percentages were calculated from the peak areas of the target ions, obtained from the GC x GC 
analysis outlined in Section 2.0.10.1. However, comparisons of different compounds only provide 
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an approximation because the relative intensities of the respective target ions, compared to the 
other ions in the spectrum, will be different. 
Underivatised bromazepam and nordiazepam were also observed but at very low amounts 
(<I%) compared to bromazepam-TBDMS and nordiazepam-TBDMS. 6-MAM and temazepam 
formed only mono-substituted derivatives. Morphine, oxazepam and lorazepam formed only di- 
substituted derivatives. Other compounds were not derivatised. It was found that TBDMS 
derivatives were not well represented within the mass spectral library database provided by the 
Chroma-ToF software package. The TBDMS derivatives are recognisable by distinct [M-57]' 
fragments. This issue is discussed further in Section 3.1.4. 
Masses: 322+208 
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Figure 4. Tarzcget ions of paracetamol-TBDMS (m/z 208) and paracetamol di-TBDMS (m/z 322). 
The di-substituted compound is the least volatile and is retained longer on the I s'dimension 
column. However. the mono-substituted compound is more polar and is retained longer on the 2 nd 
dimension column. 
Paracetamol di-TBDMS 
m/z 322 
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3.1.3 Detection 
The drug and metabolite components were all detected by the Pegasus IV in 2D mode by 
the mass spectral deconvolution algorithm software [Table 2]. The column configuration 
incorporating a relatively non-polar DB-5ms (30 mx0.25 mm x 0.25 gm) in the first dimension, 
which separates the components mainly by volatility, and a moderately polar BPX50 (2 rn x 0.1 
mm x 0.1 gm) in the second dimension, which separates the components by polarity, produced an 
orthogonal separation of the matrix constituents [Figure 5]. 
The opiates and benzodiazepines were clearly resolved chromatographically which was not 
observed in conventional ID mode. Compounds that co-elute on the first column are separated on 
the second dimension column due to differences in polarity. Opiates and benzodiazepines contain 
polar functional groups and phenyl groups which increase partitioning on the second column with 
the result that these groups are pulled away from matrix interferences in the serum and 
contaminants in the sample. Endogenous compounds such as long chain fatty acids and amides are 
typically found at concentration levels far greater than therapeutic drug levels. The ability to 
separate these compounds chromatographically may eliminate the problem of 'ion suppression' 
caused by co-eluting compounds. GC also produces a residual background of 'noise' caused by 
column bleed or siloxane. There have been great advances in column technology and the 
manufacturers have been very successful in the development of low bleed columns. However, the 
type of analysis i. e. temperature, type of solvent and matrix effects will all affect the column's 
performance. Data processing software with background subtraction can remove the bleed ions 
from the mass spectra but this does not improve the 'absolute' sensitivity whereas comprehensive 
GC x GC pulls analytes away from this background resulting in an increase in the signal to noise 
(S/N) ratios. The S/N ratios will vary depending on the level of column bleed and matrix 
interferences. Also faster mass spectral acquisition rates result in a decrease of S/N ratios. 
A separate analysis of benzodiazepines extracted from serum was found to be more 
sensitive in 2D mode compared with ID mode. This was shown by comparing the S/N ratios from... 
the same sample extract in ID and 2D mode [Table 3]. The analyses were performed on the sam 
day. The increases in S/N were shown to be as much as an order of magnitude despite a faster 
acquisition rate (50 spectra/s) in the 2D mode compared to the ID mode (6 spectra/s). 
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Figure 5. DB-5ms/BPX50 configuration: (a) GC x GC contour plot (TIC) containing 1) diazepam. 
2) iioi-diazepam-TBDMS; 3) flunitrazepam; 4) 7-amino-FN; 5) bromazepam-TBDMS, 6) 
oxazepam di-TBDMS; 7) temazepam-TBDMS; 8) lorazepam-TBDMS-, 11) acetylcodeine; 12) 
heroin, 13) codeine-TBDMS, 14) 6-MAM-TBDMS; 15) papaverine. 16) morphine di-TBDMS; 18) 
fluniti-azepam-D7; 19) 7-amino-FN-D7; (b) GC x GC surface plot (TIC). Opiates and 
benzodiazepines are clearly resolved in the second dimension. 
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Table 3. S/N ratios obtained from benzodizepines spiked in serum and extracted using a C4 (EQ 
SPE cartridge. 
Compound Concentration 
ng/ml 
Target ion (nVz) S/N ID mode S/N 2D 
Diazepwn 600 256 856 4,709 
Nordiazepam-TBDMS 800 327 1,473 28,313 
Flunitrazeparn 50 286 28 151 
7-Amino-FN 50 283 13 82 
Brornazeparn-TBDMS 400 374 221 1,444 
Oxazepam di-TBDMS 600 457 696 7,841 
Temazepam-TBDMS 800 357 742 3,838 
Lorazeparn di-TBDMS 100 491 68 143 
Comparisons of the same sample run in ID mode (6 spectra/s) and 2D mode (50 spectra/s). Analytical 
conditions were as outlined in Section 2.0.10. S/N output calculated by data processing software. 
Narcotine was not detected with a DB-5ms/BPX50 column configuration. However, it was 
detected in conventional ID mode using a DB-5ms (30 mx0.25 nun x 0.25 gm) column. This is 
almost certainly due to coupling to a narrow bore column, which results in an increase of pressure 
at the head of the column. Therefore, a different temperature elution profile is observed in the ID 
and 2D modes with the same applied temperature gradient [Table 4]. The opiates and 
benzodiazepines were observed to elute -27' C higher in 2D mode compared with 1D mode. It is 
not clear whether this is due to a decrease in the velocity of the carrier gas through the V 
dimension column or because the components are less soluble resulting in longer retention at the 
head of the column. 
Table 4. Comparison of retention times from spiked serum samples run in 1D mode (DB-5ms) and 
in 2D mode (DB-5ms, /BPX50) with same temperature gradient. 
Compound ID Mode R. T. (s) 2D Mode R. T. (s) 
Caffeine 791 1020; 2.73 
Paracetamol di-TBDMS 905 1170; 1.85 
Diazepam 1177 1500; 3.85 
Nordiazepam-TBDMS 1208 1524; 2.98 
Acetylcodeine 1228 1554; 3.70 
Flunitrazepam 1316 1638-, 4.20 
Diacetylmorphine 1321 1650; 4.05 
7-amino-FN 1333 1662; 5.03 
Bromazepwn-TBDMS 1341 1668; 3.43 
Codeine-TBDMS 1357 1686; 3.10 
Oxazepam di-TBDMS 1391 17 10; 2.65 
Temazepam-TBDMS 1446 1770; 3.58 
6-MAM-TBDMS 1450 1782; 3.33 
Papaverine 1479 1806; 4.75 
Lorazepam di-TBDMS 1496 1818; 2.85 
Morphine di-TBDMS 1567 1896; 2.92 
Narcotine 1726 ND 
* The same DB-5ms column was used as the ID mode. 
Analytical conditions were as outlined in Section 2.0.10 
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Narcotine is relatively non-volatile but because the final oven temperature was close to the 
manufacturer's recommended maximum there was not much scope to raise this temperature. The 
problem of this non-detected compound was overcome by changing the 1' dimension column to a 
less polar phase; DB-lms (30 mx0.25 min x 0.25 gm). The conditions applied were otherwise 
identical. Some elution time decrease, in the first dimension, was observed for all the sample 
components [Table 2]. The most notable decreases are observed in the underivatised components: 
diazepam, flunitrazepam, 7-amino-FN, heroin, acetylcodeine, and papaverine (>72 s in the 0 
dimension). More importantly narcotine, which was not detected with the DB-5ms configuration, 
was detected with the DB-Ims configuration. A DB-lms column is 100% dimethylpolysiloxane 
whereas the DB-5ms is activated with 5% phenyl; usually cross-linked in MS columns. This may 
shift the equilibrium between mobile phase and stationary phase. 
There were some small variations in the 2D retention times for all the sample components 
(Table 2]. However, the second dimension modulations are very rapid (6 s) and it was expected d* 
rapid cooling then re-heating of the GC eluant would result in small fluctuations in the 2D retentim 
time. 
Narcotine was also detected by using a shorter length column in the 1' dimension; VF-5ms 
(15 mx0.25 mm x 0.25 gm). 
GC x GC produces much sharper peaks compared with conventional ID-GC. Mid-point 
peak widths are typically <0.5 s and as a result fast scanning or fast acquisition MS are needed to 
obtain sufficient data points across the peak. Pegasus IV MS has a very fast acquisition rate (55 500 
spectra/s). However, a 50 spectra/s acquisition rate was found to be adequate for this analysis. 
Lower acquisition rates require smaller data files and maximise the sensitivity. A modulation time 
of 6s was sufficient to separate all of the analytes within one modulation except narcotine which 
overlapped across modulations. This is referred to as the 'wraparound' effect [Figure 61. It may be, 
necessary to tolerate a certain degree of wraparound especially if the analysis was to be extended td 
include other drug types. 
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Figure 6. GC x GC surface plot (m/z 220). Narcotine is hi, (-Yhly polar relative to the other opiates 
and as such is not retained within one 6s modulation and overlaps into the next modulation. This is 
known as the 'wraparound' effect. 
A slow oven ramp rate (5' C/min) was used to ensure the analytes eluted over two or more 
modulations and retain the first dimensional resolution. It has been reported that three modulations 
are required to preserve the first dimensional resolution, however. this is dependent on analyte 
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concentration and at very low detection levels this is unlikely to be achieved. Because the actual 
chromatographic separation is performed on the second dimension column, the theoretical k' 
values (retention factor) are kept relatively low despite the slow temperature ramp rate. The k' 
value is determined from the retention time of the target analyte and the retention time of an 
unretained analyte [Equation 3.11. 
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tR - tM 
k'= 
tm 
Equation1l. The theoretical k' value is determined by the retention time of the target analyte 
(tR) minus the retention time of an unretained, analyte, (essentially the mobile phase) (tm) and the 
total divided by tm. Low k' values (< 10) are generally considered to be more favourable especially 
if a quantitative analysis is to be performed. 
The selectivity (a) between two peaks is given as the ratio of k' values of two separate 
analytes (k/k"). A high degree of selectivity is observed using comprehensive GC x GC compared 
with conventional ID-GC. This is because compounds which co-elute, or almost co-elute, on a 
single dimension column and as such have identical or almost identical k' values will have an 
cc value =1. However, further separation on a second dimension column produces a greater 
difference in the k' values and as such greater selectivity ((x >1). 
The rapid elution on the second column results in very narrow mid-point peak widths 
across a series of modulations. The example, shown in Figure 7, demonstrates how two separate 
components which co-elute off the first column are clearly resolved on the second column. The 
chromatographic resolution between two peaks is determined by the selectivity of the peaks and the 
peak width. Therefore, the added 2D separation increases the peak capacity or the total number of 
compounds which can be separated compared to a conventional ID-GC analysis. 
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Figure 7. GC x GC raw data of 2 modulation periods. Diazeparn co-elutes, on the Is' dimension 
column, with the endogenous compound, linoleic acid. However, far greater selectivity is observed 
with 2D analysis and the two components are clearly resolved. The peaks are combined so only onc 
entry is shown in the peak table. 
. Linoleic acid was identified in the peak table. 
3.1.4 Data Processing 
The mass spectrum for each peak is compared to the library database and a peak table 
generated. Peaks from the same analyte are recognised and combined so only one entry is shown 
on the peak table [Figure 8]. The constituents that were not derivatised: diacetylmoi-phine, codeine, 
papaverine, narcotine, diazepam, flunitrazepam and caffeine were all correctly identified in the 
peak table. 7-amino-FN was not represented in the library database and the entry in the peak table 
was, therefore, incorrectly assigned. Also the internal standards, flLinitrazepani D7 and 7-amino-FN 
D7 were not identified. Bromazepam-TBDMS and temazepam-TBDMS were identified as 
benzodiazepines but not the correct ones. All the other TBDMS derivatised compounds were 
incorrectly identified in the peak table. The library database was not well represented ofTBDMS 
derivatives but this problem was easily solved by starting a new library database and adding spectra 
to it as compounds were recognised. There is also scope to import library data from other sources. 
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Figure 8. Screen Dump of Chroma-ToF software. Compounds which elute over two or more 
modulation periods are recognised by the mass spectral deconvolution software so only one entry is 
shown in the peak table. 
Pegasus IV compares the whole spectrum (based on the 10 largest peaks) with spectra 
contained in the library database, therefore, positive identification can be based on spectral 
similarity. Mass spectral deconvolution software can extract a clean mass spectrum for all the 
components even those which almost co-elute. 
Compounds identified in our database had >80% mass spectral similarity. There is no 
precedent in forensic science for compound identification by this procedure. At lower 
concentration levels the spectral similarity may be reduced because of the background noise levels 
relative to the target ions. Further identification should be verified by the presence of specific target 
ions. Each drug and/or metabolite in this study was clearly resolved and a clean mass spectrum of 
each compound generated. We determined 2-3 confirmation ions for each compound. Suggested 
fragmentation pathways have been described in Appendix 3. The TBDMS derivatives. which were 
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not well represented in our library database, were identified by distinct [M-57] ' ions, resulting 
from the loss of the tert-butyl group of the derivative [Figure 9]. 
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Figure 9. TBDMS derivatives are characterised by distinct [m-57]' ions resulting from the 
fragmentation of the tert-butyl group. 
3.1.5 Calibmtion 
Quantitative analysis of flunitrazepam and 7-amino-FN are described and evaluated. The 
calibration range was selected to reflect the variation found in drug concentrations in biological 
matrices. In this respect the analysis serves as a model for further development work. However, 
flunitrazepam is a low dose drug and concentrations in urine and serum of 5-20 ng/ml are typical. 8 
The calibrations were linear from 5 to 1,000 ng/ml (R2--0.998, flunitrazepam; R2---0.999,7-amino- 
FN) and the points of origin close to the zero point [Figure 10]. The calibration was based on the 
ratio of the peak areas of the target ions of flunitrazeparn (m/z 286) and 7-amino-FN (m/z 283) 
over the internal standard ions, flunitrazepam-D7 (m/z 293) and 7-amino-FN-D7 (290), 
respectively. The presence of the drug in the sample was verified by comparison of the whole 
spectrum and not just specific target/confirmation ions. Therefore, in certain circumstances, GC x 
Gc may provide a more reliable means of quantitation than conventional ID chromatography - 
mass spectrometry. The analytes were clearly resolved from the sample matrix [Figure 11 ]. The 
enhanced chromatographic separation should minimise some of the quantitative inaccuracies 
experienced with conventional techniques caused by ion suppression or cross-taUdng. 
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Figure 14). 5-point calibration curves (5 - 1000 ng/ml): (a) flunitrazepam; (b) 7-amino-FN. 
Deuterated analogues (1000 ng/ml) were used as internal standards. The calibratIon was based on 
the ratio for the target ions of IlLinitrazepam/flunitrazepam-D7 (m/z 286/293) and 7-amino-FN/7- 
anuno-FN-D7 (m/z 283/290). 
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Figure 11. GC x GC surface plot (TIC). Flunitrazepam and 7-amino-FN standards ( 1000 rig/ml) Z, 
spiked in serum and extracted by SPE. The standards were clearly resolved from the endogenous 
interference from the matrix. 
The precision was evaluated by quantitation of spiked serum (50 ng/ml). Deuterated 
analoLyues of each analyte were used as internal standards. This analysis was performed in triplicate 
and mean values obtained for flunitrazepam (54 ng/ml) and 7-amino-FN (44 ng/ml .) 
[Table 5 1. The 
confidence levels at 95% were 47 to 60 ng/ml (flunitrazepam) and 39 to 50 (7-arnino-FIN). The 
limits of detection (LOD), calculated by ten repeat injections of the lowest standard, were 1.6 ng/mI 
(flunitrazepam) and 2.5 ng/ml (7-amino-FN). The limits of quantitation (LOQ) were 5.4 ng/1111 
(flunitrazepam) and 8.5 ng/mI (7-amino-FN) [Table 6]. The results suggest that sufficient level of 
detection has been achieved to detect flunitrazepam in the required therapeutic range. The on- 
column sensitivity, based on the amount of injected lowest standard, was determined to be < 12.5 
pg. However, if greater sensitivity was required this could be improved by reducing the final 
solvent volume or by increasing the injection volume. An investigation of large volume in ct C Je ions 
by PTV was performed and this is discussed in Section 3.1.6. 
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Table S. Values obtained for flunitrazepam and 7-amino-FN (50 ng/ml) spiked in serum. 
Sample nunitrazepam 7 Amino-IFN 
C18 1 54.0 45.3 
C18 2 55.0 42.8 
C18 3 51.8 44.8 
mean 54 44 
on-I 1.6 1.3 
95% CI + 61 50 
95% ci - 47 38 
"Ibe values for the upper and lower confidence limits (CI±) were calculated by multiplying the standard 
deviation by 4.30. 
Table 6. Limits of detection (LOD) and quantitation (LOQ) obtained by an empirical method. 
Run Fluni&azepam 7-Amino-FN 
1 8.22 7.75 
2 6.30 5.30 
3 6.67 4.99 
4 6.51 5.21 
5 7.00 5.04 
6 6.96 5.10 
7 6.43 4.98 
8 6.80 5.13 
9 6.96 5.14 
10 6.64 4.94 
mean 6.9 5.4 
00.1 0.54 0.85 
LOD (a.., x3) 1.6 2.5 
LOQ (cil x10) SA 8.5 
Standard deviations, obtained from repeat injections (xio) of the lowest standard (5 ng/ml), were multiplied 
by 3 to give the LOD and by 10 to give the LOQ. 
3.1.6 Programmable Temperature Vaporisation. (PTV) Injections 
Large volume injection by PTV was investigated as a means to increase the sensitivity. 
Split/splitless injection volumes are usually determined by the vapour volume of the solvent. Too 
large a sample volume may overload the column and result in a poor transfer of analytes. PTV can 
be used to inject at a temperature (-201C) below the boiling point of the solvent; therefore, the 
solvent is not vaporised. Solvent venting was employed to remove the solvent. A temperature 
gradient (50C/s) was applied to the injector to focus the analytes onto the head of the column. The 
oven temperature was held for 3 min (40"C) to allow sufficient time for the transfer to the column. 
Therefore, longer I" dimension retention times were observed but the elution temperatures remain 
consistent with the splitless injection. 
72 
A comparison was made with a splitless injection. Five times more sample volume (5 W) 
was injected resulting in an increase in the on-column mass. The S/N ratios were found to increase 
by approximately 50 to 300% dependent on the analyte [Table 7]. 
The 2D separation resolved the opiates and benzodiazepines; however, with this sample 
volume (5 pl) there is some overloading of the first- and second-dimension columns due to the 
large increase of endogenous compounds [Figure 121. The problem of endogenous interference is a 
particular issue with large volume injections and is likely to result in the loss of column efficiency. 
We also observed high levels of column bleed compared with splidess injections. Some of these 
problems may be overcome by use of a more selective extraction procedure; however, this may 
also remove compounds of interest. 
Split/splitless injections tend to provide greater homogeneity and repeatability is very 
consistent. It is unlikely that PTV injections would be as repeatable. However, if acceptable 
repeatability and reproducibility could be achieved, it would enable a lower calibration range to be 
targeted. 
Table 7. Comparison of SIN values from splitless injection (1 pl) and PTV injection (5 gl). 
Number Drug Concentration Target ion Splidess F`TV 
ng/ml (nih) S/N S/N 
BenzodimMiýnes 
I Diazepam 600 256 5,936 18,567 
2 NoTdiazepam-TBDMS 800 327 29,568 64,462 
3 Flunitrazepam 50 286 92 616 
4 7-Amino-FN 50 283 148 735 
5 Bron-azepam-TBDMS 400 374 672 2,261 
6 oxazepam di-TBDMS 600 457 4,039 15,738 
7 Temazepam-TBDMS 800 357 2,334 10,983 
8 Lomzepam di-TBDMS 100 491 430 1,547 
Street Heroin 
II Acetylcodeine 400 282 23,290 46,607 
12 Diacety1morphine 2,000 327 15,953 24,876 
13 Codeine-TBDMS 200 356 11,684 25,614 
14 6-MAM-TBDMS 400 342 13,567 19,926 
15 Papaverine 200 324 11,153 19,754 
16 Morphine di-TBDMS 200 413 590 2,057 
17 Narcotine 400 220 642 2,751 
The colurrm configuration consisted of a DB-lMs/BPX50. AnalYtical conditions were as outlined in Section 
2.0.10. 
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Figure 12. GC x GC surface plot (TIC) using PTV injection (5 pl). The larger volume results in an 
increase in the sensitivity of tat-get compounds; however, the increase of matrix compounds may 
result in overloading the first- and/or second-dimension columns. 
3.1.7 Classifications 
Matrix interferences made up the bulk of the peak table. This included endogenous 
compounds, degradation products, and column and septum bleed. Over 1700 peaks were detected 
in the spiked serum samples in the first analyses which included a 10 minute solvent delay. This 
nnniber was found to greatly increase with older columns. The computer processing time for each 
sample was over 20 minutes. Also the identification of compounds is complicated by such a large 
amount of compounds in the peak table. This can make the overall analysis time very time- 
consuming. 
A more rapid approach may be employed by targeting specific areas of the chromatogram. 
The sample was processed using a classification region in the 2D chromatogram [Figure 13]. The 
classification region is manually selected from the total ion chromatogram (TIC) from the first 
analysis. It can then be applied to all subsequent analyses. 
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The benzodiazepines and street heroin mixture (except narcotine) can be detected in this 
region. Only 162 compounds (total) were detected in this region at S/N >3. Furthermore, the 
computer processing time was reduced to -5 minutes. 
There is now the potential to employ a novel approach to drug testing to be used alongside 
diagnostic screening and target analysis MS. Drugs that have similar properties in terms of their 
volatility and polarity generally have similar retention times. This tends to be related to structure; 
therefore, a targeted analysis can be performed based on prior knowledge of the drug type. The 
implications for high-throughput multi-component analysis are that a targeted analysis can be 
performed which excludes the bulk of the sample matrix. 
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Figure 13. GC x GC contour plot (TIC). Classification region (S/N >3) using a DB-5ms/BPX50 
column configuration. Classification regions target the specific area where the opiates and 
benzodiazepines are expected to elute. This can reduce the processing time in complex matrices. 
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3.1.8 BSTFA, HFBA and Underivatised Analysis 
Comparative studies were performed using BSTFA, HFBA and without derivatisation to 
compare the mass spectra with the spectra contained within the library database. Only one san4k 
was prepared and run for each technique. This was to ensure that column efficiency was preserved 
and excessive contamination of the DB-5ms column was avoided. The second-dimension column 
was shortened to 1.5 m. This was because the underivatised analysis of highly polar compounds 
was expected to result in more retention on a moderately polar BPX50 column. Therefore, all the, 
components were expected to have eluted within the 6s modulation time. All other column 
dimensions and analytical conditions were as previously described, in Section 2.0.10.1, using the 
DB-5ms/BPX50 configuration. 
BSTFA produced stable TMS derivatives of paracetamol, codeine, morphine and 6-MAK 
However, it was found not to be an effective derivatising agent of benzodiazepines containing POW 
hydroxyl and/or secondary amine groups [Table 81. Bromazeparn and nordiazepam were detected 
in their underivatised form. Oxazepam, temazeparn and lorazeparn were not detected at all. The 
derivatisation of these compounds should be possible but would probably involve the direct 
injection of the BSTFA into the GC injector. The method we employed, described in Section 
2.0.6.2, involved the removal of the excess BSTFA and reconstitution in hexane: dichloromethane. 
(1: 1). The reason for this was to maintain the column performance. It would appear the most likely 
reason these compounds were undetected was because of degradation during this evaporation step. 
Therefore, we can conclude that NITBSTFA forms more stable derivatives than IBSTFA which 
concurs with published work, 19 
HFBA formed a stable hepta-fluorobutyl (HFB) derivative with the primary amine group 
of 7-amino-FN but was not an effective derivatising agent of constituents containing polar 
hydroxyl and/or secondary amine groups. Some polar compounds were detected in their 
underivatised form (Table 91. However, morphine, nordiazepam, bromazepam, OXazepam, 
temazeparn and lorazeparn were not detected by this procedure, outlined in Section 2.0.6.3. 
Successful derivatisation of these constituents may require a larger excess of HFBA and/or more 
vigorous reaction conditions. Also the reaction with hydroxy/secondary amine groups may be 
inhibited due to steric hindrance. 
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Table 8. First- and second-dimension retention times obtained by GC x GC-TOFMS analysis of 
spiked human serum derivatised with BSTFA. 
Number Drug Concentration 
nglml 
Target ion 
(nVz) 
1DR. T (s) 2D R. T (s) 
Benzodiazoines 
I Diazepam 600 256 1434 3.25 
2 Nordiazepam 800 269 1494 3.63 
3 Flunitrazepwn 50 286 1572 3.55 
4 7-Aniinoflunitrazepam 50 293 1596 4.13 
5 Bromazepam 400 315 1596 4.25 
SuW Heroin 
10 Paracetamol-TMS 600 223 900 1.90 
9 Caffeine 600 194 972 2.38 
13 Codeine-TMS 200 371 1428 2.63 
16 Morphine di-TMS 200 429 1464 2.30 
11 Acetylcodeine 400 282 1494 3.20 
14 6-MAM-TMS 400 399 1524 2.73 
12 Diacetylmorphine 2000 327 1596 3.38 
15 Papaverine 200 324 1752 3.85 
Colurnn configuration: DB-5ms (30 mx0.25 nun x 0.25 pm)/BPX-50 (1.5 mx0.1 mm x 0.25 gm). 
Analytical conditions were as outlined in Section 2.0.10.1 
Oxazeparn, temazepam and lorazepam were not detected in this analysis. 
Table 9. First- and second-dimension retention times obtained by GC x GC-TOFMS analysis of 
spiked human serum derivatised with HFBA. 
Number Drug Concentration Target ion IDR. T (s) 2D R. T (s) 
ngtml (MIZ) 
BenzodiazeDines 
1 Diazepam 600 256 1434 3.22 
3 Flunitrazepam so 286 1578 3.53 
4 7-Amino-FN-HFB 50 293 1476 2.58 
Street Heroin 
10 Paracetarnol 600 223 912 2.03 
9 Caffeine 600 194 966 2.38 
13 Codeine 200 371 1398 3.15 
11 Acetylcodeine 400 282 1488 3.20 
14 6-MAM 400 399 1506 3.28 
12 Diacetylmorphine 2000 327 1590 3.35 
15 Papaverine 200 324 1752 3.75 
Column configuration: DB-5ms (30 mx0.25 nun x 0.25 lim)/BPX-50 (1.5 mx0.1 mm x 0.25 ILM). 
Analytical conditions were as outlined in Section 2.0.10j 
Morphine, nordiazepam, brom-eparn, oxazeparn, temazeparn and lorazepam. were not detected in this 
analysis. 
underivatised analysis failed to detect morphine, oxazepam, temazepam and loweparn 
[Table 10]. The failure to detect oxazepam, using an underivatised method, concurs with published 
work. 28 Also very poor peak shapes were observed for underivatised highly polar constituents such 
as paracetamol and codeine [Figure 
77 
Table 10. First- and second-dimension retention times obtained by GC x GC-TOFMS analysis of 
spiked human serum underivatised. 
Nurnber Drug Concentration Target ion IDR. T (s) 2D R. T (s) 
n. WmI (m/z) 
Benzodiazepines 
I Diazepam 600 256 1434 3.25 
2 Nordiazepam 800 269 1494 3.63 
3 Flunitrazepam 50 286 1572 3.55 
4 7-Aminoflunitrazepam 50 283 1596 4.13 
5 Bromazepam 400 315 1596 4.25 
Street Heroin 
10 Paracetamol 600 151 918 2.00 
9 Caffeine 600 194 966 2.35 
13 Codeine 200 299 1398 3.13 
11 Acetylcodeine 400 282 1488 3.20 
14 6-MAM 400 268 1506 3.20 
12 Diacetyl morphine 2000 327 1584 3.38 
15 Papaverine 200 324 1740 3.78 
Column configuration: DB-5ms (30 mx0.25 mm x 0.25 ýtm)/BPX-50 (1.5 mx0.1 mm x 0.25 pm). 
Analytical conditions were as outlined in Section 2.0.10.1 
Oxazepam, temazepam and lorazeparn. and morphine were not detected in this analysis. 
Masses: 151 
Aý- 
Paracetamol 
I 
*%PAZ Qoz 
C-V/ 
Figure 14. Poor peak shape is observed in the underivatised analysis of highly polar components 
such as paracetamol (acetaminophen). 
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The BSTFA derivatised and underivatised, analytes were well represented in the library database. 
All of the detected components were identified with the exception of 7-amino-FN. The issue of 
identifying derivatised compounds must be considered especially if dealing with 'unknown' 
components. 
3.1.9 LLE 
A very rapid extraction and analysis can be employed if the results are needed urgently. 
LLE involves the formation of two liquid layers usually an aqueous and an organic layer. The 
extraction of the drug components was achieved by adding ethyl acetate to the serum then after 
brief vortex and centrifuge, the organic layer was removed and evaporated to dryness. The dried 
residue was then reconstituted in acetonitrile: MTB STFA (1: 1) and heated briefly (15 min) then the 
same volume of hexane was added and an aliquot injected directly into the GC. Therefore, the 
components can be derivatised in the vial and also inside the split/splitless injector. The rest of the 
procedure was as described in Section 2.0.10.1. 
The results were obtained in less than 2 hours. The drug and metabolite components were 
all detected in 2D mode. However, direct injection of the silylating reagents does shorten column 
life and adds a lot more matrix interference [Figure 15]. It was decided not to pursue this method 
further and, therefore, the recoveries were not calculated. 
The advantage of LLE is that pre-clean is generally not required. Therefore, whole blood 
can be analysed directly. 
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Masses: TIC 
Opiates and 
benzodiazepines 
1111' 
lqý 
4 
Column bleed 
Figure 15. GC x GC surface plot (TIC). Opiates and benzodiazepines extracted from serum using 
LLE. The procedure was as described in Section 2.0.9. 
3.1.10 Urine 
The clean-up and analysis from urine was also studied in this research. Urine 'spiked' with 
the 'street' heroin mixture (200 - 2000 ng/ml) was extracted and derivatised with MTBSTFA, as 
previously described in Sections 2.0.5 and 2.0.6, respectively. The orthogonal separation afforded 
by comprehensive GC x GC clearly resolved the drug compounds from the endogenous compounds 
I Figure 16]. The endogenous make-up of the urine was found to be quite similar to serum; in 
respect of the compounds detected. Various long-chain fatty acids (e. g. oleic and palmitic acid) and 
amides (e. g. oleamide) were detected in large concentrations. The urine sample was also found to 
contain high levels of disooctylphthalate, a common plasticiser. However, these compounds. esters 
of phthalic acid, are relatively non-polar compared with drugs such as opiates and were found not 
interfere with the analysis. Therefore, it would appear that the same analytical procedures applied 
to serum analysis could be applied to urine analysis. 
I 
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Figure 16. GC x GC Surface Plot (TIC). Urine spiked with street heroin mixture (20() - 2000 
ng/mi). 
3.2 Conclusion 
The results have demonstrated that opiates and benzodiazepines can be successfully 
extracted and analysed at therapeutic levels in hurnan serum. A large concentration range (50 - 
2000 ng/ml) was chosen to reflect the variation of drug and metabolite levels in actual drug positive 
samples. The method described demonstrates that a single protocol can be employed to extract 
opiates and benzodiazepines from serum, and also enable identification of other non-specified 
compounds in the sample matrix. The defivatisation by MTBSTFA formed stable TBDMS 
derivatives of drug groups containing polar hydroxyl and/or secondary amine groups. The issue of 
incomplete derivatisation is something that would need to be addressed if the protocol were to be 
extended. However, in this study only codeine and paracetamol did not derivatise to completion. 
Clean mass spectra were obtained for all of the sample components using the mass spectral 
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deconvolution software. Therefore, we have demonstrated that drug and metabolite identification 
can be achieved by comparison of the whole mass spectrum with either a reference standard or 
spectra stored within the library database. 
The accurate quantitation at therapeutic levels for flunitrazepam and 7-amino-FN has 
demonstrated that the Pegasus IV is not just a tool for qualitative analysis but can be used as a 
comprehensive screening tool that can accurately determine drug concentrations below recognised 
cut-off values. The calibration range (5 - 1,000 ng/ml) has demonstrated that very good linearity 
can be achieved across a large concentration range. This has demonstrated the principle that low 
and high level analysis can be combined. The accurate quantitation of drugs and their metabolites is 
vitally important in forensic drug analysis. The recommended cut-off value for flunitrazepam has 
been reported at 10 ng/ml (urinary). ' 1 We were able to achieve limits of detection of 1.6 
(Flunitrazepam) and 2.5 ng/ml (7-amino-FN). Whilst specific target analysis using tandem mass 
spectrometers has achieved accurate detection below 1 ng/ml; 20 the demonstration that 
flunitrazeparn and its major metabolite 7-amino-FN can be detected below the recognised cut-off 
value indicates that in areas of clinical and investigative forensic analysis this technique should be 
considered as a tool in routine analytical drug screening of blood and urine. 
3.3 Future Work 
There is certainly scope to extend this protocol for the detection of other drugs and 
metabolites. Other basic drug groups such as cocaine and methamphetamines should also have verY 
good affinity to reverse phase SPE. Provided that sufficiently high recoveries can be achieved then 
the application to other drug groups may lead to a high-throughput protocol with the capability for 
high sensitivity screening. This could be applied to actual sample analysis of different biological 
matrices. 
The development of a validated method to screen for multiple drug groups will require 
further optimisation. In Section 3.1.1 it was noted that the affinity to reverse phase SPE is 
dependent on the charged state of the species which in turn is dependent on the pH. Therefore, any 
validated method should contain a buffer solution to maintain a consistent pH in the samples. 
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Drugs may form glucuronide or sulphate conjugates that may be part of the original drug 
structure or form after ingestion by Phase II metabolism. Morphine is often described as total and 
free morphine. '-5 These conjugates can be removed by acid hydrolysis with TBDMCS or TMCS; or 
enzymatic hydrolysis with glucuronidase or sulphatase. 
It is important to ensure that in vitro degradation or production is kept to an absolute 
minimum. Therefore, the addition of preservatives or antioxidants such as tocopherol (vitamin E) 
and sodium fluoride should be considered. Acid scavengers such as trimethylamine (TMA) may 
prevent contamination of the GC injector and/or column. These are steps which should be 
considered if a validated method was required. 
The analysis of drugs of abuse in hair is commonly employed in toxicology laboratories 
and there are significant advantages to screening hair over other biological matrices. This will be 
discussed and investigated in Chapter 4 of this thesis. 
The powerful data processing software and mass spectral deconvolution may enable non- 
I specific drug analysis or 
'omics' based techniques whereby the specific chemical effects within the 
matrix are targeted rather than the actual drug or metabolite. Metabonomics and metabolonlics are 
techniques that have attracted much interest in the pharmaceutical industry and may be beneficial 
in forensic toxicology. It is involved with the analysis of the whole matrix and how the chemical 
composition of a biological fluid is altered by a particular drug. 
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Chapter 4 
An Evaluation of GC x GC-TOFMS to the Application of 
Testing Drugs of Abuse in Hair 
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An Evaluation of GC x GC-TOFMS to the AviDlication of Testin 
Druas of Abuse in Hair 
4.0 Introduction 
4.0.1 Background 
Hair is an analytical matrix that can provide information regarding a person's drug use we# 
beyond the time frame of detection afforded with biological fluids such as urine and blood; and 
because drugs and metabolites are deposited into the hair from the bloodstream and carried along 
as the hair grows, it can provide an approximation of when drugs were used based on the rate of 
hair growth. The analysis of hair is the least invasive of all biological samples. It is routinely 
applied in workplace, rehabilitation, and post-mortem analysis. ' It can provide evidence of 'single- 
use' administration and is used in the investigation of drug facilitated crimes (DFQ in which shW- 
lived drugs such as GHB may not be detected in a urine/blood teSt. 2 
A distinction should be made between drugs detected in the actual 'hair-shaft', which bind 
to the protein matrix, and those deposited on the surface of the hair. Drugs present on the surface 
have little value to forensic toxicologists because of the risk of external contamination and, 
therefore, cannot be attributed to drug ingestion. Hair samples submitted for drug analysis will 
usually undergo various washes to remove any drugs present on the surface. For this reason the 
detection of drugs in hair refers to the actual hair-shaft unless specifically stated. 
Drugs and metabolites are incorporated in hair from the bloodstream but may also come 
from sweat/sebum and environmental exposure (e. g. smoke). 3,4 However, only incorporation fkGri 
the bloodstream can be attributed to actual drug ingestion. Although ingested drugs may be 
excreted in sweat/seburn and deposited into the hair; drugs may also be present in sweat/sebum 
5,6 from environmental exposure either from the atmosphere or from surface contact. 
Sweat testing has been described as a non-invasive technique for monitoring drug exposm 
of lipophilic drug compounds (e. g. cannabinoids, opiateS). 7,8 Drugs are absorbed from the sIdn 
using sweat patches, extracted, and analysed. Despite the limitations due to possible contaminatiM 
there are considerable advantages to this technique over hair testing. Drug compounds may enter 
the growing hair follicle almost immediately after ingestion. However, a period of time (1-2 days) 
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needs to elapse before the hair containing the drug has grown sufficiently to protrude from the skin. 
Therefore, as an indicator of recent drug exposure, hair analysis is not particularly suitable; 
whereas sweat testing offers the potential to extract drugs from the body almost immediately after 
ingestion. 
It is not possible to differentiate compounds in hair that have been deposited from blood 
from those deposited from sweat/sebum. However, the presence of drugs in hair does strongly 
indicate that drugs have been ingested. However, the issue of potential contamination must be 
considered. A recent study by Tsanaclis and Wicks suggested that the ratio of drugs present in the 
wash residues (W) compared against the levels in the hair (H) could be used as an indicator of 
external contamination. 9 In short, if the detected drug had a W/H ratio A. 1 this may indicate 
possible contamination whereas a W/H ratio >0.5 indicated almost certain contamination. 
Further evidence may be acquired by employing a more comprehensive analysis of the hair 
sample. This can be achieved by analysing hair segments and by screening for a larger range of 
metabolites and impurities. Forensic toxicologists will usually cut the hair into segments (-I cm) 
and analyse each specific segment. Each I cm segment represents about 1 month of hair growth. 
Therefore, drugs detected in two or more segments provide further proof of drug ingestion based on 
the probability of contamination occurring in two or more time periods. 
The detection of specific drug metabolites is also a strong indicator of potential drug use. 
Confirmation of drug use is often determined by detection of specific metabolites rather than the 
actual drug itself. However, the incorporation of compounds in hair is dependent on factors such as 
the rate of diffusion across the cell membrane from the bloodstream or sweat/sebum and the 
binding affinity to the hair matrix. Highly lipid soluble compounds, heroin and cocaine, are more 
readily diffused across the cell membrane than their respective metabolites, morphine and 
benzoylecgonine. Therefore, a different drug profile may be observed in hair analysis than in blood 
or urine. Studies in rats indicate that benzoylecgonine is not deposited into hair at significant 
levels. 10 However, it is detectable in hair after cocaine ingestion-, therefore, its presence must be 
attributed to in vivo conversion in the hair; essentially demethylation of the methyl ester to a free 
carboxylic acid [Figure 11. 
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CH3 *-) 
H' 
Benzoylecgonine 
FigUre 1. The presence of the cocaine metabolite, benzoylecgonine, in hair is most likely to be due 
to conversion in the hair rather than deposition from the bloodstream. 
Nakahara et aL introduced the concept of incorporation rates (ICR) into hair testing-" It it, 
based on the binding affinity and the lipophilicity of the compound. Cocaine, heroin and PCP have 
much higher ICR than amphetamines and some benzodiazepines. It is interesting to note the effixt 
of these incorporation rates on heroin metabolism. 6-MAM has a much higher ICR than morphine. 
Therefore, unlike in blood and urine, in which 6-MAM levels are much lower than morphine, in 
hair 6-MAM would be expected to be far higher relative to morphine. 
There are further complications due to binding to the hair itself. The keratin matrix of the 
hair is quite acidic (pH < 6); therefore, basic compounds tend to bind more strongly than acidic 
compounds. 12 Most drug and metabolite compounds are either weak bases or weak acids. 
Benzoylecgonine is zwitterionic and contains a basic amine group and acidic carboxyl group. 
Acidic compounds (e. g. GHB) which have a lower affinity are more likely to be removed by 
repeated washing. The hair colour has also been reported to affect the binding with darker hair 
containing more of the pigment, eumelanin, increasing the drug affinity to the hair matrix. 13"4 Thb 
has caused concerns that hair testing may be discriminatory towards the Afro-Caribbean 
populations. 15 The binding between basic compounds and eumelanin is stronger because at the 
physiological pH of hair (pH < 6) basic compounds are positively charged which interact with 
anionic eumelanin. However, studies indicate that drugs are detectable in all hair types albeit at 
varying concentrations relative to drug intake. 12 This strongly suggests that other types of 
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interactions, hydrophobic and van der Waals forces, also play an important role in the binding of 
drun in hair. 
Despite all of the concerns surrounding hair in the testing of drugs of abuse, it is widely 
used in clinical and forensic toxicology. in post-mortem analysis it provides the most reliable 
indicator that someone has used drugs whilst alive. There is always a concern that drugs may have 
been administered at the point of death to make it appear that the person has overdosed. For people 
undergoing rehabilitation, the hair test provides medical staff with a chronological profile of that 
person's drug habit and whether they have relapsed. It provides a non-invasive means of drug 
detection in areas such as workplace testing, child welfare, and legal cases. The collection of 
biological fluids (e. g. urine) can cause logistical difficulties whereas collection of hair samples is 
relatively simple and does not require trained medical staff. There is also considerable interest in 
the field of forensic archaeology whereby studies of ancient populations have shown a propensity 
to drug use. This has often caused controversy such as a famous case involving the mummified 
remains of Ramesses 11 of ancient Egypt in which drugs, cocaine and nicotine, thought only to have 
existed in the New World at this time, were detected in the hair of the pharaoh. 16 Many theories 
have been put forward as to how this could have occurred and it is beyond the scope of this thesis 
to evaluate these. However, it appears highly unlikely that it is the result of poor science. 
4.0.2 Multi-Component Drug Screening of Hair 
Jurado et al. described the simultaneous analysis of opiates, cocaine and cannabinoids in 
hair using GC-MS (SIM). 17, ne limit of detection (LOD) of the cannabis metabolite, THC-COOH 
was reported as 0.01 ngtmg. The range of measured concentrations, taken from known drug 
abusers, was 0.06 - 3.87 ng/mg. The LOD of the heroin metabolite, 6-MAM, was reported (0.02 
ngtmg) with a measured concentration range of 0.09 - 48.18 ng/mg. The LOD of the cocaine 
metabolite, 6-benzoylecgonine, was reported (0.10 ng/mg) with a measured concentration range of 
0.1 - 5.76 ngtmg. Of the 70 hair samples tested 41 were positive for cannabis, heroin and cocaine. 
It suggests that multiple drug use is fairly common and detection limits can be achieved that are 
below the expected concentration range. The development of high sensitivity tandem mass 
spectrometers has enabled detection at much lower levels. 
Huestis et aL reported an LOD of THC-COOH (0.0001 ngtmg) using GC-MS/MS. 14 
Sedative-type drugs (e. g. benzodiazepines) have been detected by LC-MS/MS (0-00001 - 0.006 
ng/mg). 18 However, sensitivity levels of this magnitude are only required for certain applications 
and conventional single stage mass spectrometry can achieve sufficient sensitivity to analyse drug-, 
groups such as cocaine and heroin at confirmation cut-off values of 0.20 ng/mg. 9 
Advances in high-throughput screening by GC-MS and LC-MS were discussed in ChapW 
3 of this thesis. The development of comprehensive GC x GC coupled to TOFMS was found to 
provide a reliable means to detect various opiates and benzodiazepines in human serum. To our 
knowledge, no publications are available which deal with comprehensive GC x GC analysis of 
drugs of abuse in hair. The advantages of enhanced chromatographic separation are that the 
analytes of interest can potentially be resolved from interfering endogenous compounds in the 
sample matrix, which should eliminate problems associated with ion suppression and co-elutin$ 
compounds with similar mass spectra. By incorporating a large spectral database there is also the 
potential to screen for a large range of compounds in one protocol and to detect unknown 
components which may be of interest to the analyst. 
4.03 Research Work 
A 'blind study' was performed on extracts from three hair samples provided by the 
Institute of Environmental Science and Research Limited (ESR). The extraction had been 
performed, by ESR, using their 'in-house' SPE method and the extracts dried. The hair samples WA 
undergone routine screening for amphetamines, methamphetamines, benzylpiperazine, codeine, 6- 
MAM and morphine; and as such, deuterated analogues of these compounds were known to have 
been added as internal standards. Each sample consisted of a 20 mg hair segment containing 50 ag" 
of each internal standard. No other details were provided. 
We derivatised the sample with MTBSTFA as described in Section 2.0.6. The use of a 
derivatising agent was used to improve the peak shape of highly polar compounds in the sample 
matrix. Although this may make the identification more complex; we know from our previous 
work that underivatised morphine is not detectable by this system a with non-polar/moderately 
polar 2D column configuration. Furthermore, the sensitivity of codeine and 6-MAM is greatly 
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ey are not amenable to this phase type and produce very reduced in underivatised analysis and th 
poor peak shapes. The samples were labelled B, D and E. These were the sample labels provided 
by ESR. 
4.1 Results and Discussion 
Detection 
The samples were screened by GC x GC-TOFMS in splitless and large volume 
programmable temperature vaporisation (PTV) injection modes. The same analytical conditions 
used in the serum analyses, described in Section 2.0.10.1, were applied. The column configuration 
was a DB-5ms (30 mx0.25 mm x 0.25 gm) in the first-dimension and a BPX50 (2 mx0.1 mm x 
0.1 gm) in the second-dimension. The results were processed using a classification region to target 
components eluting >2 s on the second column [Figure 2]. This was to remove the high number of 
endogenous compounds and column bleed from the data processing. We know from our previous 
work that basic drug compounds, generally, elute >2 s in the second dimension and although some 
constituents may be present outside of this region, they could be 'masked' by the large number of 
endogenous compounds. Because we cannot wholly rely upon the spectral library database to 
identify compounds but must also apply more conventional spectral analysis, the classification 
region keeps the number of peaks identified in the table to a manageable level. A significant level 
of column bleed was present due to gradual deterioration of the stationary phase. The exact same 
DB-5ms column was used as for the serum analysis described in Chapter 3. It was expected that 
this may result in some loss in sensitivity; however, because this was a qualitative analysis, this 
could not be quantified. 
We detected drugs in 2 out of the 3 samples (samples D and E). The remaining sample 
(sample B) was found to be negative and contained only the deuterated internal standards. The 
results for sample D and E are described in Tables 1 and 2, respectively. The positive samples 
contained evidence of common drugs of abuse: heroin, cocaine, methadone, diazepam and 
quaalude (methaqualone). Two opioid analgesics, hydrocodone and phenazocine were also detected 
in sample D. The antidepressant drug, trimipramine, was detected in the peak table of sample D in 
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the PTV injection mode. However, the similarity with the library spectrum was quite low and, 
therefore. positive identification of this compound was inconclusive. 
It is of interest to note that some retention time decrease was observed for compounds 
detected in this analysis which were also included in the serum analysis. The I" dimension 
retention times of heroin, codeine-TBDMS, 6-MAM-TBDMS, papaverine, morphine di-TBDMS 
and diazepam were >28 s less than were obtained for the serum analysis, described in Chapter 3, 
Table 2. Because the same analytical conditions were applied to both analyses, such a large 
difference was not expected. The reason for this is most likely to have been due to the gradual 
deterioration of the GC column which will result in the loss of column efficiency and. therefore. 
less partitioning to the stationary phase. 
Mosses: TIC 
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Figure 2. GC x GC contour plot (TIC) of extracted hair sample D derivatised by MTBSTFA. The 
classification (S/N >3) was employed to target the region of the chromatogram where drugs were 
most likely to be present. It removes the high concentration endogenous compounds from the 
processing task. This provides a quicker and more efficient approach to high-throughput analysis. 
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Table 1. First- and second-dimension retention times of the compounds identified by GC x GC- 
TOFMS for hair sample D. 
Compound Target ion 
(MIZ) 
Splitless (1 W) 
IDR. T. (s) 2D R. T. (s) 
PTV (5 W) 
ID R. T. (s) 2D R. T. (s) 
ORiates (or ggioids) 
Hydrocotarnine 220 980 2.26 1136 2.28 
EDDP 72 1130 2.54 1286 2.58 
Phenazocine 230 1166 2.30 1322 2.32 
Methadone 72 1208 2.52 1364 2.56 
Hydrocodone, 299 1484 3.88 1640 3.94 
Acetylcodeine 282 1520 3.60 1676 3.68 
Thebaine 296 1532 3.88 1682 3.96 
Diacetylmorphine 327 1616 3.88 1778 3.88 
Codeine-Tl3DMS 356 1658 3.00 1814 3.06 
6-MAM-TBDMS 342 1754 3.18 1904 3.22 
Papaverine 324 1778 4.42 1934 4.50 
Morphine di-TBDMS 413 1868 2.78 2024 2.82 
Narcotine 220 ND 2204 5.96 
Cocaine gEQup 
Mesocain 86 1016 2.20 1172 2.24 
Tropacaine 124 1082 2.44 1244 2.24 
Norcocaine 168 1244 2.98 1400 3.02 
Cocaine 182 1262 3.00 1424 3.02 
Cocaediylene 82 1310 2.94 1466 3.00 
Benzoylecgonine-TBDMS 82 1508 2.82 1664 2.88 
Cinnamoylcocaine 82 1532 3.42 1688 3.48 
Sedatives 
Quaalude 235 1238 3.28 1394 3.32 
Diazeparn 256 1466 3.74 1622 3.80 
Miwellaneous 
Cotinine 98 914 2.36 1070 2.38 
Meconin 165 938 2.40 1094 2.42 
Hydroxycotinine-TBDMS 249 1172 2.46 1328 2.48 
Trimipramine 249 ND 1430 2.72 
The column cOnfiguratiOn incorporated a DB-5ms/BPX50. 
Analytical conditions were as outlined in Section 2.0.10.1 and include splidess and PTV injections 
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Table 2. First- and second-dimension retention times of the compounds identified by GC x GO 
TOFMS for hair sample E. 
Compound Target ion 
(M/Z) 
Splitless (I jil) 
IDR. T. (s) 2D R. T. (s) 
PTV (5 
ID R. T. (s) 2D PLT. Oý, 
012iates (or olRioids) 
Hydrocotarnine 220 974 2.26 1136 2.28 
EDDP 72 ND 1286 2.58 
Methadone 72 1208 2.52 1364 2.56 
Hydrocodone 299 ND 1640 3.94 
Acetylcodeine 282 1520 3.60 1676 3.68 
Diacetylmorphine 327 1616 3.88 1778 3.88 
Codeine-TBDMS 356 1658 3.00 1814 3.06 
6-MAM-TBDMS 342 1754 3.18 1904 3.22 
Papaverine 324 1778 4.42 1934 4.50 
Morphine di-TBDMS 413 1868 2.78 2024 2.82 
Cocaine grouI2 
Mesocain 86 1016 2.20 1172 2.24 
Cocaine 182 1262 3.00 1424 3.02 
Benzoylecgonine-TBDMS 82 1508 2.82 1664 2.88 
Cinnarnoylcocaine 82 1532 3.42 1688 3.48 
Sedatives 
Diazeparn 256 1466 3.74 1622 3.80 
Quaalude 235 1238 3.28 1394 3.32 
Miscellaneous 
Cotinine 98 914 2.36 1070 2.38 
Hydroxycotinine-TBDMS 249 1172 2.46 1328 2.48 
The colunm configuration incorporated a DB-5rns/BPX50. ; 
"-. 
Analytical conditions were as outlined in Section 2.0.10.1 and include splitless and PTV injections. 
4.1.2 Library and spectral comparison 
The compounds were matched to the library database and a spectral similarity ascribed 
Cocaine was determined to have a similarity of 938 (93.8%) from the PTV injection [Figure 31. 
The spectral similarities of the other components are outlined in Appendix 4. The similarity is 
based on the whole mass spectra and we have observed this can often be ambiguous especially , 
because time-of-flight detectors may produce high levels of 'noise' which will reduce the similm 
value. This tends to be more apparent at lower concentrations. For this reason we have used a 
combination of spectral similarities and the more conventional approach of defined target ions. 
However, it must be noted that this work is exploratory and we are not looking to provide defWfive 
answers. The spectral analysis produced the highest similarities in the PTV mode which related to 
the higher S/N ratios compared with splitless injections [Table 3]. 
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Figure 3. The mass spectra are compared against spectra contained in the library database. Cocaine 
was found to have a spectral similarity of 938 (93.8%). 
4.1.3 Analysis 
Comprehensive GC x GC produced an orthogonal separation and clearly resolved 
constituents in the sample matrices [Figure 4]. The SIN values were higher for sample D than 
sample E indicating a higher concentration in this sample [Table 31. The SIN ratios provide a useful 
indication of the relative concentrations of the detected components. However, the determination of 
the actual concentrations would require target analysis against known reference standards. 
The PTV injection mode provided greater sensitivity than splitless injections. Five times 
more sample volume (5 A was injected and the S/N increases were >200% for all compounds with 
S/N ratios >100. It also enabled the identification of hydrocodone and EDDP, the major metabolite 
of methadone, in Sample E. These compounds were not detected, in Sample E, using the splitless 
injection mode. The minor opiate, narcotine was also detected, in Sample D, in the PTV mode. 
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Figure 4. GC x GC surface plots (TIC). Selected components present in hair sample D detected 
using: (a) Splitiess inJection, (b) PTV injection. 
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Table 3. Comparison of S/N values from samples D and E using splitless and PTV injection 
modes. 
Compound Target ion Splitless (1 gl) PTV (5 W) 
(MIZ) Sample D Sample E Sample D Sample E 
S/N S/N S/N S/N 
ORiates (or oids) 
Hydrocotarnine 220 1,015 364 4,448 1,481 
EDDP 72 152 ND 601 102 
Phenazocine 230 256 ND 965 ND 
Methadone 72 25,073 5,370 84,199 24,339 
Hydrocodone 299 14 ND 40 19 
Acetylcodeine 282 723 45 2,592 352 
71bebaine 296 21 ND 36 ND 
Diacety1morphine 327 61 12 457 318 
Papaverine 324 1,260 54 4,592 195 
Narcotine 220 ND ND 206 ND 
Cocaine gr_ouR 
Mesocain 86 56 61 7,880 165 
Tropacaine 124 151 ND 751 ND 
Norcocaine 168 195 ND 661 ND 
Cocaine 182 14,618 42 61,856 114 
Cocaethylene 82 75 ND 323 ND 
Benzoylecgonine-TBDMS 82 31,043 60 79,505 204 
Cinnarnoylcocaine 82 123 12 532 36 
Sedaxives 
Diazeparn 256 150 19 688 63 
Quaalude 235 6,254 43 24,631 117 
Miscellaneous 
Cotinine 98 8,419 2051 19,942 3,963 
Meconin 165 56 ND 132 ND 
Hydroxycotinine-TBDMS 249 2,407 734 8,389 3,373 
Trimipramine 249 ND ND 101 ND 
ND Not detected 
The comparison of S/N values for codeine, morphine and 6-MAM could not be obtained because of the 
overlap with the deuterated analogues. 
Heroin use was confirmed by the detection of morphine, codeine, and the specific 
metabolite, 6-MAM. However, the mass spectra of these components overlapped with the D3 
analogues added as internal standards. These were not resolved by the mass spectral deconvolution 
software. Therefore, the identification of these compounds was based on prior knowledge of the 
expected mass spectral fragmentation patterns observed from the spectra shown in Appendix 4. The 
quantitative analysis of these compounds should be possible using these internal standards but 
would require actual calibration standards with an initial standard -5 ng at point of analysis. 
We detected heroin itself which is not usually detected in urine or blood due to its rapid 
metabolism. We also detected various minor opiates including acetylcodeine, papaverine, 
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narcotine, meconin and thebaine, which strongly indicate that this is due to street heroin and not 
pharmaceutical diamorphine. 
Cocaine and its major metabolite benzoylecgonine were detected in both samples. 
Benzoylecgonine formed a stable TBDMS derivative but this compound was not present in our 
library database. However, the processing software did identify this compound as a TMS 
derivative. Therefore, the spectral match is quite low but we can confirm its presence by the unique 
mass ions and in particular the distinct [m-57]+ ion (Figure 5]. Cocaethylene was detected which 
indicates that alcohol must have been consumed along with the cocaine. Mesocain is a contaminant 
used to 'cut' the drug. Its presence provides an indicator of the level of purity. Cinnamoylcocaine 
and tropacaine compounds are found in the coca leaf and carried through the refining process. They 
are a marker of natural cocaine as opposed to a synthetic version. 
Methadone and its major metabolite, EDDP, were detected in both positive samples. EDDP 
is a reliable marker that methadone was actually ingested and has not been due to external 
contamination. Methadone is usually administered as a sticky liquid and as such contamination by 
contact may occur. These marker compounds are particularly useful in dealing with child-welfare 
cases in which the child may have been in contact with a drug but it is uncertain as to whether it 
was actually ingested. 
The detection of sedative-type drugs, diazepam and quaalude (methaqualone), and opioid 
analgesics, hydrocodone and phenazocine, are not surprising in drug users. These types of drugs 
are often taken to reduce the effects of withdrawal. Hydrocotamine has not been reported as an 
analgesic but may be added, in the formulation, to enhance the analgesic effect. '9 Cotinine and 3- 
hydroxycotinine are metabolites of nicotine. 
A profile of drug use can be rapidly attained in one protocol. We observed clearly resolved 
compounds with little interference from the sample matrix. The mass spectral analysis can be based 
on a whole spectral comparison and confirmed by the presence of unique ions. 
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The librarv match is for the TMS derivative but is actualiv a TBDMS derivative 
Fjgu S. Benzoylecgonine was incorrectly identified as a TMS derivative; therefore, the library , -re 
similarity is quite low. The confirmation was performed by mass spectral analysis. The presence of 
[m-571' ion is a good indicator of a TBDMS derivative. 
4.1.4 Results from ESR 
The samples were screened by LC-MS/MS for opiates (codeine, morphine and 6-MAM), 
methadone, amphetamines (amphetamine, methamphetamine, MDMA and MDA), and 
benzy1piperazine. The findings were as follows: Sample B- blank; Sample D- amphetamines 
(0.30 ng/mg), MDMA (0.15 ng/mg), codeine (1.2 ug/mg), morphine (5.85 ng/mg), 6-MAM (17.50 
ngtmg) and methadone (I ngting); Sample E- methamphetamine (<0.05 ng/mg), MDMA (0.15 
ngIrng), codeine (0-15 ng/mg), morphine (0.50 ng/mg), 6-MAM (1.25 ngtrng) and methadone (0.6 
ngling). 
We were able to positively identify 26 compounds in Sample D and 18 compounds in 
Sample E which were either drugs, specific metabolites or specific marker compounds of drugs. 
This qualitative analysis, obviously, provides a more comprehensive profile of this person(s) drug 
use than the target analysis performed by ESR. The detection of these compounds would require 
considerably more analysis time using target analysis techniques such as LC-MS/MS. 
99 
We correctly identified codeine, morphine, 6-MAM and methadone which were detected 
by ESR. The levels of sensitivity we achieved were very encouraging. These concentration ranges 
in hair are typical for drug users. However, a more involved analysis would be needed to ascertain 
limits of detection (LOD) which was beyond the scope of this research. 
We were not able detect any amphetamine-type compounds: amphetamine, MDMA and 
methamphetamine. We know from our previous analyses, where in relation to other drug 
components, the amphetamine-type compounds should elute in relation to other drug groups. We 
were also aware that GC-MS analysis of amphetamine-type compounds does not provide the levd 
of sensitivity that one would expect for many other drug-types. Levels of achievable MS sensitivity 
do vary depending upon the type of compound analysed. Therefore, the reason for the non- 
detection of these components must be either a lack of instrument sensitivity or that these 
compounds have degraded en-route from New Zealand. The concentration levels in the 
amphetarnine-type compounds, reported by ESR, are extremely low (<6 ng/20 mg hair. Howeva. - 
deuterated internal standards of these drugs were spiked at 50 ng/ 20 mg hair and these also went 
undetected. This is equivalent, in our analysis, to 250 pg on-column, in the splitless mode. This 
should be well within the detection limits of the instrument; therefore, it may be that the 
compounds have degraded to some extent. However, the LC-MS/MS system used by ESR, in this 
analysis, does represent the highest level of sensitivity currently available in MS systems. We have 
to assume that the main limitation of GC x GC-TOFMS, compared to high-sensitivity LC-MS/MS' 
is lack of sensitivity especially for amphetamine-type compounds. 
4.2 Conclusion 
We have demonstrated the potential of GC x GC-TOFMS to actual sample analysis and 
have demonstrated its ability to screen unknown components in biological matrices. This techniW 
could be useful for drug analysis work in which a general profile of drug use is required or if drug 
use is suspected but not detected in a routine diagnostic screen. it is certainly reasonable to assurae 
that comprehensive GC x GC-TOFMS could be another tool, for forensic toxicologists, to be used 
alongside diagnostic screening and high sensitivity MS platforms. 
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4.3 Future Work 
Any future work in the area of drug analysis in hair should be targeted at increasing the 
range of compounds that can be detected in a single protocol, in the concentration range that would 
indicate therapeutic drug use. Derivatisation by NffBSTFA has been shown to be an effective 
approach for the analysis of various drug types. 
Further sensitivity to amphetamine-type compounds may be achievable by use of a 
different derivatisatim method. Perfluoroacyl derivatising reagents such trifluoro-acetic anhydride 
(TFAA) should react with the primary or secondary amine groups present in amphetamine-type 
compounds. This would add a trifluoro-acetyl (TFA) group to the amine functional groups and may 
produce a derivative with greater stability for MS analysis. This hypothesis was proved in a later 
study which has been submitted for publication [Appendix 6]. However, the use of perfluoroacyl 
derivatives is not recommended for compounds which contain carboxylic acid functional groups 
(e. g. benzoylecgonine) because the reaction of an acid with an anhydride is generally 
unfavourable. Also steric hindrance effects may inhibit the reaction of the polar hydroxyl groups 
(e. g. codeine and morphine) with this reagent. Therefore, it is suggested that any further work in 
this area is aimed at combining a derivatisation procedure involving MTBSTFA followed by 
TFAA. 
This analysis was performed using a GC column that had been used extensively (-40 runs) 
in a previous study, albeit using the same derivatising reagent. However, it is strongly 
recommended that any further analysis is performed using a brand new GC column. Therefore, the 
highest level of column efficiency can be maintained. This will maximise the sensitivity and keep 
levels of column bleed and degradation products in the matrix to a minimum. 
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Chapter 5 
Stable Isotope Compositions (813C): A Proposed Means of 
Identifying the Source of Gamma-Hydroxybutyric Acid (GHB) 
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Stable Isotove Comoositions (813C): A Provosed Means of Identirving the Source at', 
Gamma-Hvdroxvbut-vric Acid (GHB) 
5.0 Introduction 
5.0.1 Background 
GHB [Figure 1] is produced naturally in the human body and is also a Class C controlled 
substance in the UK under the Misuse of Drugs Act 197 1. As a therapeutic drug it has been used 
for many years as an anaesthetic and for a range of disorders including narcolepsy, insomnia, and 
alcohol or opiate withdrawal. 1-4 It is also known for its psychotropic effects and is widely abused. It 
was legally available in the UK until 2003 and sold as a natural product. It has been reported to be 
popular as a 'club drug' due to its euphoric effects and also with bodybuilders as a putative 
5,6 stimulant of growth hormones. It became notorious because of its association with drug 
facilitated crime (DFQ and in particular drug facilitated sexual assaults (DFSA); its powerful 
sedative effect and ease of availability led to its reported use as a 'date rape' drug. 
Several studies have indicated that large variations in urinary and blood concentrations of 
endogenous GHB occur across population groups: urine (0.00-2.70 gg/Ml); 8 urine (0-16-2.14 
gg/ml); 9 urine (0.34-5.75 gg/ml) and blood (0.17-1.51 gg/ml). 10 The variation in these results am 
reported to depend on dietary factors and also in vitro production may increase levels dependent on 
storage conditions. " 
GHB and its analogue gamma-butyrolactone (GBL) [Figure 1] are found widely in various 
12 foodstuffs and beverages. GBL has been reported to be widely used in food flavouring 
formulations. 13 GBL is also as a cleaning solvent. 1,4-butanediol [Figure 1], often sold as pine 
needle oil, is also a commonly available product. These substances are used in natural products 
with a purported wide range of therapeutic benefits. Both these substances are rapidly converted to 
GHB in the human body and consequently are also abused substances. 14,15 
0 
0 
Ho**ýOH 
ýO 
HO,, -,,,,, ^ýOH 
_j 
GHB GBL 1,4-butanediol 
Figure 1. Structures of GHB and its pre-cursor compounds, GBL and 1,4-butanediol. 
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GHB is unique amongst street drugs. A person wishing to acquire this drug does not 
necessarily need to seek out a supplier. It is a relatively easy drug to make and the materials 
required are readily available. GHB is usually prepared as a sodium salt by mixing GBL with 
sodium hydroxide (NaOH) in water. NaOH is the main constituent of commonly available 
household cleaning products, caustic soda and lye soap. The pre-cursor compounds. GBL and 1,4- 
butanediol, undergo in vivo conversion to GHB and, therefore, the psychotropic effects are the 
GHB can be produced via various bio-synthetic pathways. The neuro-transmitter, gamma- 
aminobutyric acid (GABA) and 1,4-butanediamine (putrescine), as well as 1,4-butanediol and GBL 
all undergo in vivo conversion to form endogenous GHB [Figure 21.16,17 
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Figure 2. Bio-synthetic pathways of GHB. GHB may be formed in vivo and in vitro in biological 
fluids. 
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The recognised cut-off values have been reported at 10 ggtml in urine and 5 gg/ml in, 
blood. 8'10 However, this may only provide reliable evidence if the sample was taken <12 hours 
after ingestion because GHB is rapidly metabolised and excreted from the body. 18 In cases 
involving DFSA, GHB may have been administered surreptitiously to incapacitate a person prior to 
the assault and, therefore, the victim may not be aware until sometime later. Alcohol has a 
significant synergistic effect on the toxic properties of GHB. 19 Although the evidence suggests dW 
DFSA involving this or any other drug (except alcohol! ) is not widespread. A recent report by tbo 
Association of Chief Police Officers (ACPO) found that only 2 out of 120 urine samples, from 
suspected date rape victims, tested positive for GHB . 
20 However, there must be some concern 
surrounding this particular drug especially considering the ease of its availability and rapidity of 
removal from the body. 
5.0.2 Stable Isotopes (813C) 
At present, the cut-off values are widely regarded as the upper limits of naturally occurring 
GHB. However, the vast majority of the population will have endogenous GHB concentrations 
well below these cut-off values. Measurements of the composition of carbon (813 Q have been 
postulated as a means to differentiate endogenous from exogenous GHB at levels below the 
21-23 
recognised cut-off values. The 813C values of endogenous GHB are determined by dietary 
factors whereas synthetic GHB is derived from a petroleum source from different pre-cursor 
compounds using different reaction conditions. Therefore, it is reasonable to assume there may bC a 
significant difference between the two. The 813C of total GHB, in the body, is the weighted averap 
of endogenous GHB and of any exogenous GHB which may be present [Equation 5.11. TherefoM 
if exogenous GHB is present in excess of the endogenous GHB, in a sample, then this should be 
reflected in its overall g13C value. The implication being that stable isotope measurements could 
significantly increase time frames of detection in reported DFSA. 
813C"". [GHBIi,, = 
813 Cend 
- [GHBIond + 813Cexo -[GM31exo 
Equation 5.1 
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Saudan and co-workers applied gas chromatography-combustion-isotope ratio mass 
spectrometry (GC-C-IRMS) to compare S'IC values of endogenous GHB from 5 blood samples, 
taken post-mortem from people with no known drug-use, with synthetic GHB from 5 police 
seizures. 22 The endogenous GHB (-20.6 to -24.7 %o) were typical of compounds derived from C3 
plant metabolism found in the European population. The exogenous GHB values (-38.2 to -50.2 
%,, ) were significantly more depleted in the 13C (>13.5 %o) compared with endogenous GHB values. 
This represented a clear distinction between natural and synthetic GHB albeit from a very small 
sample set. This data was obtained from samples where endogenous levels (range: 13.8-86.3 
gginil) were likely to be elevated probably due to the process of putrefaction. The bacterial 
breakdown, in post-mortem fluids, and production of 1,4-butanediamine (putrescine) is hydrolysed 
to form GHB . 
17 Therefore, recognised cut-off levels are unreliable on post-mortem detection of 
GHB. Putrescine is converted to GABA and subsequently hydrolysed to GHB; therefore , 
813C 
values of GHB from these samples will have been predominantly derived from metabolised 
GABA. 
Further work by the same research group obtained 813C values for endogenous GHB from 
24 
post-mortem urine samples (-23.5 to -27.0 %o, n= 7). This was compared, in the same study, 
With 813C values (-32.1 to -42.1 %o, n= 5) obtained for urine specimens from volunteers exposed to 
synthetic GHB in a controlled study. The volunteers ingested 25 mg/kg bodyweight and the urinary 
concentrations, taken -30 min after exposure, were much higher (231 - 3742 gg/ml) than the 
10 RgtMI CUt_off. Therefore' the 813C values were clearly derived from a synthetic source. These 
VC values were in the range of the values obtained for the synthetic standards (-34.5 to -45.8 %o) 
used for this study. Unfortunately, the authors do not state which 813C values taken from the 
volunteers correspond to which synthetic standards. Saudan et aL stated that the results had 
demonstrated that 813C values were not significantly altered after excretion from the body. 24 It has 
separately been reported that only -1% GHB is removed from the body unchanged. 1,18 The 
remaining GHB undergoes rapid metabolism in the liver, as shown in Figure 2. It is reasonable to 
assume that a kinetic isotope effect will result in a slight increase in the 13C of excreted urine as 
biological reactions tend to react slightly quicker with the 12C isotope. These results tend to suggest 
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that this may, in fact, be the case because there is a slight increase (-2 %o) across the range of the 
urinary values. However, the actual data is not provided in this paper. 24 
5.0.3 Extraction and Derivatisation 
GHB is a non-volatile salt and, therefore, GC analysis requires either derivatisation of the 
polar hydroxyl/carboxyl groups or the intra-molecular conversion to GBL in strong acidic mediL. ý 
Derivatisation by BSTFA 4,5,9,10,25,26 NffBSTFA, 18 and intra-molecular conversion, 1'2' 
17,24 ha 
been described in various publications. The extraction methods described involve either SPE or 
LLE techniques. 
GC-C-IRMS is generally not as sensitive as conventional GC and GC-MS systems. The 
organic compounds are converted to C02 in the combustion interface and the isotopic values are 
derived from the m/z ions: 44,45 and 46. IRMS can detect these ions with very high precision but 
not high sensitivity. Furthermore, a clear chromatographic baseline separation from the sample 
matrix has to be achieved or the isotope values will be composites of the co-eluting components. 
Therefore, it is preferable to use a large sample volume to maximise the sensitivity. However, more 
sample volume also potentially adds more matrix interfering compounds to the final analysis. 
Therefore, the clean-up method is vitally important. 
Saudan et aL applied a multi-step clean-up procedure involving 2x SPE extractions and an 
HPLC purification step to extract GHB from 2 MI of Urine. 24 The extracts were converted to GBL 
to successfully obtain 813C values (-23.5 to -27.0 %o, n= 5) from post-mortem urine. The 
concentrations of GHB were between 5 and 10 gg/ml. However, these levels are still a lot higher 
than the expected endogenous GHB levels in ante-mortem samples. "O Moreover, some of these 
sample concentrations were much higher and the samples were diluted with water to set the 
concentration between 5 and 10 gglml. 
The use of such a complex clean-up procedure raises issues as to its practical 
implementation. There are concerns regarding the repeatability of HPLC separation especially 
when dealing with such small isotope shifts. Also there are concerns about reliability of the 
measured concentrations in post-mortem. urine. High levels of putrescine may lead to in vitro 
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production of GHB and although appropriate storage conditions were maintained after the samples 
were taken this does not exclude the possibility that more GHB was produced during the analysis. 
In addition, the concentrations were determined using a different published procedure, involving 
LLE and BSTFA derivatisation, 4 to the isotope analysis. The GHB concentrations were not 
calculated from this main method which would appear to be the most reliable way to ensure that in 
vitro production had not occurred. Also, as the samples were diluted with water to set the 
concentrations between 5 and 10 ILg/ml, this may have shifted the equilibrium between GHB and 
GBL. 27 Any appreciable concentration of GBL not detected in the initial screen may have been 
converted to GHB by the dilution which may have resulted in an increase in the pH. However, 
despite these concerns over this method it does demonstrate the potential of stable isotopes for 
pseudo-drug detection. The limits of detection (LOD) were not evaluated in this procedure. 24 Any 
future work in this area should be aimed towards detection of endogenous GHB in ante-mortem 
urine i. e. <2 gg/rnl. 
5.0.4 Research Work 
The aim of this study was to employ a more methodical approach to determine the 813C 
values of GHB in urine samples and assess the level of isotopic precision and repeatability that 
could be obtained. The main part of the study was developed to determine 813C values of GHB 
derivatised. with BSTFA. A clean-up method involving SPE was used to determine the 
concentration of endogenous GHB in urine and the 813C values of urine spiked with GHB (10 
ggiml). The analyses were run concurrently. Three different synthetic GHB standards were 
compared. Gamma-hydroxyvaleric acid (GHV) was used as an internal standard for quantitation 
purposes and as a control standard for isotopic measurements. GHV is a 5-carbon analogue of GHB 
and as such the properties are very similar. 
The addition of carbon atoms to the analyte has the effect of 'diluting' the 813C values. 
Therefore, the 813C value of silylated GHB is the carbon-weighted average of the isotope values of 
GHB and'IMS [Figure 31. The same batch of BSTFA was used throughout this study to ensure the 
results were consistent. 
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The intra-molecular conversion of GHB to GBL in acidic media was also investigated'and 
is advantageous because it does not alter the carbon composition. Derivatisation widi MTBSTFA 
was also investigated to determine if the repeatability could be improved. 
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Figure 3.813C value of derivatised GHB is the carbon-weighted average from GHB and the TMS 
ether. 
5.1 Results and Discussion 
5.1.1 Synthetic Standards 
Synthetic GHB is usually made illicitly by base hydrolysis of GBL to give the GHB UK 
[Figure 4]. GBL can be produced by hydrogenation of maleic anhydride or dehydrogenation. of 1,4- 
22 butanediol, which is derived from acetylene and formaldehyde. The different synthetic routes Md 
sources of the petroleum products determine the isotopic variability of the compound. 
The standards in this study have been derived from different sources to reflect the diverse 
nature of this drug. Standard #1 was prepared from GBL by base hydrolysis with NaOH, described 
in Section 2.2.3.1. Standard #2 was an NMIA reference standard. The synthetic route of this 
compound was not known. However, it was also a sodium salt. Standard #3 was prepared from 
GBL which had been synthesised from 1,4-butanediol by dehydrogenation using copper chromite 
catalysts, described in Section 2.2.3.4, and subsequent conversion to GHB [Figure 4]. 
The control standard GHV was prepared from its corresponding lactone, gamma- 
valerolactone (GVL) by base hydrolysis to give the GHV salt, described in Section 2.2.3.2. 
Salts of GHB and GHV are extremely hygroscopic and, therefore, every effort was made to 
ensure they were dried before quantities were weighed out. All stock standard solutions were 
prepared in concentrations equivalent to the acid. 
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Figure 4. The dehydrogenation of 1.4-butanediol to GBL and subsequent base hydi-olysis to fol-In 
GHB (sodium salt). 
5.1.2 Calibration 
Three separate urine samples, taken on different days from the same volunteer, were found 
to contain 1.62,1.50 and 1.31 pg/ml endogenous GHB. quantitated against a 7-point calibration C, I- 
curve (0.1 to 50 Vg/ml, R2 =0.997) with GHV (10 gg/ml) used as an internal standard [Figure 51. 
The standards were prepared in water and derivatised with BSTFA. The quantitation ions used 
were GHB di-TMS (m/z 233) and GHV di-TMS (m/z 247). Both quantitation ions correspond to 
[m-151+ peaks. 
GHB 
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Figure 5. GHB calibration (0.1 to 50 pg/ml). Internal standard GHV (10 Pg/ml). The qtiantitation 
is based on the peak area ratio of GHB di-TMS (nVz 233)/GHV d1-TMS (nVz 247). 
A percentage recovery (62%) was obtained for Clean Screen SPE cartridges by comparison 
of the mean peak areas (m/z 233) of three 50 pg/ml GHB standards against three 50 Vg/ml GHB 
spiked urine samples, described in Section 2.2.9. Chromatograms obtained using GC-MS indicated 
that a reasonable separation of GHB and GHV could be achieved from the matrix (Figure 61. 
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Figure 6. Chromatograms obtained from analysis of GHB by ion trap GC-MS: (a)i. TIC; ii. Mlz 
2-33,247. GHB standards (50 pg/ml) prepared in water. (b)i. TIC, ii. mJz 233,247. Spike in urine 
(50 pg/ml). 
GHB di-TMS (RT. 8.05, nVz 233) and GHV di-TMS (RT. 8.56; m/z 247) were clearly 
resolved from matrix interferences. The large peak at RT. 9.35 is derivatised phosphoric acid which 
is found in large concentrations in urine and can poses difficulties for GC-C-IRMS analysis due to 
co-elution. 
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5.1.3 GC-C-IRMS Analysis of GHB Spiked Urine and Control Samples 
Three separate urine samples, containing 1.62,1.50 and 1.31 gg/ml endogenous GHB, 
were spiked (10 ggIml GHB) with three synthetic standards (#1, #2 and #3), respectively, and the 
control standard (10 ggIml GHV). The extraction and derivatisation procedure is discussed in 
Section 5.1.4. 
The 813C values obtained were compared against values obtained for the synthetic 
standards prepared from water with no clean-up [Tables I and 2]. The samples were run in 
triplicate. The endogenous concentration was not expected to significantly alter the 813C (%0) 
values. At this level the exogenous GHB is in a large excess. The endogenous concentrations were 
determined by urine spiked only with the GHV control (10 gg/ml). GC-C-IRMS and GC-MS 
analyses were undertaken concurrently to ensure that no significant level of in vitro production had 
occurred. The sample clean-up for all the analyses was performed on the day of collection. The 
same derivatising agent was used throughout to ensure that a level of consistency was maintained. 
Table 1.813C ('Yov) values of GHB di-TMS (10 gg/ml standard preparation) 
Run Standard #l Standard #2 Standard #3 
%0 %0 %0 
1 -31.3 -35.9 42.9 
2 -29.8 -35.9 43.0 
3 -30.6 -35.0 -42.7 
Mean -30.6 -35.6 -42.9 
cyll-i 0.8 0.5 0.2 
Table 2. VC (cloo) values of GHB di-TMS (10 ggiml 'spikes' in urine) 
Run Standard A Standard #2 Standard #3 
1 -31.6 -33.2 -41.7 
2 -31.7 -34.9 -42.9 
3 -31.9 -34.0 -41.9 
Mean -31.7 . 34.0 . 42.2 
(YU-1 01 0.9 0.6 
Samples were prepared and run in triplicate. 
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The results presented in Tables I and 2 demonstrate a large variation in the isotopic 
composition of the three synthetic standards and reflect the different synthetic processes of each. 
813C values obtained for each reference standard were comparable using the standard preparation 
and extracted from urine. As expected, the addition of 10 gg/ml synthetic GHB in urine is in a 
large excess over the endogenous concentration and, therefore, the isotope ratio is not significantly 
altered. The overall repeatability is inconclusive ((Y, -, 
0.15 to a, -, 
0.85). A larger sample set would 
need to be applied to obtain a more accurate reflection of the standard deviation. This is further 
emphasised by the comparison of 813C values from the corresponding GHV control standards (an-I 
0.15 to c;,, - 1 1.88) [Table 3 and 41. The poor repeatability is likely to be due to incomplete 
derivatisation. or degradation of the derivatives in the GC injector. 
The actual GHB values (i. e. without the added carbon atoms from derivatising agents) 
were expected to show even greater variability. This has been investigated further in Section 5.1-6. 
Table 3.813C (96) values of GHV di-TMS controls (10 gg/ml standard preparation) 
Run Standard #1 Standard #2 Standard #3 
%0 %0 
1 -30.7 -32.6 -34.1 2 -30.4 -32.8 -31.1 3 -31.9 -31.8 -33.4 Mean -31.0 -32.4 -32.9 
Cyn-I 0.8 0.5 1.6 
Table 4.81 -1C (%o) values of GHV di-TMS controls (10 Rg/ml 'spikes' in urine) 
Run Standard #1 Standard #2 Standard #3 
%C %0 
1 -31.2 -28.1 -32.7 2 -30.9 -30.5 -33.6 3 -31.0 -31.8 -31.5 Mean -31.0 -30.1 -32.6 
Owl 0.2 1.9 1.1 
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MA Component Separation 
The chromatograms obtained from the GC-C-IRMS have shown that GHB and GHV 
derivatives can be separated sufficiently from the matrix interferences [Figure 7 and 8]. The 
chromatographic separation of the component analytes is necessary for isotope analysis as all the 
organic molecules are converted to C02. The clean-up procedure, described in Section 2.2.6, using 
CLEAN SCREEN GHB SPE cartridges provided a rapid and reliable clean-up of I ml of urine. 
The cartridge contains reverse phase and strong cationic exchange (SCX) components which have 
the effect of retaining the contaminants whilst the target analytes are not retained. The cartridge is 
then washed with methanol and the extracts evaporated prior to derivatisation. The rapid procedure 
should minimise any further in vitro production. One of the main contaminants in urine is urea 
which was successfully removed. The other main contaminant, phosphoric acid, was not removed. 
This compound undergoes derivatisation to form phosphate tri-TMS and is the large peak shown in 
Figure 8. These two major contaminants were highly problematic in this analysis. Although urea 
was removed from 1 ml of urine; increasing to 2 ml sample volume resulted in some urea in the 
final extract which was probably due to overloading the SPE cartridge. This compound is 
derivatised to urea di-TMS and has a similar retention time to GHB di-TMS. Also an increased 
sample volume resulted in a large increase in phosphoric acid which overloaded the GC column 
and also resulted in co-elution with GHB. Other SPE cartridges were evaluated including strong 
anionic exchange (SAX) and C 18 reverse phase but the results were poor in comparison to the 
CLEAN SCREEN GHB SPE cartridges. 
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Figure 7. GC-C-IRMS chromatogram GHB and GHV standard (10 ýlg/rnl). 
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Figure 8. GC-C-IRMS chroniatogram of synthetic GHB and GHV spiked in human urine (10 
pg/ml). The separation was sufficient to obtain satisfactory 813C values without interference froni 
the matrix. Analytical conditions were as outlined in Section 2.2.11 .1 
The method was not sensitive enough to obtain 61 1C Mc) values for enclogenous GHB and 
although Some 813C values were obtained at the 5 jug/mI level, the signal responses were very low 
and the data was not reproducible. This will have been due to interfering compounds in the sample 
matrix which restrict the sample volume that can be used. The need to improve the clean-up 
protocol appears to be a priority. This has been discussed further and a potential solution 
investigated in Chapter 6 of this thesis. 
The application of this technique to actual forensic toxicology is dependent on successful 
detection of endogenous GHB. 8"C values from endogenous GHB has been detected in post- 
niortein blood and urine where the concentration levels are a lot higher. 22.2" However, it has not yet 
been detected in ante-mortem biological samples. 
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5.1.5 GC-C-HMS Analysis of GBL and Elemental Analysis of GBB (Salt) 
The actual 813C values of underivatised GHB were explored by analysis of Standard #1 and 
its corresponding lactone. The GBL and GHB (salt) standards were prepared in triplicate and 
analysed by GC-C-IRMS and an elemental analyser/IRMS (described in Section 2.2.11.4), 
respectively [Table 51. A very high level of precision was observed for GBL and GVL standards 
(a, -, 
0.06 GBL; on-, 0.12 GVQ. It suggests that the intra-molecular conversion of GHB to GBL 
would provide a very accurate means to determine 813C of GHB especially because it does not add 
additional carbon atoms to the molecule. Unfortunately recoveries obtained for this conversion was 
very low. This is discussed further in Section 5.1.8. 
The mean 813C value of GBL (-26.5 %o) was very similar to the mean value obtained for 
the corresponding sodium salt (-27.0 %o) obtained from the elemental analysis. The percentage 
yield obtained from the base hydrolysis was quite high (87%). It would appear that significant 
isotopic fractionation has not occurred. The 813 C GHB (salt) from the elemental analyser showed a 
much lower level of precision (cF. -I 0.51 GHB; c;, -, 
0.83 GHV) than the GBL standards. The three 
standards were weighed out equivalent to -320 jig carbon. However, an exact weight at this level is 
difficult to obtain because the GHB (salt) is very hygroscopic. The variation in the weighed 
amounts may affect the instrument precision and, therefore, be the reason for the variation in the 
isotopic data. 
The 813C values are also higher than were expected for the synthetic GHB. The values 
obtained are actually at the lower limits expected of endogenous compounds from a C3 diet. 
Saudan et aL reported 813C values ranging from -23.5 to -27.0 %o for endogenous GHB and -34.5 to 
-45.8 %o for synthetic GHB. 
24 This appears to suggest there may not always be a clear distinction 
between exogenous and endogenous compounds. 
We had hoped to present isotope data for the other two reference standards using elemental 
analysis. Unfortunately, this was not made possible due to prolonged problems with the instrument. 
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Table 5.813C (9.6) values of GBL and GVL compared with 81 3C (176) values from the 
corresponding sodium salts. 
Run GBL GVL GHB (Ref #1) GHV 
%0 %V %0 91" 
1 -26.5 -26.6 -27.6 
mono 
-27.3 
2 -26.6 -26.6 -26.7 -27.3 3 -26.5 -26.8 -26.7 -28.9 Mean -26.5 -26.7 -27.0 -27J 
cyn-I 0.1 0.1 0.5 0.8 
GBL and GVL standards (50 ligIml) were prepared and run in triplicate. Analytical conditions were as 
outlined in Section 2.2.11.1 
Quantities of GHB and GHV (salts) used for the elemental analysis were: GHB 1.25,0.99 and 0.89 Mg, 
GHV 1.06,0.78 and 1.18 mg. Analytical conditions were as outlined in Section 2.2.11.4 
5.1.6 Isotopic Precision of BSTFA Derivatives 
The precision of the GC-C-IRMS was evaluated by three repeat injections of GHB 
Standards #1 and #2 (50 gg/ml), and GHV (50 gg/ml) [Table 6]. Further repeat injections were 
performed for Standard #2 (sample and standard preparation) at 50 Jig/ml [Table 71. The 
repeatability has not improved relative to the replicate samples, prepared at 10 ggIml [Tables I to 
41. The isotopic precision for these repeat injections of GHB di-TMS and GHV di-TMS indicde 
that these derivatives may not be completely stable. Degradation in the sample injector may explids 
the small variations in the 813C values. There will be a kinetic isotope effect involved in this 
process whereby 13C containing molecules may degrade at a slightly different rate. This lack of 
repeatability suggest that BSTFA derivatisation would only be suitable to differentiate GHB 
differences >-2%o. 
Table 6.813C (%o) values of GHB di-TMS (Ref #1), GHB di-TMS (Ref #2) and GHV di-TMS. 
Run GHB #1 GHB #2 GHV 
50 gg/ml 50 gg/ml 50 WW 
%0 %0 %C 
1 -31.2 -35.1 -31.7 2 -32.2 -36.0 -31.2 
3 -31.2 -35.9 -30.4 
Mean -3l. S -3S. 7 -31.1 
crn-l 0.6 O. S 0.7 
Repeat injections (0) 
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Table 7.813C (%cc) values of GHB di-TMS (Ref #2) from standard and SPE preparation. 
Run GHB (Std. Prep) GHB (SPE Prep. ) 
50 gg/ml 50 gg/ml 
%C 
1 -37.1 -36.9 
2 -36.5 -37.9 
3 -36.7 -37.5 
Mean -36.8 -37.4 
(Fn-l 0.3 0.5 
Repeat injections (0) 
An estimate of 813C for TMS groups from BSTFA (-34.5 %o) was obtained from the 
equation in Figure 3 using the mean 813C value of GHB di-TMS (#I) in Table 6. The BSTFA value 
was derived from the carbon-weighted difference of the GHB (#l) salt (-27.0 %o) and the 
derivatised compound (-31.5 %o). This value was then incorporated into the equation in Figure 3 to 
obtain approximate 813C values for the other two standards. 813C values (-33.3 %o (#2) and -53.8 %o 
(#3)) were calculated from the spiked urine values outlined in Table 2. They provide useful 
approximations of the actual 813C values. However, because of the lack of repeatability observed 
for the TMS derivatives and unknown potential kinetic isotope effect, we cannot apply any sort of 
statistical analysis to this data. 
5.1.7 MTBSTFA Derivatisation 
GHB derivatised with N-methyl-N-(tert-butyldimethylsilyl)trifluoroacetamide 
(WBSTFA) was also evaluated as an alternative to BSTFA. GHB di-TBDMS 8 13C values were 
found to be more reproducible [Table 8] compared with GHB di-TMS [Table 6]. This is almost 
certainly due to improved stability of TBDMS derivative which form more stable compounds with 
much higher boiling points. Better sensitivity was observed (i. e. greater signal response) which is 
due in part to the addition of 12 carbon atoms compared to 6 carbon atoms for the BSTFA 
derivatisation. However, factors such as incomplete formation during the silylation reaction and 
degradation of the derivative in the injector port must be more prevalent with TMS compared with 
TBDMS derivatives. This may explain why the isotopic shifts are less repeatable using BSTFA. 
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The addition of 12 carbon atoms to a unit containing only 4 carbons shifts the overall 
isotopic value towards the TBDMS ether. This dilution of the isotopic signature of GHB means. 00 
only compounds with fairly large isotopic shifts are likely to be differentiated. However, more 
refined differentiations are unlikely to be realised by this approach. 
Table 8.813C (%c) values of GHB di-TBDMS (10 ggImI standard preparation). 
Run Standard #l Standard #2 Standard #3 GHV di-TBDNB 
%0 %0 %0 %0 
waft 1 -28.0 -30.2 -33.9 -27.7 2 -28.1 -30.2 -34.4 -27.8 3 -28.4 -30.5 -34.1 -27.5 Mean -28.2 -30-3 -34.1 -27.7 
(Yn. i 0.2 0.2 0.3 0.2 
Samples were prepared and run in triplicate. 
The 813C (%v) values from the TBDMS derivatives were used to obtain estimates for the 
actual 813C of reference standards #2 and #3. The procedure was as detailed in Section 5.1.6 using 
the mean values of GHB (#I) di-TBDMS (-28.2 %o) from Table 8 and the GHB (#I) salt (-27.0 %o). 
The equation in Figure 3 was altered to account for the 12 additional carbons added to the molecide 
[Figure 9]. The 813C value of the TBDMS groups was calculated at -28.6 %v. 813C values of the 
reference standards #2 and #3 were calculated at -35.4 %o and 50.6 %v, respectively. Because beftr 
repeatability was observed for NffBSTFA derivative these values are potentially more reliable than 
those obtained using BSTFA. 
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Figure 9.813C value of derivatised GHB is the carbon-weighted average from GHB and the 
TBDMS ether. A 813C value of the TBDMS carbons can be derived from a known reference and 
applied to calculate 'actual' values of different reference standards. 
5.1.8 Intra-molecular conversion to GBL 
GBL was analysed by GC-C-IRMS by preparation of standards (50 gg/ml) in TBME 
[Table 51. The volatility of this compound makes it ideal for GC analysis. The isotopic data was 
highly reproducible. However, the sensitivity was not as high as the BSTFA and MTBSTFA 
derivatised standards. GBL standards prepared at 10 jig/ml were not detected by GC-C-IRMS. 
The intra-molecular conversion of GHB to GBL in strong acidic media was investigated. It 
was found that the recoveries were not sufficient to obtain isotopic data [Table 9). The recoveries 
were calculated by comparing the peak areas (m/z 42) obtained from 4x GBL standards (50 Rg/ml) 
prepared in TBME with the peak areas obtained from urine spiked with GHB (salt) (50 Rg/mi)-, 
extracted and analysed by our method outlined in Section 2.2.10. A correction was made to take 
into account the difference in relative molecular mass (RMM) between GBL and GHB (salt). The 
recoveries achieved were quite low and further investigations were undertaken. 
The results were obtained using an ion trap GC-MS. A comparison was made using 
quadrupole GC-MS which produced a different mass spectrum than the ion trap [Figure 10 and II]. 
This highlights some of the difficulties associated with mass spectrometry as repeatable spectra are 
not always observed with different instrument types. 
A published procedure, described by Ferrara et al. and using LLE, obtained 76.4% 
recovery from urine for the conversion of GHB to GBL. 1 A similar method was employed by 
saudan et al. for the intra-molecular conversion of GHB prior to GC-C-IRMS analysis although the 
percentage recoveries were not reported. 24 Both of these published procedures were investigated 
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and replicated in our laboratory to ascertain whether we could achieve a high level of recovery. 
Urine spiked with GHB (50 gg/ml) was extracted according to the methodology preseMat 
Unfortunately neither of these methods proved to be successful and no GBL was detected. It is 
unclear as to why this may be the case. 
GHB and GBL exist in equilibrium dependent upon the pH. 27 Therefore, the final pH 
adiustment prior to extraction into organic solvent is very important to obtain high recoveries. u 
Ferrara et aL reported an adjustment to pH 6.5, by addition of NaOH. They also state that 
increasing the pH may prevent the protonation of the lactone and thereby improve the extractiom- 
efficiency! Saudan et A did not adjust the pH prior to LLE. " The intramolecular conversion was 
carried out in 6M HCI and the aqueous acidic mixture was then extracted directly into DCM. LLE 
extraction without pH adjustment was also reported by LeBeau et al .2 
Our own studies have indicated that the optimum pH for liquid-liquid extraction from the 
aqueous phase to the organic phase to be pH -4. At higher pH (>5) we did not detect GBL which 
we assumed was due to hydroloysis of the lactone back to GHB. Also at low pH (<2) GBL was not 
detected which we assumed to be due to protonation of the lactone. Therefore, our studies indicate 
a pH range 2-5 should be achieved prior to extraction. 
There are some interesting issues raised here that may require further investigation but am 
beyond the scope of this study. Most published methods employ derivatisation and this may be a 
reflection of the inherent difficulties with lactone conversion. 
Table 9. Percentage recoveries obtained for intramolecular conversion of GHB (50 gg/ml in urirg) 
to GBL, in strong acidic media, compared against GBL standards (50 ggtml). 
Spiked Samples (50 ug/ml GHB) % Recovery 
Liguid-liguid extraction 
Samplo_a 19 
Sampleýb 16 
Sampliý_c 17 
Samplo_d 15 
4x replicates. The analytical conditions were as outlined in Section 2.2.11.2. 
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Figure 10. GBL and GVL standards (50 gg/ml) run on an ion trap GC-MS with Rxi-5ms column: 
(a) the components are clearly resolved; (b) mass spectrum for GBL (RMM 86). The peak areas (x 
4) from the target ion (m/z 42) were used as a reference to calculate the recoveries from GHB 
spiked urine converted to the lactone by intramolecular conversion in strong acid. 
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FigUre 11. GBL and GVL standards (50 gg/ml) run on a quadrupole GC-MS with J&W DB-5MS 
column: (a) chromatographic separation of GBL and GVL; (b) mass spectrum for GBL (RMM 
The spectrum is quite different from the Ion Trap analysis [Figure 101. 
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5.2 Conclusion 
The work so far has demonstrated that GHB, derivatised with BSTFA and MTBSTFA, can 
be effectively analysed by GC-C-IRMS. 813C (%0) values were successfully obtained for 10 ggIml 
(acid equivalent) spiked in urine and extracted by SPE. The LOD was not determined but reliable 
isotopic data was not obtained below this level. 
Further investigation is required to detennine if GC-C-IRMS can be used as a reliable 
technique to differentiate exogenous from endogenous GHB. The most promising technique is the 
intra-molecular conversion to GBL which produced highly reproducible isotopic data albeit with 
only 3 standards of GBL and GVL (50 gg/ml) and does not alter the carbon composition of the 
molecule. However, the recoveries obtained for conversion to GBL (< 19%) were too low for this 
approach to be realised and the sensitivity was also insufficient. GBL standards were not detected, 
by GC-C-IRMS, at 10 gg/ml. This is equivalent to -25 ng carbon on column. The instrument can 
potentially detect <5 ng so this should have been within its limits. GBL is highly polar and, 
therefore, better sensitivity and separation from the matrix may be achieved using a moderately 
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polar phase instead of a non-polar DB-5. Saudan et al. used a DB- l7ms (50% phenyl) column. 
Derivatisation of GHB with BSTFA provided far greater sensitivity and is more amenable 
to non-polar phase columns. However, the addition of 6 carbon atoms has the effect of 'diluting' 
the isotopic values so that only relatively large isotopic shifts (>2 %o) may be expected to be 
resolved. The BSTFA derivatives were less stable than MTBSTFA. Therefore, the isotopic 
precision and overall sensitivity with NMSTFA was very good compared with BSTFA but the 
addition of 12 carbon atoms to a4 carbon molecule would only allow for very large isotope shifts 
to be realised. 
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53 Future Work 
We did not have the opportunity to test our method on actual samples. There is the 
potential to develop a validated method to test actual samples. GHB is a commonly abused dMg 
that may go undetected because of the relatively high cut-off values necessary to differentiate it 
from the endogenous compound. Despite the lack of sensitivity it may be possible to develop a 
method whereby a sample that is very close to the 10 ggtml (urinary) threshold i. e. 5- 15 ggInIL 
may be subjected to an additional test for further clarification. This would require further 
optimisation of the method and determination of the limit of detection. 
There is certainly a need to investigate the isotopic shift from administered GHB, excreWd 
in urine, compared with the actual value of the synthetic drug. However, this will require 
partnership with a medical/toxicology facility that is equipped to perform these types of studies. It 
has been reported that only -1% of administered GHB is excreted unchanged in urine. 8 Saudan ef 
aL observed no significant alteration in 813 C between synthetic standards and the excreted drug in 
volunteers administered that same drug. 24 However, as we discussed in Section 5.0.2, the authors 
only reported a range of 813C values and not the specific sample data. An isotopic shift of -+2 %0 
would be expected in excreted GHB. 
The problem of lack of sensitivity could be overcome by use of a larger sample volume. 
This will require removal of more matrix interferences which tend to overload the GC column. 
Saudan et aL applied a combined SPE clean-up and HpLc purification but this may have practical 
difficulties as we discussed in Section 5.0.3. 
This problem may be overcome by the development of an affinity column to selectivelY 
remove GHB from the matrix. Development work is discussed and investigated in Chapter 6 of NS 
Thesis. 
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Chapter 6 
Preparation of an Immunising Antigen for Raising an Antibody 
Specific to the Structure of Gamma-Hydroxybutyric Acid 
(GHB) 
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Prevaration of an Immunisine Antieen for Raisinia an Antibodv Svecific to the 
Structure of Gamma-Hvdroxvbutvric Acid (GIJB) 
6.0 Introduction 
6.0.1 Background 
In Chapter 5 of this thesis it was postulated that stable isotope measurements of 813C OGUM 
differentiate endogenous from exogenous GHB. We developed a method using gas 
chromatography-combustion-isotope ratio mass spectrometry (GC-C-IIRMS) to determine the VC 
(%o) values for GHB in urine spiked with 10 gg/ml of synthetic GHB. This is the widely recOSOW 
urinary cut-off value of this drug. Below this level it is assumed that any GHB is derived from aft 
endogenous source. However, we were not able to achieve precise isotopic data <10 gg/Ml. 
Although recent work has demonstrated that a larger sample volume (2 ml) can be used to obtWU 
813C values below the recognised urinary cut-off value (10 gg/ml); this involved a complex Clera- 
up procedure involving two SPE extractions and further purification by HPLC. 1 Also the 
concentration levels (5 - 10 gg/ml), obtained from post-mortern urine, were relatively high 
compared with ante-mortem samples and a method to extract and analyse carbon isotopic data fMM 
ante-mortem urine is not available. 
There is a need to detect endogenous GHB at lower levels which may provide a reliable 
means to differentiate enclogenous from exogenous GHB. The length of time needed to perfoM do 
analysis was a key consideration in our evaluation. A rapid analysis, preferably involving one 
clean-up step, should allow better repeatability and reproducibility. A single step SPE analysis, 
described in Section 2.2.6, did not remove enough of the sample matrix to enable the larger 
volumes required to achieve the sensitivity. 
A novel approach to this problem has been explored with the aim of developing an 
immuno-affinity column to selectively remove GHB from the sample matrix and remove all the 
interferences. This would have the great advantage in that a larger sample volume of urine COUWN 
used without the concern of overloading the column or the instrument. The process requires dw use 
of a target specific antibody. However, immunoassays are not available for GHB detection. 2 
Therefore, this could not be achieved by commercially available materials. 
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This chapter has explored this novel approach to GHB extraction and sought to develop a 
method to produce an immunising antigen containing the GHB sub-structure. If successful then it 
would be reasonable to assume that an antigenic; response in vivo would create antibodies with 
binding sites specific to this structure. This would require further work by a commercial partner to 
raise the antibodies. 
The development of a selective extraction technique for GHB would have far wider 
implications than isotopic analysis of GHB. A routine diagnostic technique is not available to 
screen for GHB. Therefore, screening and confirmation is determined by GC-FID, GC-MS or LC- 
MS. An antibody specific to GHB would create the opportunity to develop an immunoassay 
method and a rapid approach to GHB detection. 
6.0.2 Research Work 
The synthesis of tetrahydro-5-oxo-3-furanyl acetic acid (furanyl acetic acid) has been 
described .3 We identified this compound as having the appropriate sub-structure to react with the 
lysine residue of a protein to make the antigen [Figure 1]. The method has been developed to 
synthesise this compound. 
Furanyl acetic acid was synthesised from furfural (2-furaldehyde) via a 4-step synthetic 
process involving photochemical oxidation and ethoxidation. to 5-ethoxy-2 (51f)-furanone, Michael 
Addition to trans diethyl 5-ethoxytetrahydro-2-oxo-4-furanylmalonate, decarboxylation to cis 
dihydrofuro[4,51 furan-2,2'-dione and finally reduction to furanyl acetic acid [Figure 2]. 
Furanyl acetic acid 
H2 
Protein 
Antigen 
j[pigure 1. Proposed reaction scheme of the GHB pre-cursor (furanyl acetic acid) with the lysine 
residue of a protein. The aim was to make an antigen which contains the GHB sub-structure. 
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Figure 2. Reaction scheme for the synthesis of fiiranyl acetic acid from furfural (2-furaldehYde)- 
The synthetic reaction is described in Section 2.3.3. 
6.1 Results and Discussion 
6.1.1 Furanyl Acetic Acid Synthesis 
Furanyl acetic acid was successfully synthesised using the method described by Walravo, 
and Pandit. 3 The structural confirmation was confirmed by NMR and IR analysis [Appendix 11. 
However, it was difficult to achieve good percentage yields which reflect the complex nature Of di 
synthesis. Photochemical oxidation and ethoxidation of furfural to 5-ethoxy-2 (5H)-furanone WIS 
monitored by IR. Furfural has distinct carbonyl absorbances at 1680 and 1700 cm-1; the 
disappearance of these two bands and the appearance of ketone absorption at 1762 and 1796 Cie 
were an indication that the oxidation had occurred. This took 72 hours to complete. After 
distillation of the crude product, a 48% yield was obtained. 
The next stage of the reaction involved a Michael addition (3.75 g starting material. ) to 
trans diethyl 5-ethoxytetrahydro-2-oxo-4-furanylmalonate using diethyl malonate. The crude 
product (8.5 g) was obtained as slightly discoloured oil. The NMR analysis indicated very few 
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impurities in the product. Therefore, we decided not to further distil compounds because of the 
high boiling point of the compound. Therefore, we were not able to calculate the percentage yields 
for this compound or for the next compound. 
The compound, cis dihydrofuro[4,51 furan-2,2'-dione, was prepared by decarboxylation of 
crude trans diethyl 5-ethoxytetrahydro-2-oxo-4-furanylmalonate (4.0 g). The reaction, by reflux in 
HBr acetic acid, produced 1.2 g product. The reaction conditions were quite harsh and produced 
quite a lot of brown oily residue. Therefore, there may have been some polymerisation during the 
reaction. However, sufficient product was obtained to perform the final stage of the reaction. 
The compound, cis dihydrofuro(4,5] furan-2,2'-dione (1 g) was converted to a dicarboxylic 
potassium salt then acidified to give the target compound (320 mg) in 32% yield. 
6.1.2 Reaction with N-wAcetyllysine 
The reaction of furanyl acetic acid with N-a-Acetyllysine was chosen as a model to 
determine if our compound would react with the e-amine of lysine [Figure 31. N-(x-Acetyllysine 
has a good UV chromaphore so we could monitor the reaction by HPLC-DAD. Unfortunately the 
successful reaction of these two compounds was not achieved. The reason appears to be hydrolysis 
of the lactone compound during the reaction. A high pH (-9) was needed to ensure deprotonation 
of the e-amine. However, this is likely to deprotonate the carboxyl group of furanyl acetic acid 
which would then also become nucleophilic. An aqueous solution was required because N-(x- 
acetyllysine is not soluble in organic solvents (DMSO, DMF or methanol). These problems may be 
overcome by using a large excess of furanyl acetic acid and then performing a separation by prep 
HPLC. This would require further synthetic work to obtain more furanyl acetic acid. These 
reactions and procedures are highly complex and out of the scope of this research project. 
However, this should be considered if further development work was to be undertaken. 
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Figure 3. Proposed reaction scheme of furanyl acetic acid with N-a-Acetyllysine 
6.2 Conclusion 
The development of a diagnostic approach to screen GHB would have a big impact for 
forensic drug testing. Our studies have demonstrated the complex nature of antibody developmeot 
work. Furanyl acetic acid was successfully synthesised but was found to be unreactive with N-M 
acetyllysine. 
Other considerations relating to this approach concern the small size Of the target MOIOQ* 
The nature of antibody interactions depends upon the binding to the whole antigen Le. the pwtdA 
molecule and the substrate. The GHB sub-structure represents only a tiny fraction of this mokcik - 
and as such specific binding sites may not be achievable or the selectivity may be poor. Thm an 
many compounds found in biological fluids with similar structures to GHB (e. g. alpha- 
hydroxybutyric acid and beta-hydroxybutyric acid). 
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6.3 Future Work 
There are other possible routes to achieve selective affinity chromatography. This includes 
molecular imprinted polymers (NfiPs) which are synthesised using the drug as a template and 
aptamers (ofigo-nucleotides) selected from a library that may contain specific binding sites to the 
GHB structure. 
Selective targeting of other drug compounds has been reported using molecular imprinted 
polymers (MiPs) and oligonucleotide, aptamers selected from a library. It may be necessary to 
explore these avenues of research. 
A recent study by Bugey et aL outlined a novel affinity chromatographic clean-up using 
WPs for the highly selective extraction of flunitrazepam and its major metabolite. 4 Ansell et aL 
5 developed a chiral specific NHP for the detection of (-)-ephedrine. These developments in the field 
of testing for drugs of abuse may have great potential. It is reasonable to assume that a similar 
technique could be used for GHB detection. 
DNA/RNA aptamers are short single stranded oligonucleotides consisting of randomised 
sequences and lengths contained within a library. The selection of aptamers using systematic 
evolution of ligands by exponential enrichment (SELEX) is a highly specialised procedure and is 
beyond the scope of this research project. Research has shown that aptamers, have specific binding 
affinities to various large bio-molecules and like antibodies could be used to target smaller organic 
molecules 6. A work plan is outlined, in Section 6.3.1, which would enable this procedure to be 
explored. GHB immobilised to a column containing sepharose by an activator such as EDC may be 
employed as a means to target specific aptamers from a library. Any aptamers that bind to the GHB 
molecule could then be worked up using polymerase chain reaction (PCR) and, cloned and 
sequenced from E. cofi bacteria. 
The development of these techniques requires specialised skills which are outside of the 
scope of this research project. Despite issues such as poor selectivity and cross-reactivity which 
may be more apparent with such a small molecule as GHB; this is an area of research that certainly 
warrants further investigation. 
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6.3.1 Aptamer Selection Procedure using SELEX 
The techniques and procedures involved in the selection of oligo-aptamers, from a library and 
proposed means to develop aptarner selection to a GHB target. 
1. Make up the ligand (GHB) in distilled water and adjust pH 4.5 to 6 
2. Prepare matrix (EAH sepharose) 
3. Add matrix and ligand to a column 
4. Add the activator (EDC (I-Ethyl-3-[3-dimethylaminopropyllcarbodiimide hydrochloride)) 
5. Agitate the mixture 
6. Wash the column 
7. Add binding buffer (phosphate buffer pH 6-7) 
8. Add amplified library 
9. Incubate the column (I h, room temperature) 
10. Wash the column with binding buffer 
11. Elute aptamers (i. e. bound aptamers) with high concentration salt in binding buffer 
12. Collect the eluant and de-salt using Microcon 
13. Make multiple copies of the binding aptamers using PCR 
14. Regenerate column by adding binding buffer (no salt) 
15. Redissolve PCR fraction in the buffer, add to the column and incubate (I h, room temperatwe) 
16. Repeat steps 10 to 15 (x 10) 
17. Clone and sequence fractions i. e. express the bound aptamers from E. coli 
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